

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 December 2001 (13.12.2001)

PCT

(10) International Publication Number  
**WO 01/94390 A2**

(51) International Patent Classification<sup>7</sup>: **C07K 14/00** (74) Agents: MYERS, Louis et al.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).

(21) International Application Number: **PCT/US01/18340**

(22) International Filing Date: 6 June 2001 (06.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/209,845 6 June 2000 (06.06.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 60/209,845 (CIP)  
Filed on 6 June 2000 (06.06.2000)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): **MILLENNIUM PHARMACEUTICALS, INC. [US/US]; 75 Sidney Street, Cambridge, MA 02139 (US).**

Published:

— without international search report and to be republished upon receipt of that report

(72) Inventor; and

(75) Inventor/Applicant (for US only): **CURTIS, Rory, A., J. [US/US]; 31 Constitution Drive, Southborough, MA 01772 (US).**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**WO 01/94390 A2**

(54) Title: 52906, 33408, AND 12189, NOVEL POTASSIUM CHANNEL FAMILY MEMBERS AND USES THEREOF

(57) Abstract: The invention provides isolated nucleic acids molecules, designated 52906, 33408, or 12189 nucleic acid molecules, which encode novel potassium channel members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 52906, 33408, or 12189 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 52906, 33408, or 12189 gene has been introduced or disrupted. The invention still further provides isolated 52906, 33408, or 12189 proteins, fusion proteins, antigenic peptides and anti-52906, 33408, or 12189 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

**52906, 33408, AND 12189, NOVEL POTASSIUM CHANNEL FAMILY  
MEMBERS AND USES THEREOF**

Related Applications

5 This application claims priority to U.S. provisional application number 60/209,845 filed on June 6, 2000, the contents of which are incorporated herein by reference.

Background of the Invention

Potassium ( $K^+$ ) channels are ubiquitous proteins which are involved in the setting 10 of the resting membrane potential as well as in the modulation of the electrical activity of cells. In excitable cells,  $K^+$  channels influence action potential waveforms, firing frequency, and neurotransmitter secretion (Rudy, B. (1988) *Neuroscience*, 25, 729-749; Hille, B. (1992) *Ionic Channels of Excitable Membranes*, 2nd Ed.). In non-excitable 15 cells, they are involved in hormone secretion, cell volume regulation and potentially in cell proliferation and differentiation (Lewis *et al.* (1995) *Annu. Rev. Immunol.*, 13, 623-653). Developments in electrophysiology have allowed the identification and the characterization of an astonishing variety of  $K^+$  channels that differ in their biophysical 20 properties, pharmacology, regulation and tissue distribution (Rudy, B. (1988) *Neuroscience*, 25, 729-749; Hille, B. (1992) *Ionic Channels of Excitable Membranes*, 2nd Ed.). More recently, cloning efforts have shed considerable light on the mechanisms that determine this functional diversity. Furthermore, analyses of structure-function 25 relationships have provided an important set of data concerning the molecular basis of the biophysical properties (selectivity, gating, assembly) and the pharmacological properties of cloned  $K^+$  channels.

Functional diversity of  $K^+$  channels arises mainly from the existence of a great 25 number of genes coding for pore-forming subunits, as well as for other associated regulatory subunits. Two main structural families of pore-forming subunits have been identified. The first one consists of subunits with a conserved hydrophobic core containing six transmembrane domains (TMDs). These  $K^+$  channel  $\alpha$  subunits participate 30 in the formation of outward rectifier voltage-gated ( $K_v$ ) and  $Ca^{2+}$ -dependent  $K^+$  channels.

The fourth TMD contains repeated positive charges involved in the voltage gating of these channels and hence in their outward rectification (Logothetis *et al.* (1992) *Neuron*, 8, 531-540; Bezanilla *et al.* (1994) *Biophys. J.* 66, 1011-1021).

5 The second family of pore-forming subunits have only two TMDs. They are essential subunits of inward-rectifying (IRK), G-protein-coupled (GIRK) and ATP-sensitive ( $K_{ATP}$ )  $K^+$  channels. The inward rectification results from a voltage-dependent block by cytoplasmic  $Mg^{2+}$  and polyamines (Matsuda, H. (1991) *Annu. Rev. Physiol.*, 53, 289-298). A conserved domain, called the P domain, is present in all members of both families (Pongs, O. (1993) *J. Membr. Biol.*, 136, 1-8; Heginbotham *et al.* (1994) *Biophys. 10 J.* 66, 1061-1067; Mackinnon, R. (1995) *Neuron*, 14, 889-892; Pascual *et al.*, (1995) *Neuron*, and 14, 1055-1063). This domain is an essential element of the aqueous  $K^+$ -selective pore. In both groups, the assembly of four subunits is necessary to form a functional  $K^+$  channel (Mackinnon, R. (1991) *Nature*, 350, 232-235; Yang *et al.*, (1995) *Neuron*, 15, 1441-1447).

15 In both six TMD and two TMD pore-forming subunit families, different subunits coded by different genes can associate to form heterotetramers with new channel properties (Isacoff *et al.*, (1990) *Nature*, 345, 530-534). A selective formation of heteropolymeric channels may allow each cell to develop the best  $K^+$  current repertoire suited to its function. Pore-forming  $\alpha$  subunits of  $K_v$  channels are classified into 20 different subfamilies according to their sequence similarity (Chandy *et al.* (1993) *Trends Pharmacol. Sci.*, 14, 434). Tetramerization is believed to occur preferentially between members of each subgroup (Covarrubias *et al.* (1991) *Neuron*, 7, 763-773). The domain responsible for this selective association is localized in the N-terminal region and is conserved between members of the same subgroup. This domain is necessary for hetero- 25 but not homomultimeric assembly within a subfamily and prevents co-assembly between subfamilies. Recently, pore-forming subunits with two TMDs were also shown to co-assemble to form heteropolymers (Duprat *et al.* (1995) *Biochem. Biophys. Res. Commun.*, 212, 657-663. This heteropolymerization seems necessary to give functional GIRKs. IRKs are active as homopolymers but also form heteropolymers.

Summary of the Invention

The present invention is based, in part, on the discovery of novel potassium channel family members, referred to herein as "52906," "33408," and "12189." The nucleotide sequence of a cDNA encoding 52906 is shown in SEQ ID NO:1, and the 5 amino acid sequence of a 52906 polypeptide is shown in SEQ ID NO:2. In addition, the nucleotide sequences of the coding region are depicted in SEQ ID NO:3. The nucleotide sequence of a cDNA encoding 33408 is shown in SEQ ID NO:4, and the amino acid sequence of a 33408 polypeptide is shown in SEQ ID NO:5. In addition, the nucleotide sequences of the coding region are depicted in SEQ ID NO:6. The nucleotide sequence 10 of a cDNA encoding 12189 is shown in SEQ ID NO:7, and the amino acid sequence of a 12189 polypeptide is shown in SEQ ID NO:8. In addition, the nucleotide sequences of the coding region are depicted in SEQ ID NO:7.

Accordingly, in one aspect, the invention features a nucleic acid molecule that encodes a 52906, 33408, or 12189 protein or polypeptide, e.g., a biologically active 15 portion of the 52906, 33408, or 12189 protein. In a preferred embodiment the isolated nucleic acid molecule encodes a polypeptide having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8. In other embodiments, the invention provides isolated 52906, 33408, or 12189 nucleic acid molecules having the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, the 20 sequence of the DNA insert of the plasmid deposited with ATCC Accession Number \_\_\_\_\_, the sequence of the DNA insert of the plasmid deposited with ATCC Accession Number \_\_\_\_\_, or the sequence of the DNA insert of the plasmid deposited with ATCC Accession Number \_\_\_\_\_. In still other embodiments, the invention provides nucleic acid molecules that are substantially identical (e.g., naturally occurring allelic variants) to the 25 nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, the sequence of the DNA insert of the plasmid deposited with ATCC Accession Number \_\_\_\_\_, the sequence of the DNA insert of the plasmid deposited with ATCC Accession Number \_\_\_\_\_, or the sequence of the DNA insert of the plasmid deposited with ATCC Accession Number \_\_\_\_\_. In other embodiments, the invention 30 provides a nucleic acid molecule which hybridizes under a stringency condition described herein to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1,

SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, the sequence of the DNA insert of the plasmid deposited with ATCC Accession Number \_\_\_, the sequence of the DNA insert of the plasmid deposited with ATCC Accession Number \_\_\_, or the sequence of the DNA insert of the plasmid deposited with ATCC Accession Number \_\_\_ 5 \_\_\_, wherein the nucleic acid encodes a full length 52906, 33408, or 12189 protein or an active fragment thereof.

In a related aspect, the invention further provides nucleic acid constructs that include a 52906, 33408, or 12189 nucleic acid molecule described herein. In certain embodiments, the nucleic acid molecules of the invention are operatively linked to native 10 or heterologous regulatory sequences. Also included, are vectors and host cells containing the 52906, 33408, or 12189 nucleic acid molecules of the invention e.g., vectors and host cells suitable for producing 52906, 33408, or 12189 nucleic acid molecules and polypeptides.

In another related aspect, the invention provides nucleic acid fragments suitable as 15 primers or hybridization probes for the detection of 52906, 33408, or 12189 -encoding nucleic acids.

In still another related aspect, isolated nucleic acid molecules that are antisense to a 52906, 33408, or 12189 encoding nucleic acid molecule are provided.

In another aspect, the invention features, 52906, 33408, or 12189 polypeptides, 20 and biologically active or antigenic fragments thereof that are useful, e.g., as reagents or targets in assays applicable to treatment and diagnosis of 52906, 33408, or 12189-mediated or -related disorders. In another embodiment, the invention provides 52906, 33408, or 12189 polypeptides having a 52906, 33408, or 12189 activity. Preferred 25 polypeptides are 52906, 33408, or 12189 proteins including at least one ion transport protein domain, and, preferably, having a 52906, 33408, or 12189 activity, e.g., a 52906, 33408, or 12189 activity as described herein.

In other embodiments, the invention provides 52906, 33408, or 12189 polypeptides, e.g., a 52906, 33408, or 12189 polypeptide having the amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, the amino acid sequence encoded 30 by the cDNA insert of the plasmid deposited with ATCC Accession Number \_\_\_, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC

Accession Number \_\_\_\_\_ or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC Accession Number \_\_\_\_\_; an amino acid sequence that is substantially identical to the amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC Accession Number \_\_\_\_\_, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC Accession Number \_\_\_\_\_, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC Accession Number \_\_\_\_\_; or an amino acid sequence encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under a stringency condition described herein to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, the sequence of the DNA insert of the plasmid deposited with ATCC Accession Number \_\_\_\_\_, the sequence of the DNA insert of the plasmid deposited with ATCC Accession Number \_\_\_\_\_, or the sequence of the DNA insert of the plasmid deposited with ATCC Accession Number \_\_\_\_\_, wherein the nucleic acid encodes a full length 52906, 33408, or 12189 protein or an active fragment thereof.

In a related aspect, the invention further provides nucleic acid constructs which include a 52906, 33408, or 12189 nucleic acid molecule described herein.

In a related aspect, the invention provides 52906, 33408, or 12189 polypeptides or fragments operatively linked to non-52906, 33408, or 12189 polypeptides to form fusion proteins.

In another aspect, the invention features antibodies and antigen-binding fragments thereof, that react with, or more preferably specifically bind 52906, 33408, or 12189 polypeptides or fragments thereof, e.g., an ion transport protein domain, a cyclic nucleotide-binding domain, a potassium channel tetramerisation domain, a transmembrane domain, a cytoplasmic domain, an extracellular domain, a Pore-loop domain, or a PAS domain. In one embodiment, the antibodies or antigen-binding fragment thereof competitively inhibit the binding of a second antibody to a 52906, 33408, or 12189 polypeptide or a fragment thereof, e.g., an ion transport protein domain, a cyclic nucleotide-binding domain, a potassium channel tetramerisation domain, a

transmembrane domain, a cytoplasmic domain, an extracellular domain, a Pore-loop domain, or a PAS domain.

In another aspect, the invention provides methods of screening for compounds that modulate the expression or activity of the 52906, 33408, or 12189 polypeptides or 5 nucleic acids.

In still another aspect, the invention provides a process for modulating 52906, 33408, or 12189 polypeptide or nucleic acid expression or activity, e.g. using the screened compounds. In certain embodiments, the methods involve treatment of conditions related to aberrant activity or expression of the 52906, 33408, or 12189 10 polypeptides or nucleic acids, such as conditions characterized by abnormal ion flux such as a neurological disorder or a cardiac disorder.

The invention also provides assays for determining the activity of or the presence or absence of 52906, 33408, or 12189 polypeptides or nucleic acid molecules in a biological sample, including for disease diagnosis.

15 In yet another aspect, the invention provides methods for modulating (increasing or decreasing) the ion flux, e.g., the flow of  $K^+$  ions, in a 52906, 33408, or 12189-expressing cell. The method includes contacting the cell with a compound (e.g., a compound identified using the methods described herein) that modulates the activity, or expression, of the 52906, 33408, or 12189 polypeptide or nucleic acid. In a preferred 20 embodiment, the contacting step is effective *in vitro* or *ex vivo*. In other embodiments, the contacting step is effected *in vivo*, e.g., in a subject (e.g., a mammal, e.g., a human), as part of a therapeutic or prophylactic protocol. In a preferred embodiment, the cell is an electrically excitable cell, e.g., a neuronal cell or a muscle cell (e.g., a heart cell). For example, the cell can be from brain or cardiac tissues.

25 In a preferred embodiment, the compound is an inhibitor of a 52906, 33408, or 12189 polypeptide. Preferably, the inhibitor is chosen from a peptide, a phosphopeptide, a small organic molecule, a small inorganic molecule and an antibody (e.g., an antibody conjugated to a therapeutic moiety). In another preferred embodiment, the compound is an inhibitor of a 52906, 33408, or 12189 nucleic acid, e.g., an antisense, a ribozyme, or a 30 triple helix molecule.

In another aspect, the invention features methods for treating or preventing a disorder characterized by the abnormal ion flux of a 52906, 33408, or 12189-expressing cell, in a subject. Preferably, the method includes administering to the subject (e.g., a mammal, e.g., a human) an effective amount of a compound (e.g., a compound identified using the methods described herein) that modulates the activity, or expression, of the 52906, 33408, or 12189 polypeptide or nucleic acid. In a preferred embodiment, the disorder is a neurological disorder or a cardiac disorder.

In a further aspect, the invention provides methods for evaluating the efficacy of a treatment of a disorder, e.g., a disorder characterized by abnormal ion flux such as a neurological disorder or a cardiac disorder. The method includes: treating a subject, e.g., a patient or an animal, with a protocol under evaluation (e.g., treating a subject with a compound identified using the methods described herein); and evaluating the expression of a 52906, 33408, or 12189 nucleic acid or polypeptide before and after treatment. A change, e.g., a decrease or increase, in the level of a 52906, 33408, or 12189 nucleic acid (e.g., mRNA) or polypeptide after treatment, relative to the level of expression before treatment, is indicative of the efficacy of the treatment of the disorder. The level of 52906, 33408, or 12189 nucleic acid or polypeptide expression can be detected by any method described herein.

In a preferred embodiment, the evaluating step includes obtaining a sample (e.g., a tissue sample, e.g., a biopsy, or a fluid sample) from the subject, before and after treatment and comparing the level of expressing of a 52906, 33408, or 12189 nucleic acid (e.g., mRNA) or polypeptide before and after treatment.

In another aspect, the invention provides methods for evaluating the efficacy of a therapeutic or prophylactic agent. The method includes: contacting a sample with an agent (e.g., a compound identified using the methods described herein) and, evaluating the expression of 52906, 33408, or 12189 nucleic acid or polypeptide in the sample before and after the contacting step. A change, e.g., a decrease or increase, in the level of 52906, 33408, or 12189 nucleic acid (e.g., mRNA) or polypeptide in the sample obtained after the contacting step, relative to the level of expression in the sample before the contacting step, is indicative of the efficacy of the agent. The level of 52906, 33408, or

12189 nucleic acid or polypeptide expression can be detected by any method described herein. In a preferred embodiment, the sample includes neuronal cells or muscle cells.

In further aspect, the invention provides assays for determining the presence or absence of a genetic alteration in a 52906, 33408, or 12189 polypeptide or nucleic acid molecule, including for disease diagnosis.

5 In another aspect, the invention features a two dimensional array having a plurality of addresses, each address of the plurality being positionally distinguishable from each other address of the plurality, and each address of the plurality having a unique capture probe, e.g., a nucleic acid or peptide sequence. At least one address of the 10 plurality has a capture probe that recognizes a 52906, 33408, or 12189 molecule. In one embodiment, the capture probe is a nucleic acid, e.g., a probe complementary to a 52906, 33408, or 12189 nucleic acid sequence. In another embodiment, the capture probe is a polypeptide, e.g., an antibody specific for 52906, 33408, or 12189 polypeptides. Also 15 featured is a method of analyzing a sample by contacting the sample to the aforementioned array and detecting binding of the sample to the array.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

#### Brief Description of the Drawings

20 *Figure 1* depicts a hydropathy plot of human 52906. Relative hydrophobic residues are shown above the dashed horizontal line, and relative hydrophilic residues are below the dashed horizontal line. Numbers corresponding to positions in the amino acid sequence of human 52906 are indicated. Polypeptides of the invention include fragments which include: all or part of a hydrophobic sequence, i.e., a sequence above the dashed line, e.g., the sequence from about amino acid 785-800 of SEQ ID NO:2; all or part of a 25 hydrophilic sequence, i.e., a sequence below the dashed line, e.g., the sequence of from about amino acid 241-265 of SEQ ID NO:2.

*Figure 2* depicts an alignment of the ion transport protein domain of human 52906 with a consensus amino acid sequence derived from a hidden Markov model (HMM) from PFAM. The upper sequence is the consensus amino acid sequence (SEQ ID NO:9),

while the lower amino acid sequence corresponds to amino acids 472 to 661 of SEQ ID NO:2.

5 *Figure 3* depicts a hydropathy plot of human 33408. Relative hydrophobic residues are shown above the dashed horizontal line, and relative hydrophilic residues are below the dashed horizontal line. Numbers corresponding to positions in the amino acid sequence of human 33408 are indicated. Polypeptides of the invention include fragments which include: all or part of a hydrophobic sequence, i.e., a sequence above the dashed line, e.g., the sequence from about amino acid 585-600 of SEQ ID NO:5; all or part of a hydrophilic sequence, i.e., a sequence below the dashed line, e.g., the sequence of from 10 about amino acid 710-740 of SEQ ID NO:5.

15 *Figure 4A* depicts an alignment of the ion transport protein domain of human 33408 with a consensus amino acid sequence derived from a hidden Markov model (HMM) from PFAM. The upper sequence is the consensus amino acid sequence (SEQ ID NO:9), while the lower amino acid sequence corresponds to amino acids 247 to 467 of SEQ ID NO:5.

20 *Figure 4B* depicts an alignment of the cyclic nucleotide-binding domain of human 33408 with a consensus amino acid sequence derived from a hidden Markov model (HMM) from PFAM. The upper sequence is the consensus amino acid sequence (SEQ ID NO:10), while the lower amino acid sequence corresponds to amino acids 565 to 655 of SEQ ID NO:5.

*Figures 4C-4D* depict an alignment of the amino acid sequence of human 33408 (upper sequence) with the amino acid sequence of rat Eag2 (lower sequence; Accession Number AF185637; SEQ ID NO:12).

25 *Figure 5* depicts a hydropathy plot of human 12189. Relative hydrophobic residues are shown above the dashed horizontal line, and relative hydrophilic residues are below the dashed horizontal line. Numbers corresponding to positions in the amino acid sequence of human 12189 are indicated. Polypeptides of the invention include fragments which include: all or part of a hydrophobic sequence, i.e., a sequence above the dashed line, e.g., the sequence from about amino acid 75-95 of SEQ ID NO:8; all or part of a 30 hydrophilic sequence, i.e., a sequence below the dashed line, e.g., the sequence of from about amino acid 35-55 of SEQ ID NO:8.

5 *Figure 6A* depicts an alignment of the potassium channel tetramerisation domain of human 12189 with a consensus amino acid sequence derived from a hidden Markov model (HMM) from PFAM. The upper sequence is the consensus amino acid sequence (SEQ ID NO:11), while the lower amino acid sequence corresponds to amino acids 3 to 101 of SEQ ID NO:8.

10 *Figure 6B* depicts an alignment of the ion transport protein domain of human 12189 with a consensus amino acid sequence derived from a hidden Markov model (HMM) from PFAM. The upper sequence is the consensus amino acid sequence (SEQ ID NO:9), while the lower amino acid sequence corresponds to amino acids 198 to 383 of SEQ ID NO:8.

15 *Figure 6C* depicts an alignment of the amino acid sequence of human 12189 (lower sequence) with the amino acid sequence of mouse Kv1.7 (upper sequence; Accession Number AF032099; SEQ ID NO:13).

#### Detailed Description

##### 15 Human 52906

20 The human 52906 sequence (see SEQ ID NO:1, as recited in Example 1), which is approximately 3525 nucleotides long including untranslated regions, contains a predicted methionine-initiated coding sequence of about 2544 nucleotides, including the termination codon. The coding sequence encodes a 847 amino acid protein (see SEQ ID NO:2, as recited in Example 1). The hydropathy plot of 52906 is depicted in Figure 1.

25 Human 52906 contains the following regions or structural features: an ion transport protein domain (PFAM Accession Number PF00520) located at about amino acid residues 472 to 661 of SEQ ID NO:2 (see Figure 2); and a core membrane region consisting of six transmembrane domains, four cytoplasmic domains, three extracellular domains, and a Pore-loop domain. The core membrane region is located at about amino acid 402 to about amino acid 662 of SEQ ID NO:2. The six transmembrane domains are located at about amino acid 402 (cytoplasmic end) to about amino acid 419 (extracellular end) of SEQ ID NO:2, about amino acid 433 (extracellular end) to about amino acid 456 (cytoplasmic end) of SEQ ID NO:2, about amino acid 482 (cytoplasmic end) to about 30 amino acid 498 (extracellular end) of SEQ ID NO:2, about amino acid 524 (extracellular

end) to about amino acid 543 (cytoplasmic end) of SEQ ID NO:2, about amino acid 573 (cytoplasmic end) to about amino acid 597 (extracellular end) of SEQ ID NO:2, and about amino acid 641 (extracellular end) to about amino acid 662 (cytoplasmic end) of SEQ ID NO:2. The four cytoplasmic domains are located at about amino acids 1 to 401 (amino terminus), 457 to 481, 544 to 572, and 663 to 847 (carboxy terminus) of SEQ ID NO:2. The three extracellular domains are located at about amino acids 420 to 432, 499 to 523, and 598 to 640 of SEQ ID NO:2. The extracellular domain located at about amino acids 598 to 640 includes a Pore-loop domain (P-loop domain) located at about amino acid residues 616 to 639 of SEQ ID NO:2.

The 52906 protein also includes the following domains: six predicted N-glycosylation sites (PS00001) located at about amino acids 10-13, 141-144, 182-185, 284-287, 342-345, and 500-503 of SEQ ID NO:2; one predicted glycosaminoglycan attachment site (PS00002) located at about amino acids 367-370 of SEQ ID NO:2; four predicted cAMP- and cGMP-dependent protein kinase phosphorylation sites (PS00004) located at about amino acids 176-179, 258-261, 400-403, and 832-835 of SEQ ID NO:2; 13 predicted Protein Kinase C phosphorylation sites (PS00005) located at about amino acids 9-11, 12-14, 174-176, 271-273, 288-290, 377-379, 506-508, 552-554, 596-598, 684-686, 732-734, 799-801, and 829-831 of SEQ ID NO:2; seven predicted Casein Kinase II phosphorylation sites (PS00006) located at about amino acids 330-333, 337-340, 518-521, 668-671, 746-749, 780-783, and 842-845 of SEQ ID NO:2; 15 predicted N-myristylation sites (PS00008) located at about amino acids 21-26, 42-47, 118-123, 132-137, 153-158, 165-170, 178-183, 227-232, 309-314, 351-356, 359-364, 366-371, 374-379, 647-652, and 787-792 of SEQ ID NO:2; and one predicted coiled coil located at about amino acids 719-791 of SEQ ID NO:2.

For general information regarding PFAM identifiers, PS prefix and PF prefix domain identification numbers, refer to Sonnhammer *et al.* (1997) *Protein* 28:405-420 and <http://www.psc.edu/general/software/packages/pfam/pfam.html>.

A plasmid containing the nucleotide sequence encoding human 52906 (clone "Fbh52906FL") was deposited with American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, on \_\_\_\_\_ and assigned Accession Number \_\_\_\_\_. This deposit will be maintained under the terms of the Budapest Treaty

on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

5 An alignment of the human 52906 amino acid sequence with the rat SK2 amino acid sequence (Accession Number U69882) suggests that 52906 is a human ortholog of rat SK2, a calcium activated potassium channel (Köhler et al. (1996) *Science* 273:1709-1714).

#### Human 33408

10 The human 33408 sequence (see SEQ ID NO:4, as recited in Example 1), which is approximately 3553 nucleotides long including untranslated regions, contains a predicted methionine-initiated coding sequence of about 2967 nucleotides, including the termination codon. The coding sequence encodes a 988 amino acid protein (see SEQ ID NO:5, as recited in Example 1). The hydropathy plot of 33408 is depicted in Figure 3.

15 Human 33408 contains the following regions or structural features: an ion transport protein domain (PFAM Accession Number PF00520) located at about amino acid residues 247 to 467 of SEQ ID NO:5 (see Figure 4A); a cyclic nucleotide-binding domain (PFAM Accession Number PF00027) located at about amino acid residues 565 to 655 of SEQ ID NO:5 (see Figure 4B); and a core membrane region consisting of six 20 transmembrane domains, four cytoplasmic domains, three extracellular domains, a Pore-loop domain, and a PAS domain. The core membrane region is located at about amino acid 219 to about amino acid 471 of SEQ ID NO:5. The six transmembrane domains are located at about amino acid 219 (cytoplasmic end) to about amino acid 236 (extracellular end) of SEQ ID NO:5, about amino acid 245 (extracellular end) to about amino acid 264 (cytoplasmic end) of SEQ ID NO:5, about amino acid 292 (cytoplasmic end) to about amino acid 309 (extracellular end) of SEQ ID NO:5, about amino acid 320 (extracellular end) to about amino acid 337 (cytoplasmic end) of SEQ ID NO:5, about amino acid 344 (cytoplasmic end) to about amino acid 368 (extracellular end) of SEQ ID NO:5, and about amino acid 447 (extracellular end) to about amino acid 471 (cytoplasmic end) of 25 SEQ ID NO:5. The four cytoplasmic domains are located at about amino acids 1 to 218 (amino terminus), 265 to 291, 338 to 343, and 472 to 988 (carboxy terminus) of SEQ ID 30 NO:5.

NO:5. The three extracellular domains are located at about amino acids 237 to 244, 310 to 319, and 369 to 446 of SEQ ID NO:5. The extracellular domain located at about amino acids 369 to 446 includes a Pore-loop domain (P-loop domain) located at about amino acid residues 420 to 440 of SEQ ID NO:5. The cytoplasmic domain located at about amino acids 1 to 218 includes a PAS domain located at about amino acid residues 1-134 of SEQ ID NO:5 and a PAC domain located at about amino acid residues 92-132 of SEQ ID NO:5.

5 The 33408 protein also includes the following domains: seven predicted N-glycosylation sites (PS00001) located at about amino acids 170-173, 235-238, 403-406, 10 466-469, 663-666, 743-746, and 830-833 of SEQ ID NO:5; two predicted cAMP- and cGMP-dependent protein kinase phosphorylation sites (PS00004) located at about amino acids 21-24 and 677-680 of SEQ ID NO:5; 13 predicted Protein Kinase C phosphorylation sites (PS00005) located at about amino acids 73-75, 127-129, 142-144, 237-239, 322-324, 478-480, 502-504, 521-523, 773-775, 925-927, 943-945, 952-954, and 15 981-983 of SEQ ID NO:5; 16 predicted Casein Kinase II phosphorylation sites (PS00006) located at about amino acids 14-17, 127-130, 215-218, 252-255, 369-372, 442-445, 634-637, 725-728, 832-835, 847-850, 869-872, 883-886, 909-912, 929-932, 974-977, and 981-984 of SEQ ID NO:5; eight predicted N-myristoylation sites (PS00008) located at about amino acids 3-8, 407-412, 465-470, 557-562, 723-728, 744-20 749, 806-811, and 867-872 of SEQ ID NO:5; one predicted amidation site (PS00009) located at about amino acids 3-6 of SEQ ID NO:5; one predicted leucine zipper pattern (PS00029) located at about amino acids 910-931 of SEQ ID NO:5; and one predicted coiled coil located at about amino acids 906-944 of SEQ ID NO:5.

25 A plasmid containing the nucleotide sequence encoding human 33408 (clone "Fbh33408FL") was deposited with American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, on \_\_\_\_\_ and assigned Accession Number \_\_\_\_\_. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in 30 the art and is not an admission that a deposit is required under 35 U.S.C. §112.

An alignment of the human 33408 amino acid sequence with the rat Eag2 amino acid sequence (SEQ ID NO:12; Accession Number AF185637) is depicted in Figures 4C-4D. 33408 appears to be a human ortholog of rat Eag2, a subthreshold activating potassium channel (Saganich et al. (1999) *J. Neuroscience* 19:10789-10802).

5

### Human 12189

The human 12189 sequence (see SEQ ID NO:7, as recited in Example 1), which is approximately 1341 nucleotides long, contains a predicted coding sequence, including a termination codon. The coding sequence encodes a 446 amino acid protein (see SEQ ID 10 NO:8, as recited in Example 1). The hydropathy plot of 12189 is depicted in Figure 5.

Human 12189 contains the following regions or structural features: a potassium channel tetramerisation domain (PFAM Accession Number PF02214) located at about amino acid residues 3 to 101 of SEQ ID NO:8 (see Figure 6A); an ion transport protein domain (PFAM Accession Number PF00520) located at about amino acid residues 198 to 15 383 of SEQ ID NO:8 (see Figure 6B); and a core membrane region consisting of six transmembrane domains, four cytoplasmic domains, three extracellular domains, and a Pore-loop domain. The core membrane region is located at about amino acid 134 to about amino acid 384 of SEQ ID NO:8. The six transmembrane domains are located at about amino acid 134 (cytoplasmic end) to about amino acid 152 (extracellular end) of 20 SEQ ID NO:8, about amino acid 200 (extracellular end) to about amino acid 222 (cytoplasmic end) of SEQ ID NO:8, about amino acid 231 (cytoplasmic end) to about amino acid 248 (extracellular end) of SEQ ID NO:8, about amino acid 266 (extracellular end) to about amino acid 286 (cytoplasmic end) of SEQ ID NO:8, about amino acid 302 (cytoplasmic end) to about amino acid 323 (extracellular end) of SEQ ID NO:8, and 25 about amino acid 363 (extracellular end) to about amino acid 384 (cytoplasmic end) of SEQ ID NO:8. The four cytoplasmic domains are located at about amino acids 1 to 133 (amino terminus), 223 to 230, 287 to 301, and 385 to 446 (carboxy terminus) of SEQ ID NO:8. The three extracellular domains are located at about amino acids 153 to 199, 249 to 265, and 324 to 362 of SEQ ID NO:8. The extracellular domain located at about 30 amino acids 324 to 362 includes a Pore-loop domain (P-loop domain) located at about amino acid residues 339 to 355 of SEQ ID NO:8.

The 12189 protein also includes the following domains: two predicted N-glycosylation sites (PS00001) located at about amino acids 181-184 and 386-389 of SEQ ID NO:8; two predicted Protein Kinase C phosphorylation sites (PS00005) located at about amino acids 294-296 and 298-300 of SEQ ID NO:8; five predicted Casein Kinase II phosphorylation sites (PS00006) located at about amino acids 154-157, 298-301, 334-337, 395-398, and 404-407 of SEQ ID NO:8; one predicted tyrosine kinase phosphorylation site (PS00007) located at about amino acids 52-60 of SEQ ID NO:8; five predicted N-myristoylation sites (PS00008) located at about amino acids 87-92, 164-169, 248-253, 365-370, and 421-426 of SEQ ID NO:8; and one predicted leucine zipper pattern (PS00029) located at about amino acids 281-302 of SEQ ID NO:8.

A plasmid containing the nucleotide sequence encoding human 12189 (clone "Fbh12189 FL") was deposited with American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209, on \_\_\_\_\_ and assigned Accession Number \_\_\_\_\_. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

An alignment of the human 12189 amino acid sequence with the mouse Kv1.7 amino acid sequence (SEQ ID NO:13; Accession Number AF032099) is depicted in Figure 6C. 12189 appears to be a human ortholog of mouse Kv1.7, a voltage-gated potassium channel (Kalman et al. (1998) *J. Biol. Chem.* 273:5851-5857).

**Table 1: Summary of Sequence Information for 52906, 33408, and 12189**

Gene	cDNA	ORF	Polypeptide	ATCC Accession Number
52906	SEQ ID NO:1	SEQ ID NO:3	SEQ ID NO:2	
33408	SEQ ID NO:4	SEQ ID NO:6	SEQ ID NO:5	
12189	SEQ ID NO:7		SEQ ID NO:8	

**Table 2: Summary of Domains of 52906, 33408, and 12189**

Domain	52906	33408	12189
Transmembrane Region	amino acids 402-662 of SEQ ID NO:2	amino acids 219-471 of SEQ ID NO:5	amino acids 134-384 of SEQ ID NO:8
Transmembrane Domain 1	amino acids 402-419 of SEQ ID NO:2	amino acids 219-236 of SEQ ID NO:5	amino acids 134-152 of SEQ ID NO:8
Transmembrane Domain 2	amino acids 433-456 of SEQ ID NO:2	amino acids 245-264 of SEQ ID NO:5	amino acids 200-222 of SEQ ID NO:8
Transmembrane Domain 3	amino acids 482-498 of SEQ ID NO:2	amino acids 292-309 of SEQ ID NO:5	amino acids 231-248 of SEQ ID NO:8
Transmembrane Domain 4	amino acids 524-543 of SEQ ID NO:2	amino acids 320-337 of SEQ ID NO:5	amino acids 266-286 of SEQ ID NO:8
Transmembrane Domain 5	amino acids 573-597 of SEQ ID NO:2	amino acids 344-368 of SEQ ID NO:5	amino acids 302-323 of SEQ ID NO:8
Transmembrane Domain 6	amino acids 641-662 of SEQ ID NO:2	amino acids 447-471 of SEQ ID NO:5	amino acids 363-384 of SEQ ID NO:8
Cytoplasmic Domain 1	amino acids 1-401 of SEQ ID NO:2	amino acids 1-218 of SEQ ID NO:5	amino acids 1-133 of SEQ ID NO:8
Cytoplasmic Domain 2	amino acids 457-481 of SEQ ID NO:2	amino acids 265-291 of SEQ ID NO:5	amino acids 223-230 of SEQ ID NO:8
Cytoplasmic Domain 3	amino acids 544-572 of SEQ ID NO:2	amino acids 338-343 of SEQ ID NO:5	amino acids 287-301 of SEQ ID NO:8
Cytoplasmic Domain 4	amino acids 663-847 of SEQ ID NO:2	amino acids 472-988 of SEQ ID NO:5	amino acids 385-446 of SEQ ID NO:8
Extracellular Domain 1	amino acids 420-432 of SEQ ID NO:2	amino acids 237-244 of SEQ ID NO:5	amino acids 153-199 of SEQ ID NO:8
Extracellular Domain 2	amino acids 499-523 of SEQ ID NO:2	amino acids 310-319 of SEQ ID NO:5	amino acids 249-265 of SEQ ID NO:8
Extracellular Domain 3	amino acids 598-640 of SEQ ID NO:2	amino acids 369-446 of SEQ ID NO:5	amino acids 324-362 of SEQ ID NO:8
Pore-loop Domain	amino acids 616-639 of SEQ ID NO:2	amino acids 420-440 of SEQ ID NO:5	amino acids 339-355 of SEQ ID NO:8
ion transport protein domain	amino acids 472-661 of SEQ ID NO:2	amino acids 247-467 of SEQ ID NO:5	amino acids 198-383 of SEQ ID NO:8
cyclic nucleotide binding domain		amino acids 565-655 of SEQ ID NO:5	
potassium channel tetramerisation domain			amino acids 3-101 of SEQ ID NO:8

The 52906, 33408, and 12189 proteins contain a significant number of structural characteristics in common with members of the potassium channel family. The term

"family" when referring to the protein and nucleic acid molecules of the invention means two or more proteins or nucleic acid molecules having a common structural domain or motif and having sufficient amino acid or nucleotide sequence homology as defined herein. Such family members can be naturally or non-naturally occurring and can be 5 from either the same or different species. For example, a family can contain a first protein of human origin as well as other distinct proteins of human origin, or alternatively, can contain homologues of non-human origin, e.g., rat or mouse proteins. Members of a family can also have common functional characteristics.

As used herein, a "potassium channel" includes a protein or polypeptide which is 10 involved in receiving, conducting, and transmitting signals in an electrically excitable cell, e.g., a neuronal cell or a muscle cell. Potassium channels are potassium ion selective, and can determine membrane excitability (the ability of, for example, a neuron to respond to a stimulus and convert it into an impulse). Potassium channels can also influence the resting potential of membranes, wave forms and frequencies of action 15 potentials, and thresholds of excitation. Potassium channels are typically expressed in electrically excitable cells, e.g., neurons, muscle, endocrine, and egg cells, and may form heteromultimeric structures, e.g., composed of pore-forming  $\alpha$  and cytoplasmic  $\beta$  subunits. Potassium channels may also be found in nonexcitable cells (e.g., thymus cells), where they may play a role in, e.g., signal transduction. Potassium channel proteins 20 contain six transmembrane helices, wherein the last two helices flank a loop (a P-loop) which determines potassium ion selectivity. Examples of potassium channels include: (1) the voltage-gated potassium channels, (2) the ligand-gated potassium channels, e.g., neurotransmitter-gated potassium channels, and (3) cyclic-nucleotide-gated potassium channels. Voltage-gated and ligand-gated potassium channels are expressed in the brain, 25 e.g., in brainstem monoaminergic and forebrain cholinergic neurons, where they are involved in the release of neurotransmitters, or in the dendrites of hippocampal and neocortical pyramidal cells, where they are involved in the processes of learning and memory formation. For a detailed description of potassium channels, see Kandel E.R. *et al.*, Principles of Neural Science, second edition, (Elsevier Science Publishing Co., Inc., 30 N.Y. (1985)), the contents of which are incorporated herein by reference.

A 52906, 33408, or 12189 polypeptide can include a "transmembrane domain" or regions homologous with a "transmembrane domain".

As used herein, the term "transmembrane domain" includes an amino acid sequence of about 15 amino acid residues in length which spans the plasma membrane.

5 More preferably, a transmembrane domain includes about at least 20, 25, 30, 35, 40, or 45 amino acid residues and spans the plasma membrane. Transmembrane domains are rich in hydrophobic residues, and typically have an alpha-helical structure. In a preferred embodiment, at least 50%, 60%, 70%, 80%, 90%, 95% or more of the amino acids of a transmembrane domain are hydrophobic, *e.g.*, leucines, isoleucines, tyrosines, or 10 tryptophans. Transmembrane domains are described in, for example, Zagotta W.N. *et al.*, (1996) *Annual Rev. Neurosci.* 19: 235-263, the contents of which are incorporated herein by reference. Amino acid residues 402-419, 433-456, 482-498, 524-543, 573-597, and 641-662 of the 52906 protein (SEQ ID NO:2) are predicted to comprise transmembrane domains (see Figure 2). Accordingly, 52906 proteins having at least 50-60% homology, 15 preferably about 60-70%, more preferably about 70-80%, or about 80-90% homology with a transmembrane domain of human 52906 are within the scope of the invention. Amino acid residues 219-236, 245-264, 292-309, 320-337, 344-368, and 447-471 of the 33408 protein (SEQ ID NO:5) are predicted to comprise transmembrane domains (see Figure 5). Accordingly, 33408 proteins having at least 50-60% homology, preferably 20 about 60-70%, more preferably about 70-80%, or about 80-90% homology with a transmembrane domain of human 33408 are within the scope of the invention. Amino acid residues 134-152, 200-222, 231-248, 266-286, 302-323, and 363-384 of the 12189 protein (SEQ ID NO:8) are predicted to comprise transmembrane domains (see Figure 8). Accordingly, 12189 proteins having at least 50-60% homology, preferably about 60-70%, 25 more preferably about 70-80%, or about 80-90% homology with a transmembrane domain of human 12189 are within the scope of the invention.

A 52906, 33408, or 12189 polypeptide can further include a "Pore loop" or regions homologous with a "Pore loop domain".

As used herein, the term "Pore loop" or "P-loop" includes amino acid sequence 30 of about 15-45 amino acid residues in length, preferably about 15-35 amino acid residues in length, and most preferably about 15-25 amino acid residues in length, which is

hydrophobic and which is involved in lining the potassium channel pore. A P-loop is typically found between transmembrane domains of potassium channels and is believed to be a major determinant of ion selectivity in potassium channels. Preferably, P-loops contain a G-[HYDROPHOBIC AMINO ACID]-G sequence, e.g., a GYG, GLG, or GFG sequence. P-loops are described in, for example, Warmke et al. (1991) *Science* 252:1560-1562; Zagotta W.N. et al., (1996) *Annual Rev. Neurosci.* 19:235-63 (Pongs, O. (1993) *J. Membr. Biol.*, 136, 1-8; Heginbotham et al. (1994) *Biophys. J.* 66,1061-1067; Mackinnon, R. (1995) *Neuron*, and 14, 889-892; Pascual et al., (1995) *Neuron*, 14, 1055-1063), the contents of which are incorporated herein by reference. Amino acid residues 616-639 of SEQ ID NO:2, 420-440 of SEQ ID NO:5, and 339-355 of SEQ ID NO:8 comprise P-loop domains. Accordingly, proteins having at least 50-60% homology, preferably about 60-70%, more preferably about 70-80%, or about 80-90% homology with a -loop domain of human 52906, 33408, or 12189 are within the scope of the invention.

In one embodiment, a 52906, 33408, or 12189 protein includes at least one cytoplasmic domain. When located at the N-terminal domain the cytoplasmic domain is referred to herein as an "N-terminal cytoplasmic domain". As used herein, an "N-terminal cytoplasmic domain" includes an amino acid sequence having about 1-500, preferably about 1-450, preferably about 1-400, preferably about 1-380, more preferably about 1-350, more preferably about 1-300, more preferably about 1-220, or even more preferably about 1-135 amino acid residues in length and is located inside of a cell or intracellularly. The C-terminal amino acid residue of a "N-terminal cytoplasmic domain" is adjacent to an N-terminal amino acid residue of a transmembrane domain in a 52906, 33408, or 12189 protein. For example, an N-terminal cytoplasmic domain is located at about amino acid residues 1-401 of SEQ ID NO:2, 1-218 of SEQ ID NO:5, or 1-133 of SEQ ID NO:8.

In a preferred embodiment, a 52906, 33408, or 12189 polypeptide or protein has at least one cytoplasmic domain or a region which includes at least about 5, preferably about 5-10, and more preferably about 10-20 amino acid residues and has at least about 60%, 70% 80% 90% 95%, 99%, or 100% homology with an "cytoplasmic domain," e.g., at least one cytoplasmic domain of human 52906, 33408, or 12189 (e.g., residues 1-401,

457-481, 544-572, and 663-847 of SEQ ID NO:2; residues 1-218, 265-291, 338-343, and 447-988 of SEQ ID NO:5; and residues 1-133, 223-230, 287-301, and 385-446 of SEQ ID NO:8).

In another embodiment, a 52906, 33408, or 12189 protein includes at least one extracellular loop. As used herein, the term "loop" includes an amino acid sequence having a length of at least about 4, preferably about 5-10, and more preferably about 10-20 amino acid residues, and has an amino acid sequence that connects two transmembrane domains within a protein or polypeptide. Accordingly, the N-terminal amino acid of a loop is adjacent to a C-terminal amino acid of a transmembrane domain in a 52906, 33408, or 12189 molecule, and the C-terminal amino acid of a loop is adjacent to an N-terminal amino acid of a transmembrane domain in a 52906, 33408, or 12189 molecule. As used herein, an "extracellular loop" includes an amino acid sequence located outside of a cell, or extracellularly. For example, an extracellular loop can be found at about amino acids 420-432, 499-523, and 598-640 of SEQ ID NO:2; at about amino acids 237-244, 310-319, and 369-446 of SEQ ID NO:5; and at about amino acids 153-199, 249-265, and 324-362 of SEQ ID NO:8.

In a preferred embodiment, a 52906, 33408, or 12189 polypeptide or protein has at least one extracellular loop or a region which includes at least about 4, preferably about 5-10, preferably about 10-20, and more preferably about 20-30 amino acid residues and has at least about 60%, 70% 80% 90% 95%, 99%, or 100% homology with an "extracellular loop," e.g., at least one extracellular loop of human 52906, 33408, or 12189 (e.g., residues 420-432, 499-523, and 598-640 of SEQ ID NO:2; residues 237-244, 310-319, and 369-446 of SEQ ID NO:5; and residues 153-199, 249-265, and 324-362 of SEQ ID NO:8).

In another embodiment, a 52906, 33408, or 12189 protein includes a "C-terminal cytoplasmic domain", also referred to herein as a C-terminal cytoplasmic tail, in the sequence of the protein. As used herein, a "C-terminal cytoplasmic domain" includes an amino acid sequence having a length of at least about 50, preferably about 500-550, preferably about 150-200, more preferably about 50-70 amino acid residues and is located within a cell or within the cytoplasm of a cell. Accordingly, the N-terminal amino acid residue of a "C-terminal cytoplasmic domain" is adjacent to a C-terminal

amino acid residue of a transmembrane domain in a 52906, 33408, or 12189 protein. For example, a C-terminal cytoplasmic domain is found at about amino acid residues 663-847 of SEQ ID NO:2; at about amino acid residues 472-988 of SEQ ID NO:5; and at about amino acid residues 385-446 of SEQ ID NO:8.

5 In a preferred embodiment, a 52906, 33408, or 12189 polypeptide or protein has a C-terminal cytoplasmic domain or a region which includes at least about 50, preferably about 150-550, more preferably about 50-70 amino acid residues and has at least about 60%, 70% 80% 90% 95%, 99%, or 100% homology with an "C-terminal cytoplasmic domain," e.g., the C-terminal cytoplasmic domain of human 52906, 33408, or 12189  
10 (e.g., residues 663-847 of SEQ ID NO:2; residues 472-988 of SEQ ID NO:5; and residues 385-446 of SEQ ID NO:8).

A 52906, 33408, or 12189 polypeptide can include an "ion transport protein domain" or regions homologous with an "ion transport protein domain."

15 As used herein, the term "ion transport protein domain" includes an amino acid sequence of about 100 to 300 amino acid residues in length and having a bit score for the alignment of the sequence to the ion transport protein domain profile (Pfam HMM) of at least 50. Preferably, a ion transport protein domain includes at least about 150 to 280 amino acids, more preferably about 170 to 260 amino acid residues, or about 180 to 230 amino acids and has a bit score for the alignment of the sequence to the ion transport  
20 protein domain (HMM) of at least 90 or greater. The ion transport protein domain (HMM) has been assigned the PFAM Accession Number PF00520  
(<http://genome.wustl.edu/Pfam/.html>). An alignment of the ion transport protein domain (amino acids 472-661 of SEQ ID NO:2) of human 52906 with a consensus amino acid sequence (SEQ ID NO:9) derived from a hidden Markov model is depicted in Figure 2.  
25 An alignment of the ion transport protein domain (amino acids 247-467 of SEQ ID NO:5) of human 33408 with a consensus amino acid sequence (SEQ ID NO:9) derived from a hidden Markov model is depicted in Figure 4A. An alignment of the ion transport protein domain (amino acids 198-383 of SEQ ID NO:8) of human 12189 with a consensus amino acid sequence (SEQ ID NO:9) derived from a hidden Markov model is depicted in Figure  
30 6B.

In a preferred embodiment, a 52906, 33408, or 12189 polypeptide or protein has an "ion transport protein domain" or a region which includes at least about 150 to 280 more preferably about 170 to 260 or 180 to 230 amino acid residues and has at least about 50%, 60%, 70% 80% 90% 95%, 99%, or 100% homology with a "ion transport protein domain," e.g., the ion transport protein domain of human 52906, 33408, or 12189 (e.g., residues 472-661 of SEQ ID NO:2, 247-467 of SEQ ID NO:5, or 198-383 of SEQ ID NO:8).

A 33408 molecule can further include a cyclic nucleotide binding domain or regions homologous with a "cyclic nucleotide binding domain."

As used herein, the term "cyclic nucleotide binding domain" includes an amino acid sequence of about 40-180 amino acid residues in length and having a bit score for the alignment of the sequence to the cyclic nucleotide binding domain (HMM) of at least 50. Preferably, a cyclic nucleotide binding domain is capable of binding a cyclic nucleotide. Preferably, a cyclic nucleotide binding domain includes at least about 50-150 amino acids, more preferably about 70-120 amino acid residues, or about 80-100 amino acids and has a bit score for the alignment of the sequence to the cyclic nucleotide binding domain (HMM) of at least 80 or greater. The cyclic nucleotide binding domain (HMM) has been assigned the PFAM Accession PF00027 (<http://genome.wustl.edu/Pfam/html>). An alignment of the cyclic nucleotide binding domain (amino acids 565 to 655 of SEQ ID NO:5) of human 33408 with a consensus amino acid sequence (SEQ ID NO:10) derived from a hidden Markov model is depicted in Figure 4B.

In a preferred embodiment a 33408 polypeptide or protein has a "cyclic nucleotide binding domain" or a region which includes at least about 50-150, more preferably about 70-120 or 80-100 amino acid residues and has at least about 50%, 60%, 70% 80% 90% 95%, 99%, or 100% homology with a "cyclic nucleotide binding domain," e.g., the cyclic nucleotide binding domain of human 33408 (e.g., residues 565 to 655 of SEQ ID NO:5).

A 12189 polypeptide can further include a "potassium channel tetramerisation domain" or regions homologous with a "potassium channel tetramerisation domain."

As used herein, the term "potassium channel tetramerisation domain" includes an amino acid sequence of about 50 to 200 amino acid residues in length and having a bit

score for the alignment of the sequence to the potassium channel tetramerisation domain profile (Pfam HMM) of at least 100. A “potassium channel tetramerisation domain” promotes the assembly of alpha-subunits into functional tetrameric channels. Preferably, a potassium channel tetramerisation domain includes at least about 60 to 150 amino acids, more preferably about 70 to 130 amino acid residues, or about 90 to 110 amino acids and has a bit score for the alignment of the sequence to the potassium channel tetramerisation domain (HMM) of at least 165 or greater. The potassium channel tetramerisation domain (HMM) has been assigned the PFAM Accession Number PF02214 (<http://genome.wustl.edu/Pfam/.html>). An alignment of the potassium channel tetramerisation domain (amino acids 3-101 of SEQ ID NO:8) of human 12189 with a consensus amino acid sequence (SEQ ID NO:11) derived from a hidden Markov model is depicted in Figure 6A.

In a preferred embodiment, a 12189 polypeptide or protein has a “potassium channel tetramerisation domain” or a region which includes at least about 60 to 150 more preferably about 70 to 130 or 90 to 110 amino acid residues and has at least about 50%, 60%, 70% 80% 90% 95%, 99%, or 100% homology with a “potassium channel tetramerisation domain,” e.g., the potassium channel tetramerisation domain of human 12189 (e.g., residues 3-101 of SEQ ID NO:8).

To identify the presence of an “ion transport protein” domain, a “cyclic nucleotide-binding” domain, or a “potassium channel tetramerisation” domain in a 52906, 33408, or 12189 protein sequence, and make the determination that a polypeptide or protein of interest has a particular profile, the amino acid sequence of the protein can be searched against the Pfam database of HMMs (e.g., the Pfam database, release 2.1) using the default parameters ([http://www.sanger.ac.uk/Software/Pfam/HMM\\_search](http://www.sanger.ac.uk/Software/Pfam/HMM_search)).

For example, the hmmsf program, which is available as part of the HMMER package of search programs, is a family specific default program for MILPAT0063 and a score of 15 is the default threshold score for determining a hit. Alternatively, the threshold score for determining a hit can be lowered (e.g., to 8 bits). A description of the Pfam database can be found in Sonhammer *et al.* (1997) *Proteins* 28(3):405-420 and a detailed description of HMMs can be found, for example, in Gribskov *et al.* (1990) *Meth. Enzymol.* 183:146-159; Gribskov *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:4355-4358; Krogh *et al.* (1994)

*J. Mol. Biol.* 235:1501-1531; and Stultz *et al.*(1993) *Protein Sci.* 2:305-314, the contents of which are incorporated herein by reference.

5 A 33408 polypeptide can further include a "PAS domain" or regions homologous with a "PAS domain". As used herein, a "PAS domain" includes an amino acid sequence of about 100-200 amino acid residues in length that is involved in ligand and/or protein-protein interactions. Preferably, the PAS domain interacts with the body of the channel, affecting gating, inactivation, and/or voltage sensitivity. Preferably, the PAS domain is located at the N-terminal cytoplasmic region of the 33408 polypeptide.

10 In a preferred embodiment, a 33408 polypeptide or protein has a "PAS domain" or a region which includes at least about 50-220, more preferably about 100-200 or 120-140 amino acid residues and has at least about 50%, 60%, 70% 80% 90% 95%, 99%, or 100% homology with a "PAS domain," e.g., the PAS domain of human 33408 (e.g., residues 1-134 of SEQ ID NO:5).

15 A 33408 polypeptide can further include a "PAC domain" or regions homologous with a "PAC domain". As used herein, a "PAC domain" includes an amino acid sequence of about 30-50 amino acid residues in length. Preferably, the PAC domain contributes to the folding of the PAS domain. Preferably, the PAC domain is located at the C-terminal end of the PAS domain in a 33408 polypeptide.

20 In a preferred embodiment, a 33408 polypeptide or protein has a "PAC domain" or a region which includes at least about 20-70 or 30-50 amino acid residues and has at least about 50%, 60%, 70% 80% 90% 95%, 99%, or 100% homology with a "PAC domain," e.g., the PAC domain of human 33408 (e.g., residues 92-132 of SEQ ID NO:5).

25 A 52906 family member can include at least one (preferably two, three, four, five, or six) transmembrane domain, at least one (preferably two or three) cytoplasmic domain, at least one (preferably two or three) extracellular domain, at least one P-loop domain, and at least one ion transport protein domain. Furthermore, a 52906, 33408, or 12189 family member can include: at least one, two, three, four, five, and preferably six predicted N-glycosylation sites (PS00001); at least one predicted glycosaminoglycan attachment site (PS00002); at least one, two, three, and preferably four predicted cAMP-30 and cGMP-dependent protein kinase phosphorylation sites (PS00004); at least one, two, three, four, five, six, seven, eight, nine, 10, 11, 12, and preferably 13 predicted Protein

Kinase C phosphorylation sites (PS00005); at least one, two, three, four, five, six, and preferably seven predicted Casein Kinase II phosphorylation sites (PS00006); at least one, two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, and preferably 15 predicted N-myristoylation sites (PS00008); and at least one predicted coiled coil

5 domain.

A 33408 family member can include at least one (preferably two, three, four, five, or six) transmembrane domain, at least one (preferably two or three) cytoplasmic domain, at least one (preferably two or three) extracellular domain, at least one P-loop domain, and at least one ion transport protein domain. A 33408 family member can further

10 include a cyclic nucleotide-binding domain. A 33408 family member can further include a PAS domain and a PAC domain. Furthermore, a 33408 family member can include: at least one, two, three, four, five, six, and preferably seven predicted N-glycosylation sites (PS00001); at least one and preferably two predicted cAMP- and cGMP-dependent protein kinase phosphorylation sites (PS00004); at least one, two, three, four, five, six,

15 seven, eight, nine, 10, 11, 12, and preferably 13 predicted Protein Kinase C phosphorylation sites (PS00005); at least one, two, three, four, five, six, seven, eight, nine, 10, 11, 12, 13, 14, 15, and preferably 16 predicted Casein Kinase II phosphorylation sites (PS00006); at least one, two, three, four, five, six, seven, and preferably eight predicted N-myristoylation sites (PS00008); at least one predicted amidation site

20 (PS00009); at least one predicted leucine zipper pattern (PS00029); and at least one predicted coiled coil domain.

A 12189 family member can include at least one (preferably two, three, four, five, or six) transmembrane domain, at least one (preferably two or three) cytoplasmic domain, at least one (preferably two or three) extracellular domain, at least one P-loop domain, and at least one ion transport protein domain. A 12189 family member can further

25 include a potassium channel tetramerisation domain. Furthermore, a 12189 family member can include: at least one and preferably two predicted N-glycosylation sites (PS00001); at least one and preferably two predicted Protein Kinase C phosphorylation sites (PS00005); at least one, two, three, four, and preferably five predicted Casein Kinase II phosphorylation sites (PS00006); at least one predicted tyrosine kinase phosphorylation site (PS00007); at least one, two, three, four, and preferably five

predicted N-myristoylation sites (PS00008); and at least one predicted leucine zipper pattern (PS00029).

As the 52906, 33408, or 12189 polypeptides of the invention may modulate 52906, 33408, or 12189-mediated activities, e.g., potassium channel mediated activities, 5 they may be useful as of for developing novel diagnostic and therapeutic agents for 52906, 33408, or 12189-mediated or related disorders, e.g., potassium channel associated disorders, as described below.

As used herein, a "52906, 33408, or 12189 activity", "biological activity of 52906, 33408, or 12189" or "functional activity of 52906, 33408, or 12189", refers to an 10 activity exerted by a 52906, 33408, or 12189 protein, polypeptide or nucleic acid molecule. For example, a 52906, 33408, or 12189 activity can be an activity exerted by 52906, 33408, or 12189 in a physiological milieu on, e.g., a 52906, 33408, or 12189- responsive cell or on a 52906, 33408, or 12189 substrate, e.g., a protein substrate. A 52906, 33408, or 12189 activity can be determined *in vivo* or *in vitro*. In one 15 embodiment, a 52906, 33408, or 12189 activity is a direct activity, such as an association with a 52906, 33408, or 12189 target molecule. A "target molecule" or "binding partner" is a molecule with which a 52906, 33408, or 12189 protein binds or interacts in nature. In an exemplary embodiment, 52906, 33408, or 12189 is an ion channel, e.g., a potassium channel.

20 A 52906, 33408, or 12189 activity can also be an indirect activity, e.g., a cellular signaling activity mediated by interaction of the 52906, 33408, or 12189 protein with a 52906, 33408, or 12189 ligand, e.g., a potassium ion. The features of the 52906, 33408, or 12189 molecules of the present invention can provide similar biological activities as potassium channel family members. For example, the 52906, 33408, or 12189 proteins 25 of the present invention can have one or more of the following activities: (1) interacting with a non-52906, 33408, or 12189 protein molecule; (2) activating a 52906, 33408, or 12189-dependent signal transduction pathway; (3) modulating the release of neurotransmitters; (4) modulating membrane excitability; (5) influencing the resting potential of membranes, wave forms and frequencies of action potentials, and thresholds 30 of excitation; (6) binding a cyclic nucleotide; (7) contributing to the formation of potassium channels; (8) contributing to the formation of calcium-activated, voltage

independent potassium channels; (9) modulating repolarization of the neuronal cell membrane; (10) contributing to the formation of voltage-gated potassium channels; (11) contributing to the formation of cyclic nucleotide-gated potassium channels; (12) modulating the flow of  $K^+$  ions through a cell membrane; and (13) modulating processes 5 which underlie learning and memory, such as integration of sub-threshold synaptic responses and the conductance of back-propagating action potentials.

Based on the above-described sequence similarities, the 52906, 33408, or 12189 molecules of the present invention are predicted to have similar biological activities as potassium channel family members. In addition, 52906 and 33408 mRNA was found to 10 be highly expressed in cells derived from brain and heart (see Tables 3 and 4). Thus, the 52906, 33408, or 12189 molecules can act as novel diagnostic targets and therapeutic agents for controlling potassium channel associated disorders. Examples of such disorders include neurological disorders and cardiac-related disorders.

As used herein, a "potassium channel associated disorder" includes a disorder, 15 disease or condition which is characterized by a misregulation of a potassium channel mediated activity. Potassium channel associated disorders can detrimentally affect conveyance of sensory impulses from the periphery to the brain and/or conductance of motor impulses from the brain to the periphery; integration of reflexes; interpretation of sensory impulses; cellular proliferation, growth, differentiation, or migration, and 20 emotional, intellectual (*e.g.*, learning and memory), or motor processes. Examples of potassium channel associated disorders include CNS disorders such as cognitive and neurodegenerative disorders, examples of which include, but are not limited to, Alzheimer's disease, dementias related to Alzheimer's disease (such as Pick's disease), Parkinson's and other Lewy diffuse body diseases, senile dementia, Huntington's disease, 25 Gilles de la Tourette's syndrome, multiple sclerosis, amyotrophic lateral sclerosis, progressive supranuclear palsy, epilepsy, and Jakob-Creutzfieldt disease; autonomic function disorders such as hypertension and sleep disorders, and neuropsychiatric disorders, such as depression, schizophrenia, schizoaffective disorder, korsakoff's psychosis, mania, anxiety disorders, or phobic disorders; learning or memory disorders, 30 *e.g.*, amnesia or age-related memory loss, attention deficit disorder, dysthymic disorder, major depressive disorder, mania, obsessive-compulsive disorder, psychoactive substance

use disorders, anxiety, phobias, panic disorder, as well as bipolar affective disorder, *e.g.*, severe bipolar affective (mood) disorder (BP-1), and bipolar affective neurological disorders, *e.g.*, migraine and obesity. Further CNS-related disorders include, for example, those listed in the American Psychiatric Association's Diagnostic and Statistical 5 manual of Mental Disorders (DSM), the most current version of which is incorporated herein by reference in its entirety.

Further examples of potassium channel associated disorders include cardiac-related disorders. Cardiovascular system disorders in which the 52906, 33408, or 12189 molecules of the invention may be directly or indirectly involved include arteriosclerosis, 10 ischemia reperfusion injury, restenosis, arterial inflammation, vascular wall remodeling, ventricular remodeling, rapid ventricular pacing, coronary microembolism, tachycardia, bradycardia, pressure overload, aortic bending, coronary artery ligation, vascular heart disease, atrial fibrillation, Jervell syndrome, Lange-Nielsen syndrome, long-QT syndrome, congestive heart failure, sinus node dysfunction, angina, heart failure, 15 hypertension, atrial fibrillation, atrial flutter, dilated cardiomyopathy, idiopathic cardiomyopathy, myocardial infarction, coronary artery disease, coronary artery spasm, and arrhythmia. 52906, 33408, or 12189-mediated or related disorders also include disorders of the musculoskeletal system such as paralysis and muscle weakness, *e.g.*, ataxia, myotonia, and myokymia.

20 As used herein, a "potassium channel mediated activity" includes an activity which involves a potassium channel, *e.g.*, a potassium channel in a neuronal cell, a muscle cell, or a thymus cell associated with receiving, conducting, and transmitting signals in, for example, the nervous system. Potassium channel mediated activities include release of neurotransmitters, *e.g.*, dopamine or norepinephrine, from cells, *e.g.*, 25 neuronal cells; modulation of resting potential of membranes, wave forms and frequencies of action potentials, and thresholds of excitation; participation in signal transduction pathways, and modulation of processes such as integration of sub-threshold synaptic responses and the conductance of back-propagating action potentials in, for example, neuronal cells or muscle cells.

30 The presence of 52906, 33408, or 12189 RNA or protein can be used to identify a cell or tissue, or other biological sample, as being derived from the brain, *e.g.*, cerebral

cortex, from the heart, from a muscle, or of neuronal origin. Expression can be determined by evaluating RNA, e.g., by hybridization of a 52906, 33408, or 12189 specific probe, or with a 52906, 33408, or 12189 specific antibody.

The 52906, 33408, or 12189 protein, fragments thereof, and derivatives and other variants of the sequence in SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8 thereof are collectively referred to as "polypeptides or proteins of the invention" or "52906, 33408, or 12189 polypeptides or proteins". Nucleic acid molecules encoding such polypeptides or proteins are collectively referred to as "nucleic acids of the invention" or "52906, 33408, or 12189 nucleic acids." 52906, 33408, or 12189 molecules refer to 52906, 33408, or 12189 nucleic acids, polypeptides, and antibodies.

As used herein, the term "nucleic acid molecule" includes DNA molecules (e.g., a cDNA or genomic DNA), RNA molecules (e.g., an mRNA) and analogs of the DNA or RNA. A DNA or RNA analog can be synthesized from nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

The term "isolated nucleic acid molecule" or "purified nucleic acid molecule" includes nucleic acid molecules that are separated from other nucleic acid molecules present in the natural source of the nucleic acid. For example, with regards to genomic DNA, the term "isolated" includes nucleic acid molecules which are separated from the chromosome with which the genomic DNA is naturally associated. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and/or 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of 5' and/or 3' nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

As used herein, the term "hybridizes under low stringency, medium stringency, high stringency, or very high stringency conditions" describes conditions for hybridization and washing. Guidance for performing hybridization reactions can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 5 6.3.1-6.3.6, which is incorporated by reference. Aqueous and nonaqueous methods are described in that reference and either can be used. Specific hybridization conditions referred to herein are as follows: 1) low stringency hybridization conditions in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by two washes in 0.2X SSC, 0.1% SDS at least at 50°C (the temperature of the washes can be increased to 55°C 10 for low stringency conditions); 2) medium stringency hybridization conditions in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 60°C; 3) high stringency hybridization conditions in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C; and preferably 4) very high stringency 15 hybridization conditions are 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65°C. Very high stringency conditions (4) are the preferred conditions and the ones that should be used unless otherwise specified.

Preferably, an isolated nucleic acid molecule of the invention that hybridizes under a stringency condition described herein to the sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7, corresponds to a naturally- 20 occurring nucleic acid molecule.

As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature. For example a naturally occurring nucleic acid molecule can encode a natural protein.

As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules 25 which include at least an open reading frame encoding a 52906, 33408, or 12189 protein. The gene can optionally further include non-coding sequences, e.g., regulatory sequences and introns. Preferably, a gene encodes a mammalian 52906, 33408, or 12189 protein or derivative thereof.

An "isolated" or "purified" polypeptide or protein is substantially free of cellular 30 material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free from chemical precursors or other chemicals when

chemically synthesized. "Substantially free" means that a preparation of 52906, 33408, or 12189 protein is at least 10% pure. In a preferred embodiment, the preparation of 52906, 33408, or 12189 protein has less than about 30%, 20%, 10% and more preferably 5% (by dry weight), of non-52906, 33408, or 12189 protein (also referred to herein as a "contaminating protein"), or of chemical precursors or non-52906, 33408, or 12189 chemicals. When the 52906, 33408, or 12189 protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation. The invention includes isolated or purified preparations of at least 0.01, 0.1, 1.0, and 10 milligrams in dry weight.

A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of 52906, 33408, or 12189 without abolishing or substantially altering a 52906, 33408, or 12189 activity. Preferably the alteration does not substantially alter the 52906, 33408, or 12189 activity, e.g., the activity is at least 20%, 40%, 60%, 70% or 80% of wild-type. An "essential" amino acid residue is a residue that, when altered from the wild-type sequence of 52906, 33408, or 12189, results in abolishing a 52906, 33408, or 12189 activity such that less than 20% of the wild-type activity is present. For example, conserved amino acid residues in 52906, 33408, or 12189 are predicted to be particularly unamenable to alteration.

A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a 52906, 33408, or 12189 protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment,

mutations can be introduced randomly along all or part of a 52906, 33408, or 12189 coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for 52906, 33408, or 12189 biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ 5 ID NO:6, or SEQ ID NO:7, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

As used herein, a "biologically active portion" of a 52906, 33408, or 12189 protein includes a fragment of a 52906, 33408, or 12189 protein which participates in an interaction, e.g., an intramolecular or an inter-molecular interaction. An inter-molecular 10 interaction can be a specific binding interaction or an enzymatic interaction (e.g., the interaction can be transient and a covalent bond is formed or broken). An inter-molecular interaction can be between a 52906, 33408, or 12189 molecule and a non-52906, 33408, or 12189 molecule or between a first 52906, 33408, or 12189 molecule and a second 52906, 33408, or 12189 molecule (e.g., a dimerization interaction). Biologically active 15 portions of a 52906, 33408, or 12189 protein include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequence of the 52906, 33408, or 12189 protein, e.g., the amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8, which include less amino acids than the full length 52906, 33408, or 12189 proteins, and exhibit at least one activity of a 52906, 33408, or 20 12189 protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the 52906, 33408, or 12189 protein, e.g., the ability to modulate the flow of K<sup>+</sup> ions through a cell membrane and/or the ability to modulate the transmission of signals in an electrically excitable cell, e.g., a neuronal cell or a muscle cell. A biologically active portion of a 52906, 33408, or 12189 protein can be a polypeptide 25 which is, for example, 10, 25, 50, 100, 200 or more amino acids in length. Biologically active portions of a 52906, 33408, or 12189 protein can be used as targets for developing agents which modulate a 52906, 33408, or 12189 mediated activity, e.g., the ability to modulate the flow of K<sup>+</sup> ions through a cell membrane and/or the ability to modulate the transmission of signals in an electrically excitable cell, e.g., a neuronal cell or a muscle 30 cell.

Calculations of homology or sequence identity between sequences (the terms are used interchangeably herein) are performed as follows.

To determine the percent identity of two amino acid sequences, or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps 5 can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length 10 of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid 15 or nucleic acid "homology").

The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

20 The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) *J. Mol. Biol.* 48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package (available at 25 <http://www.gcg.com>), using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at 30 <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used unless otherwise specified) are a Blossum 62

scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.

5 The percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

10 The nucleic acid and protein sequences described herein can be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to 52906, 33408, or 12189 nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid 15 sequences homologous to 52906, 33408, or 12189 protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, (1997) *Nucleic Acids Res.* 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See <http://www.ncbi.nlm.nih.gov>.

20 Particularly preferred 52906, 33408, or 12189 polypeptides of the present invention have an amino acid sequence substantially identical to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8. In the context of an amino acid sequence, the term "substantially identical" is used herein to refer to a first amino acid that contains a sufficient or minimum number of amino acid residues that are i) identical to, or ii) conservative substitutions of aligned amino acid residues in a second amino acid sequence such that the first and second amino acid sequences can have a common structural domain and/or common functional activity. For example, amino acid sequences that contain a common structural domain having at least about 60%, or 65% identity, likely 75% identity, more likely 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 25 97%, 98% or 99% identity to SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8 are termed 30 substantially identical.

In the context of nucleotide sequence, the term "substantially identical" is used herein to refer to a first nucleic acid sequence that contains a sufficient or minimum number of nucleotides that are identical to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having

5 common functional activity, or encode a common structural polypeptide domain or a common functional polypeptide activity. For example, nucleotide sequences having at least about 60%, or 65% identity, likely 75% identity, more likely 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7 are termed substantially identical.

10 "Misexpression or aberrant expression", as used herein, refers to a non-wildtype pattern of gene expression at the RNA or protein level. It includes: expression at non-wild type levels, i.e., over- or under-expression; a pattern of expression that differs from wild type in terms of the time or stage at which the gene is expressed, e.g., increased or decreased expression (as compared with wild type) at a predetermined developmental

15 period or stage; a pattern of expression that differs from wild type in terms of altered, e.g., increased or decreased, expression (as compared with wild type) in a predetermined cell type or tissue type; a pattern of expression that differs from wild type in terms of the splicing size, translated amino acid sequence, post-transitional modification, or biological activity of the expressed polypeptide; a pattern of expression that differs from wild type

20 in terms of the effect of an environmental stimulus or extracellular stimulus on expression of the gene, e.g., a pattern of increased or decreased expression (as compared with wild type) in the presence of an increase or decrease in the strength of the stimulus.

"Subject," as used herein, refers to human and non-human animals. The term "non-human animals" of the invention includes all vertebrates, e.g., mammals, such as

25 non-human primates (particularly higher primates), sheep, dog, rodent (e.g., mouse or rat), guinea pig, goat, pig, cat, rabbits, cow, and non-mammals, such as chickens, amphibians, reptiles, etc. In a preferred embodiment, the subject is a human. In another embodiment, the subject is an experimental animal or animal suitable as a disease model.

A "purified preparation of cells", as used herein, refers to an in vitro preparation of cells. In the case cells from multicellular organisms (e.g., plants and animals), a purified preparation of cells is a subset of cells obtained from the organism, not the entire

intact organism. In the case of unicellular microorganisms (e.g., cultured cells and microbial cells), it consists of a preparation of at least 10% and more preferably 50% of the subject cells.

Various aspects of the invention are described in further detail below.

5 **Isolated Nucleic Acid Molecules**

In one aspect, the invention provides, an isolated or purified, nucleic acid molecule that encodes a 52906, 33408, or 12189 polypeptide described herein, e.g., a full-length 52906, 33408, or 12189 protein or a fragment thereof, e.g., a biologically active portion of 52906, 33408, or 12189 protein. Also included is a nucleic acid 10 fragment suitable for use as a hybridization probe, which can be used, e.g., to identify a nucleic acid molecule encoding a polypeptide of the invention, 52906, 33408, or 12189 mRNA, and fragments suitable for use as primers, e.g., PCR primers for the amplification or mutation of nucleic acid molecules.

In one embodiment, an isolated nucleic acid molecule of the invention includes 15 the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:4, or SEQ ID NO:7, or a portion of any of these nucleotide sequences. In one embodiment, the nucleic acid molecule includes sequences encoding the human 52906, 33408, or 12189 protein (i.e., "the coding region" of SEQ ID NO:1, as shown in SEQ ID NO:3 or "the coding region" of SEQ ID NO:4, as shown in SEQ ID NO:6), as well as 5' untranslated sequences. 20 Alternatively, the nucleic acid molecule can include only the coding region of SEQ ID NO:1, SEQ ID NO:4, or SEQ ID NO:7 (e.g., SEQ ID NO:3 or SEQ ID NO:6) and, e.g., no flanking sequences which normally accompany the subject sequence. In another embodiment, the nucleic acid molecule encodes a sequence corresponding to a fragment of the protein from about amino acids 472-661 of SEQ ID NO:2, amino acids 247-467 of 25 SEQ ID NO:5, amino acids 565-655 of SEQ ID NO:5, amino acids 3-101 of SEQ ID NO:8, or amino acids 198-383 of SEQ ID NO:8.

In another embodiment, an isolated nucleic acid molecule of the invention includes a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7, 30 or a portion of any of these nucleotide sequences. In other embodiments, the nucleic acid

molecule of the invention is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7, such that it can hybridize (e.g., under a stringency condition described herein) to the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7, thereby forming a stable duplex.

5 In one embodiment, an isolated nucleic acid molecule of the present invention includes a nucleotide sequence which is at least about: 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to the entire length of the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ  
10 ID NO:4, SEQ ID NO:6, or SEQ ID NO:7, or a portion, preferably of the same length, of any of these nucleotide sequences.

#### 52906, 33408, or 12189 Nucleic Acid Fragments

A nucleic acid molecule of the invention can include only a portion of the nucleic acid sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID  
15 NO:7. For example, such a nucleic acid molecule can include a fragment which can be used as a probe or primer or a fragment encoding a portion of a 52906, 33408, or 12189 protein, e.g., an immunogenic or biologically active portion of a 52906, 33408, or 12189 protein. A fragment can comprise those nucleotides of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7, which encode an ion transport protein  
20 domain of human 52906, 33408, or 12189. The nucleotide sequence determined from the cloning of the 52906, 33408, or 12189 gene allows for the generation of probes and primers designed for use in identifying and/or cloning other 52906, 33408, or 12189 family members, or fragments thereof, as well as 52906, 33408, or 12189 homologues, or fragments thereof, from other species.

25 In another embodiment, a nucleic acid includes a nucleotide sequence that includes part, or all, of the coding region and extends into either (or both) the 5' or 3' noncoding region. Other embodiments include a fragment which includes a nucleotide sequence encoding an amino acid fragment described herein. Nucleic acid fragments can encode a specific domain or site described herein (e.g., an ion transport protein domain, a cyclic  
30 nucleotide-binding domain, a potassium channel tetramerisation domain, a

transmembrane domain, a cytoplasmic domain, an extracellular domain, a Pore-loop domain, or a PAS domain) or fragments thereof, particularly fragments thereof which are at least 100, 200, 300, 400, or 500 amino acids in length. Fragments also include nucleic acid sequences corresponding to specific amino acid sequences described above or fragments thereof. Nucleic acid fragments should not to be construed as encompassing those fragments that may have been disclosed prior to the invention.

5 A nucleic acid fragment can include a sequence corresponding to a domain, region, or functional site described herein. A nucleic acid fragment can also include one or more domain, region, or functional site described herein. Thus, for example, a 52906, 33408, or 10 12189 nucleic acid fragment can include a sequence corresponding to an ion transport protein domain, a cyclic nucleotide-binding domain, a potassium channel tetramerisation domain, a transmembrane domain, a cytoplasmic domain, an extracellular domain, a Pore-loop domain, or a PAS domain.

15 52906, 33408, or 12189 probes and primers are provided. Typically a probe/primer is an isolated or purified oligonucleotide. The oligonucleotide typically includes a region of nucleotide sequence that hybridizes under a stringency condition described herein to at least about 7, 12 or 15, preferably about 20 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 consecutive nucleotides of a sense or antisense sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7, or of a naturally occurring allelic variant or mutant of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7.

20 25 In a preferred embodiment the nucleic acid is a probe which is at least 5 or 10, and less than 200, more preferably less than 100, or less than 50, base pairs in length. It should be identical, or differ by 1, or less than in 5 or 10 bases, from a sequence disclosed herein. If alignment is needed for this comparison the sequences should be aligned for maximum homology. "Looped" out sequences from deletions or insertions, or mismatches, are considered differences.

30 A probe or primer can be derived from the sense or anti-sense strand of a nucleic acid which encodes: an ion transport protein domain, a cyclic nucleotide-binding domain, a potassium channel tetramerisation domain, a transmembrane domain, a cytoplasmic domain, an extracellular domain, a Pore-loop domain, or a PAS domain.

The locations of these domains in SEQ ID NO:2, SEQ ID NO:5, and SEQ ID NO:8 are described in Table 2.

In another embodiment a set of primers is provided, e.g., primers suitable for use in a PCR, which can be used to amplify a selected region of a 52906, 33408, or 12189 sequence, e.g., a domain, region, site or other sequence described herein. The primers should be at least 5, 10, or 50 base pairs in length and less than 100, or less than 200, base pairs in length. The primers should be identical, or differs by one base from a sequence disclosed herein or from a naturally occurring variant. For example, primers suitable for amplifying all or a portion of any of the following regions are provided: an ion transport 10 protein domain, a cyclic nucleotide-binding domain, a potassium channel tetramerisation domain, a transmembrane domain, a cytoplasmic domain, an extracellular domain, a Pore-loop domain, or a PAS domain.

A nucleic acid fragment can encode an epitope bearing region of a polypeptide described herein.

15 A nucleic acid fragment encoding a "biologically active portion of a 52906, 33408, or 12189 polypeptide" can be prepared by isolating a portion of the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7, which encodes a polypeptide having a 52906, 33408, or 12189 biological activity (e.g., the biological activities of the 52906, 33408, or 12189 proteins are described herein), expressing the encoded portion of the 52906, 33408, or 12189 protein (e.g., by recombinant expression *in vitro*) and assessing the activity of the encoded portion of the 52906, 33408, or 12189 protein. For example, a nucleic acid fragment encoding a biologically active portion of 52906, 33408, or 12189 includes ion transport protein domain, e.g., amino acids 472-661 of SEQ ID NO:2, amino acids 247-467 of SEQ ID 20 NO:5, or amino acids 198-383 of SEQ ID NO:8. A nucleic acid fragment encoding a biologically active portion of a 52906, 33408, or 12189 polypeptide, may comprise a nucleotide sequence which is greater than 300 or more nucleotides in length.

25 In preferred embodiments, a nucleic acid includes a nucleotide sequence which is about 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 2000, 2500, 3000, 3300, 3400, 3500, or more nucleotides in length and hybridizes under a

stringency condition described herein to a nucleic acid molecule of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7.

In preferred embodiments, the fragment includes at least one, and preferably at least 5, 10, 15, 25, 50, 100, 200, 300, 400, or 500 nucleotides from nucleotides 1-2962, 5 3437-3525, 1-1441, 3182-3525, or 1-2687 of SEQ ID NO:1.

In preferred embodiments, the fragment includes at least one, and preferably at least 5, 10, 15, 25, 50, 75, 100, 200, 300, 500, 1000, or 1500 nucleotides encoding a protein including 5, 10, 15, 20, 25, 30, 40, 50, 100, 200, 300, 400, or 500 amino acids from amino acids 1-775, 1-268, 1-683 of SEQ ID NO:2.

10 In preferred embodiments, the nucleic acid fragment includes a nucleotide sequence that is other than the sequence of AA418096, V35457, Z51630, W63707, or W63702.

In preferred embodiments, the fragment comprises the coding region of 52906, e.g., the nucleotide sequence of SEQ ID NO:3.

15 In preferred embodiments, the fragment includes at least one, and preferably at least 5, 10, 15, 25, 50, 100, 200, 300, 400, or 500 nucleotides from nucleotides 1-1844, 1-277, 1-252, or 3245-3553, of SEQ ID NO:4.

20 In preferred embodiments, the fragment includes the nucleotide sequence of SEQ ID NO:6 and at least one, and preferably at least 5, 10, 15, 25, 50, 75, 100, 200, 300, or 500 nucleotides, e.g., consecutive nucleotides, of SEQ ID NO:4.

In preferred embodiments, the fragment includes at least one, and preferably at least 5, 10, 15, 25, 50, 75, 100, 200, 300, 500, 1000, or 1500 nucleotides encoding a protein including 5, 10, 15, 20, 25, 30, 40, 50, 100, 200, 300, 400, or 500 amino acids from amino acids 1-522 of SEQ ID NO:5.

25 In preferred embodiments, the nucleic acid fragment includes a nucleotide sequence that is other than the sequence of U69185 or a sequence described in WO01/04133 or WO01/29068.

In preferred embodiments, the fragment comprises the coding region of 33408, e.g., the nucleotide sequence of SEQ ID NO:6.

52906, 33408, or 12189 Nucleic Acid Variants

The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7. Such differences can be due to degeneracy of the genetic code 5 (and result in a nucleic acid which encodes the same 52906, 33408, or 12189 proteins as those encoded by the nucleotide sequence disclosed herein. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence which differs, by at least 1, but less than 5, 10, 20, 10 50, or 100 amino acid residues that shown in SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8. If alignment is needed for this comparison the sequences should be aligned for maximum homology. "Looped" out sequences from deletions or insertions, or mismatches, are considered differences.

Nucleic acids of the inventor can be chosen for having codons, which are preferred, or non-preferred, for a particular expression system. E.g., the nucleic acid can 15 be one in which at least one codon, at preferably at least 10%, or 20% of the codons has been altered such that the sequence is optimized for expression in *E. coli*, yeast, human, insect, or CHO cells.

Nucleic acid variants can be naturally occurring, such as allelic variants (same 20 locus), homologs (different locus), and orthologs (different organism) or can be non naturally occurring. Non-naturally occurring variants can be made by mutagenesis techniques, including those applied to polynucleotides, cells, or organisms. The variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions (as compared in the encoded 25 product).

In a preferred embodiment, the nucleic acid differs from that of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7, e.g., as follows: by at least one but less than 10, 20, 30, or 40 nucleotides; at least one but less than 1%, 5%, 10% or 20% of the nucleotides in the subject nucleic acid. If necessary for this analysis the sequences 30 should be aligned for maximum homology. "Looped" out sequences from deletions or insertions, or mismatches, are considered differences.

Orthologs, homologs, and allelic variants can be identified using methods known in the art. These variants comprise a nucleotide sequence encoding a polypeptide that is 50%, at least about 55%, typically at least about 70-75%, more typically at least about 80-85%, and most typically at least about 90-95% or more identical to the nucleotide sequence shown 5 in SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8 or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under a stringency condition described herein, to the nucleotide sequence shown in SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8 or a fragment of the sequence. Nucleic acid molecules corresponding to orthologs, homologs, and allelic variants of the 52906, 33408, or 12189 10 cDNAs of the invention can further be isolated by mapping to the same chromosome or locus as the 52906, 33408, or 12189 gene.

Preferred variants include those that are correlated with the ability to modulate the flow of K<sup>+</sup> ions through a cell membrane and/or the ability to modulate the transmission of signals in an electrically excitable cell, e.g., a neuronal cell or a muscle cell.

15 Allelic variants of 52906, 33408, or 12189, e.g., human 52906, 33408, or 12189, include both functional and non-functional proteins. Functional allelic variants are naturally occurring amino acid sequence variants of the 52906, 33408, or 12189 protein within a population that maintain the ability to modulate the flow of K<sup>+</sup> ions through a cell membrane and/or the ability to modulate the transmission of signals in an electrically 20 excitable cell, e.g., a neuronal cell or a muscle cell. Functional allelic variants will typically contain only conservative substitution of one or more amino acids of SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8, or substitution, deletion or insertion of non-critical residues in non-critical regions of the protein. Non-functional allelic variants are naturally-occurring amino acid sequence variants of the 52906, 33408, or 12189, e.g., 25 human 52906, 33408, or 12189, protein within a population that do not have the ability to modulate the flow of K<sup>+</sup> ions through a cell membrane and/or the ability to modulate the transmission of signals in an electrically excitable cell, e.g., a neuronal cell or a muscle cell. Non-functional allelic variants will typically contain a non-conservative substitution, a deletion, or insertion, or premature truncation of the amino acid sequence 30 of SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8, or a substitution, insertion, or deletion in critical residues or critical regions of the protein.

Moreover, nucleic acid molecules encoding other 52906, 33408, or 12189 family members and, thus, which have a nucleotide sequence which differs from the 52906, 33408, or 12189 sequences of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7 are intended to be within the scope of the invention.

5 Antisense Nucleic Acid Molecules, Ribozymes and Modified 52906, 33408, or 12189 Nucleic Acid Molecules

In another aspect, the invention features, an isolated nucleic acid molecule which is antisense to 52906, 33408, or 12189. An "antisense" nucleic acid can include a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a 10 protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. The antisense nucleic acid can be complementary to an entire 52906, 33408, or 12189 coding strand, or to only a portion thereof (e.g., the coding region of human 52906, 33408, or 12189 corresponding to SEQ ID NO:3 or SEQ ID NO:6). In another embodiment, the antisense nucleic acid molecule 15 is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding 52906, 33408, or 12189 (e.g., the 5' and 3' untranslated regions).

An antisense nucleic acid can be designed such that it is complementary to the entire coding region of 52906, 33408, or 12189 mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of 20 52906, 33408, or 12189 mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of 52906, 33408, or 12189 mRNA, e.g., between the -10 and +10 regions of the target gene nucleotide sequence of interest. An antisense oligonucleotide can be, for example, about 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, or more nucleotides in length.

25 An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical 30 stability of the duplex formed between the antisense and sense nucleic acids, e.g.,

phosphorothioate derivatives and acridine substituted nucleotides can be used. The antisense nucleic acid also can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject (e.g., by direct injection at a tissue site), or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a 52906, 33408, or 12189 protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an  $\alpha$ -anomeric nucleic acid molecule. An  $\alpha$ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett.* 215:327-330).

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. A ribozyme having specificity for a 52906, 33408, or 12189 -encoding nucleic acid can include one or more sequences complementary to the nucleotide sequence of a 52906, 33408, or 12189 cDNA disclosed herein (i.e., SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, or SEQ ID NO:7), and a sequence having known catalytic sequence responsible for mRNA cleavage (see U.S. Pat. No. 5,093,246 or Haselhoff and

Gerlach (1988) *Nature* 334:585-591). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a 52906, 33408, or 12189 - encoding mRNA. See, e.g., Cech *et al.* U.S. Patent No. 4,987,071; and Cech *et al.* U.S. 5 Patent No. 5,116,742. Alternatively, 52906, 33408, or 12189 mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-1418.

5 2906, 33408, or 12189 gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the 52906, 33408, or 12189 (e.g., 10 the 52906, 33408, or 12189 promoter and/or enhancers) to form triple helical structures that prevent transcription of the 52906, 33408, or 12189 gene in target cells. See generally, Helene, C. (1991) *Anticancer Drug Des.* 6:569-84; Helene, C. i (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioassays* 14:807-15. The potential sequences that can be targeted for triple helix formation can be increased by creating a 15 so-called "switchback" nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

20 The invention also provides detectably labeled oligonucleotide primer and probe molecules. Typically, such labels are chemiluminescent, fluorescent, radioactive, or colorimetric.

25 A 52906, 33408, or 12189 nucleic acid molecule can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For non-limiting examples of synthetic oligonucleotides with modifications see Toulmé (2001) *Nature Biotech.* 19:17 and Faria *et al.* (2001) *Nature Biotech.* 19:40-44. Such phosphoramidite oligonucleotides can be effective antisense agents.

30 For example, the deoxyribose phosphate backbone of the nucleic acid molecules can be modified to generate peptide nucleic acids (see Hyrup B. *et al.* (1996) *Bioorganic & Medicinal Chemistry* 4: 5-23). As used herein, the terms "peptide nucleic acid" or "PNA" refers to a nucleic acid mimic, e.g., a DNA mimic, in which the deoxyribose

phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of a PNA can allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup B. *et al.* (1996) *supra* and Perry-O'Keefe *et al.* *Proc. Natl. Acad. Sci.* 93: 14670-675.

PNAs of 52906, 33408, or 12189 nucleic acid molecules can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or 10 antigenic agents for sequence-specific modulation of gene expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNAs of 52906, 33408, or 12189 nucleic acid molecules can also be used in the analysis of single base pair mutations in a gene, (e.g., by PNA-directed PCR clamping); as 'artificial restriction enzymes' when used in combination with other enzymes, (e.g., S1 nucleases (Hyrup B. *et al.* (1996) *supra*)); or as probes or primers for DNA sequencing or hybridization (Hyrup B. *et al.* (1996) *supra*; Perry-O'Keefe *supra*).

In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86:6553-6556; Lemaitre *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84:648-652; 20 PCT Publication No. W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol *et al.* (1988) *Bio-Techniques* 6:958-976) or 25 intercalating agents. (see, e.g., Zon (1988) *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, (e.g., a peptide, hybridization-triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent).

The invention also includes molecular beacon oligonucleotide primer and probe molecules having at least one region which is complementary to a 52906, 33408, or 12189 nucleic acid of the invention, two complementary regions one having a fluorophore and one a quencher such that the molecular beacon is useful for quantitating 30 the presence of the 52906, 33408, or 12189 nucleic acid of the invention in a sample. Molecular beacon nucleic acids are described, for example, in Lizardi *et al.*, U.S. Patent

No. 5,854,033; Nazarenko *et al.*, U.S. Patent No. 5,866,336, and Livak *et al.*, U.S. Patent 5,876,930.

Isolated 52906, 33408, or 12189 Polypeptides

In another aspect, the invention features, an isolated 52906, 33408, or 12189 protein, or fragment, e.g., a biologically active portion, for use as immunogens or antigens to raise or test (or more generally to bind) anti-52906, 33408, or 12189 antibodies. 52906, 33408, or 12189 protein can be isolated from cells or tissue sources using standard protein purification techniques. 52906, 33408, or 12189 protein or fragments thereof can be produced by recombinant DNA techniques or synthesized chemically.

Polypeptides of the invention include those which arise as a result of the existence of multiple genes, alternative transcription events, alternative RNA splicing events, and alternative translational and post-translational events. The polypeptide can be expressed in systems, e.g., cultured cells, which result in substantially the same post-translational modifications present when expressed the polypeptide is expressed in a native cell, or in systems which result in the alteration or omission of post-translational modifications, e.g., glycosylation or cleavage, present when expressed in a native cell.

In a preferred embodiment, a 52906, 33408, or 12189 polypeptide has one or more of the following characteristics:

- 20 (i) it has the ability to modulate the flow of K<sup>+</sup> ions through a cell membrane, e.g., to allow for the flow of K<sup>+</sup> ions in and/or out of a cell under certain conditions;
- 15 (ii) it has the ability to modulate the transmission of signals in an electrically excitable cell, e.g., a neuronal cell or a muscle cell;
- 25 (iii) it has a molecular weight, e.g., a deduced molecular weight, preferably ignoring any contribution of post translational modifications, amino acid composition or other physical characteristic of a 52906, 33408, or 12189 polypeptide, e.g., a polypeptide of SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8;
- 30 (iv) it has an overall sequence similarity of at least 60%, more preferably at least 70, 80, 90, or 95%, with a polypeptide a of SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8;

(v) it can be found in neuronal cells or muscle cells (e.g., heart cells);  
(vi) it has the ability to modulate the resting potential of membranes;  
(vii) it has a P-loop domain which is preferably about 70%, 80%, 90% or 95% similar with amino acids 616-639 of SEQ ID NO:2, amino acids 420-440 of SEQ ID NO:5, or amino acids 339-355 of SEQ ID NO:8;  
5 (viii) it has an ion transport protein domain which is preferably about 70%, 80%, 90% or 95% similar with amino acids 472-661 of SEQ ID NO:2, amino acids 247-467 of SEQ ID NO:5, or amino acids 198-383 of SEQ ID NO:8;  
(ix) it has a cyclic nucleotide-binding domain which is preferably about 70%,  
10 80%, 90% or 95% similar with amino acids 565-655 of SEQ ID NO:5;  
(x) it has a potassium channel tetramerisation domain which is preferably about 70%, 80%, 90% or 95% similar with amino acids 3-101 of SEQ ID NO:8; or  
(xi) it has least 70%, preferably 80%, and most preferably 90% of the cysteines found amino acid sequence of the native protein.

15 In a preferred embodiment the 52906, 33408, or 12189 protein, or fragment thereof, differs from the corresponding sequence in SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8. In one embodiment it differs by at least one but by less than 15, 10 or 5 amino acid residues. In another it differs from the corresponding sequence in SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8 by at least one residue but less than 20%, 15%,  
20 10% or 5% of the residues in it differ from the corresponding sequence in SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8. (If this comparison requires alignment the sequences should be aligned for maximum homology. "Looped" out sequences from deletions or insertions, or mismatches, are considered differences.) The differences are, preferably, differences or changes at a non essential residue or a conservative substitution. In a  
25 preferred embodiment the differences are not in the ion transport protein domain. In another preferred embodiment one or more differences are in the ion transport protein domain.

Other embodiments include a protein that contain one or more changes in amino acid sequence, e.g., a change in an amino acid residue which is not essential for activity.  
30 Such 52906, 33408, or 12189 proteins differ in amino acid sequence from SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8, yet retain biological activity.

In one embodiment, the protein includes an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8.

A 52906 protein or fragment is provided which varies from the sequence of SEQ 5 ID NO:2 in regions defined by amino acids about 1-471 and/or 662-847 by at least one but by less than 15, 10 or 5 amino acid residues in the protein or fragment but which does not differ from SEQ ID NO:2 in regions defined by amino acids about 472-661. A 33408 protein or fragment is provided which varies from the sequence of SEQ ID NO:5 in regions defined by amino acids about 1-246 and/or 468-988 by at least one but by less 10 than 15, 10 or 5 amino acid residues in the protein or fragment but which does not differ from SEQ ID NO:2 in regions defined by amino acids about 247-467. A 12189 protein or fragment is provided which varies from the sequence of SEQ ID NO:8 in regions defined by amino acids about 1-197 and/or 384-446 by at least one but by less than 15, 10 or 5 amino acid residues in the protein or fragment but which does not differ from SEQ 15 ID NO:2 in regions defined by amino acids about 198-383. (If this comparison requires alignment the sequences should be aligned for maximum homology. "Looped" out sequences from deletions or insertions, or mismatches, are considered differences.) In some embodiments the difference is at a non-essential residue or is a conservative substitution, while in others the difference is at an essential residue or is a non-conservative 20 substitution.

In one embodiment, a biologically active portion of a 52906, 33408, or 12189 protein includes an ion transport protein domain, a cyclic nucleotide-binding domain, a potassium channel tetramerisation domain, a transmembrane domain, a cytoplasmic domain, an extracellular domain, a Pore-loop domain, or a PAS domain. Moreover, other 25 biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native 52906, 33408, or 12189 protein.

In a preferred embodiment, the 52906, 33408, or 12189 protein has an amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8. In other 30 embodiments, the 52906, 33408, or 12189 protein is substantially identical to SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8. In yet another embodiment, the 52906, 33408, or

12189 protein is substantially identical to SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8 and retains the functional activity of the protein of SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8, as described in detail in the subsections above.

52906, 33408, or 12189 Chimeric or Fusion Proteins

5 In another aspect, the invention provides 52906, 33408, or 12189 chimeric or fusion proteins. As used herein, a 52906, 33408, or 12189 "chimeric protein" or "fusion protein" includes a 52906, 33408, or 12189 polypeptide linked to a non-52906, 33408, or 12189 polypeptide. A "non-52906, 33408, or 12189 polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially 10 homologous to the 52906, 33408, or 12189 protein, e.g., a protein which is different from the 52906, 33408, or 12189 protein and which is derived from the same or a different organism. The 52906, 33408, or 12189 polypeptide of the fusion protein can correspond to all or a portion e.g., a fragment described herein of a 52906, 33408, or 12189 amino acid sequence. In a preferred embodiment, a 52906, 33408, or 12189 fusion protein 15 includes at least one (or two) biologically active portion of a 52906, 33408, or 12189 protein. The non-52906, 33408, or 12189 polypeptide can be fused to the N-terminus or C-terminus of the 52906, 33408, or 12189 polypeptide.

The fusion protein can include a moiety which has a high affinity for a ligand. For example, the fusion protein can be a GST-52906, 33408, or 12189 fusion protein in 20 which the 52906, 33408, or 12189 sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant 52906, 33408, or 12189. Alternatively, the fusion protein can be a 52906, 33408, or 12189 protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of 52906, 33408, or 12189 can 25 be increased through use of a heterologous signal sequence.

Fusion proteins can include all or a part of a serum protein, e.g., an IgG constant region, or human serum albumin.

The 52906, 33408, or 12189 fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject *in vivo*. The 52906, 30 33408, or 12189 fusion proteins can be used to affect the bioavailability of a 52906,

33408, or 12189 substrate. 52906, 33408, or 12189 fusion proteins may be useful therapeutically for the treatment of disorders caused by, for example, (i) aberrant modification or mutation of a gene encoding a 52906, 33408, or 12189 protein; (ii) mis-regulation of the 52906, 33408, or 12189 gene; and (iii) aberrant post-translational 5 modification of a 52906, 33408, or 12189 protein.

Moreover, the 52906, 33408, or 12189 -fusion proteins of the invention can be used as immunogens to produce anti-52906, 33408, or 12189 antibodies in a subject, to purify 52906, 33408, or 12189 ligands and in screening assays to identify molecules which inhibit the interaction of 52906, 33408, or 12189 with a 52906, 33408, or 12189 10 substrate.

Expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A 52906, 33408, or 12189 -encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the 52906, 33408, or 12189 protein.

## 15 Variants of 52906, 33408, or 12189 Proteins

In another aspect, the invention also features a variant of a 52906, 33408, or 12189 polypeptide, e.g., which functions as an agonist (mimetics) or as an antagonist. Variants of the 52906, 33408, or 12189 proteins can be generated by mutagenesis, e.g., discrete point mutation, the insertion or deletion of sequences or the truncation of a 20 52906, 33408, or 12189 protein. An agonist of the 52906, 33408, or 12189 proteins can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of a 52906, 33408, or 12189 protein. An antagonist of a 52906, 33408, or 12189 protein can inhibit one or more of the activities of the naturally occurring form of the 52906, 33408, or 12189 protein by, for example, competitively modulating a 25 52906, 33408, or 12189 -mediated activity of a 52906, 33408, or 12189 protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. Preferably, treatment of a subject with a variant having a subset of the biological 30 activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the 52906, 33408, or 12189 protein.

Variants of a 52906, 33408, or 12189 protein can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of a 52906, 33408, or 12189 protein for agonist or antagonist activity.

5 Libraries of fragments e.g., N terminal, C terminal, or internal fragments, of a 52906, 33408, or 12189 protein coding sequence can be used to generate a variegated population of fragments for screening and subsequent selection of variants of a 52906, 33408, or 12189 protein. Variants in which a cysteine residues is added or deleted or in which a residue which is glycosylated is added or deleted are particularly preferred.

10 Methods for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property are known in the art. Such methods are adaptable for rapid screening of the gene libraries generated by combinatorial mutagenesis of 52906, 33408, or 12189 proteins. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the 15 screening assays to identify 52906, 33408, or 12189 variants (Arkin and Yourvan (1992) *Proc. Natl. Acad. Sci. USA* 89:7811-7815; Delgrave *et al.* (1993) *Protein Engineering* 6:327-331).

20 Cell based assays can be exploited to analyze a variegated 52906, 33408, or 12189 library. For example, a library of expression vectors can be transfected into a cell line, e.g., a cell line, which ordinarily responds to 52906, 33408, or 12189 in a substrate-dependent manner. The transfected cells are then contacted with 52906, 33408, or 12189 and the effect of the expression of the mutant on signaling by the 52906, 33408, or 12189 substrate can be detected, e.g., by measuring potassium channel activity, e.g., ion flux 25 through a potassium channel. Plasmid DNA can then be recovered from the cells which score for inhibition, or alternatively, potentiation of signaling by the 52906, 33408, or 12189 substrate, and the individual clones further characterized.

30 In another aspect, the invention features a method of making a 52906, 33408, or 12189 polypeptide, e.g., a peptide having a non-wild type activity, e.g., an antagonist, agonist, or super agonist of a naturally occurring 52906, 33408, or 12189 polypeptide, e.g., a naturally occurring 52906, 33408, or 12189 polypeptide. The method includes: altering the sequence of a 52906, 33408, or 12189 polypeptide, e.g., altering the sequence

, e.g., by substitution or deletion of one or more residues of a non-conserved region, a domain or residue disclosed herein, and testing the altered polypeptide for the desired activity.

5 In another aspect, the invention features a method of making a fragment or analog of a 52906, 33408, or 12189 polypeptide a biological activity of a naturally occurring 52906, 33408, or 12189 polypeptide. The method includes: altering the sequence, e.g., by substitution or deletion of one or more residues, of a 52906, 33408, or 12189 polypeptide, e.g., altering the sequence of a non-conserved region, or a domain or residue described herein, and testing the altered polypeptide for the desired activity.

10 Anti-52906, 33408, or 12189 Antibodies

In another aspect, the invention provides an anti-52906, 33408, or 12189 antibody, or a fragment thereof (e.g., an antigen-binding fragment thereof). The term "antibody" as used herein refers to an immunoglobulin molecule or immunologically active portion thereof, i.e., an antigen-binding portion. As used herein, the term 15 "antibody" refers to a protein comprising at least one, and preferably two, heavy (H) chain variable regions (abbreviated herein as VH), and at least one and preferably two light (L) chain variable regions (abbreviated herein as VL). The VH and VL regions can be further subdivided into regions of hypervariability, termed "complementarity determining regions" ("CDR"), interspersed with regions that are more conserved, termed 20 "framework regions" (FR). The extent of the framework region and CDR's has been precisely defined (see, Kabat, E.A., *et al.* (1991) *Sequences of Proteins of Immunological Interest, Fifth Edition*, U.S. Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. *et al.* (1987) *J. Mol. Biol.* 196:901-917, which are incorporated herein by reference). Each VH and VL is composed of three CDR's and 25 four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

The anti-52906, 33408, or 12189 antibody can further include a heavy and light chain constant region, to thereby form a heavy and light immunoglobulin chain, respectively. In one embodiment, the antibody is a tetramer of two heavy 30 immunoglobulin chains and two light immunoglobulin chains, wherein the heavy and

light immunoglobulin chains are inter-connected by, e.g., disulfide bonds. The heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. The light chain constant region is comprised of one domain, CL. The variable region of the heavy and light chains contains a binding domain that interacts with an antigen. The constant regions of the antibodies typically mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.

As used herein, the term "immunoglobulin" refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes. The recognized 10 human immunoglobulin genes include the kappa, lambda, alpha (IgA1 and IgA2), gamma (IgG1, IgG2, IgG3, IgG4), delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Full-length immunoglobulin "light chains" (about 25 KDa or 214 amino acids) are encoded by a variable region gene at the NH2-terminus (about 110 amino acids) and a kappa or lambda constant region gene at the 15 COOH-terminus. Full-length immunoglobulin "heavy chains" (about 50 KDa or 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of the other aforementioned constant region genes, e.g., gamma (encoding about 330 amino acids).

The term "antigen-binding fragment" of an antibody (or simply "antibody portion," or "fragment"), as used herein, refers to one or more fragments of a full-length antibody that retain the ability to specifically bind to the antigen, e.g., 52906, 33408, or 12189 polypeptide or fragment thereof. Examples of antigen-binding fragments of the anti-52906, 33408, or 12189 antibody include, but are not limited to: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')<sub>2</sub> fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward *et al.*, (1989) *Nature* 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the 25 two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made 30

as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird *et al.* (1988) *Science* 242:423-426; and Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879-5883). Such single chain antibodies are also encompassed within the term "antigen-binding fragment" of an antibody. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

5 The anti-52906, 33408, or 12189 antibody can be a polyclonal or a monoclonal antibody. In other embodiments, the antibody can be recombinantly produced, e.g.,  
10 produced by phage display or by combinatorial methods.

Phage display and combinatorial methods for generating anti-52906, 33408, or 12189 antibodies are known in the art (as described in, e.g., Ladner *et al.* U.S. Patent No. 5,223,409; Kang *et al.* International Publication No. WO 92/18619; Dower *et al.* International Publication No. WO 91/17271; Winter *et al.* International Publication WO 15 92/20791; Markland *et al.* International Publication No. WO 92/15679; Breitling *et al.* International Publication WO 93/01288; McCafferty *et al.* International Publication No. WO 92/01047; Garrard *et al.* International Publication No. WO 92/09690; Ladner *et al.* International Publication No. WO 90/02809; Fuchs *et al.* (1991) *Bio/Technology* 9:1370-1372; Hay *et al.* (1992) *Hum Antibod Hybridomas* 3:81-85; Huse *et al.* (1989) *Science* 246:1275-1281; Griffiths *et al.* (1993) *EMBO J* 12:725-734; Hawkins *et al.* (1992) *J Mol Biol* 226:889-896; Clackson *et al.* (1991) *Nature* 352:624-628; Gram *et al.* (1992) *PNAS* 89:3576-3580; Garrad *et al.* (1991) *Bio/Technology* 9:1373-1377; Hoogenboom *et al.* (1991) *Nuc Acid Res* 19:4133-4137; and Barbas *et al.* (1991) *PNAS* 88:7978-7982, the contents of all of which are incorporated by reference herein).

25 In one embodiment, the anti-52906, 33408, or 12189 antibody is a fully human antibody (e.g., an antibody made in a mouse which has been genetically engineered to produce an antibody from a human immunoglobulin sequence), or a non-human antibody, e.g., a rodent (mouse or rat), goat, primate (e.g., monkey), camel antibody. Preferably, the non-human antibody is a rodent (mouse or rat antibody). Method of 30 producing rodent antibodies are known in the art.

Human monoclonal antibodies can be generated using transgenic mice carrying the human immunoglobulin genes rather than the mouse system. Splenocytes from these transgenic mice immunized with the antigen of interest are used to produce hybridomas that secrete human mAbs with specific affinities for epitopes from a human protein (see, 5 e.g., Wood et al. International Application WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741; Lonberg et al. International Application WO 92/03918; Kay et al. International Application 92/03917; Lonberg, N. et al. 1994 *Nature* 368:856-859; Green, L.L. et al. 1994 *Nature Genet.* 7:13-21; Morrison, S.L. et al. 1994 *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Bruggeman et al. 1993 *Year Immunol* 7:33-40; Tuailon et 10 al. 1993 *PNAS* 90:3720-3724; Bruggeman et al. 1991 *Eur J Immunol* 21:1323-1326).

An anti-52906, 33408, or 12189 antibody can be one in which the variable region, or a portion thereof, e.g., the CDR's, are generated in a non-human organism, e.g., a rat or mouse. Chimeric, CDR-grafted, and humanized antibodies are within the invention. Antibodies generated in a non-human organism, e.g., a rat or mouse, and then modified, 15 e.g., in the variable framework or constant region, to decrease antigenicity in a human are within the invention.

Chimeric antibodies can be produced by recombinant DNA techniques known in the art. For example, a gene encoding the Fc constant region of a murine (or other species) monoclonal antibody molecule is digested with restriction enzymes to remove 20 the region encoding the murine Fc, and the equivalent portion of a gene encoding a human Fc constant region is substituted (see Robinson et al., International Patent Publication PCT/US86/02269; Akira, et al., European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., International Application WO 86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al., European Patent Application 125,023; Better et al. (1988 *Science* 240:1041-1043); Liu et al. (1987) *PNAS* 84:3439-3443; Liu et al., 1987, *J. Immunol.* 139:3521-3526; Sun et al. (1987) *PNAS* 84:214-218; Nishimura et al., 1987, *Canc. Res.* 47:999-1005; Wood et al. (1985) *Nature* 314:446-449; and Shaw et al., 1988, *J. Natl Cancer Inst.* 80:1553-1559).

30 A humanized or CDR-grafted antibody will have at least one or two but generally all three recipient CDR's (of heavy and or light immuoglobulin chains) replaced with a

donor CDR. The antibody may be replaced with at least a portion of a non-human CDR or only some of the CDR's may be replaced with non-human CDR's. It is only necessary to replace the number of CDR's required for binding of the humanized antibody to a 52906, 33408, or 12189 or a fragment thereof. Preferably, the donor will be a rodent 5 antibody, e.g., a rat or mouse antibody, and the recipient will be a human framework or a human consensus framework. Typically, the immunoglobulin providing the CDR's is called the "donor" and the immunoglobulin providing the framework is called the "acceptor." In one embodiment, the donor immunoglobulin is a non-human (e.g., rodent). The acceptor framework is a naturally-occurring (e.g., a human) framework or a 10 consensus framework, or a sequence about 85% or higher, preferably 90%, 95%, 99% or higher identical thereto.

As used herein, the term "consensus sequence" refers to the sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related sequences (See e.g., Winnacker, *From Genes to Clones* (Verlagsgesellschaft, Weinheim, Germany 15 1987). In a family of proteins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence. A "consensus framework" refers to the framework region in the consensus immunoglobulin sequence.

An antibody can be humanized by methods known in the art. Humanized 20 antibodies can be generated by replacing sequences of the Fv variable region which are not directly involved in antigen binding with equivalent sequences from human Fv variable regions. General methods for generating humanized antibodies are provided by Morrison, S. L., 1985, *Science* 229:1202-1207, by Oi et al., 1986, *BioTechniques* 4:214, and by Queen et al. US 5,585,089, US 5,693,761 and US 5,693,762, the contents of all of 25 which are hereby incorporated by reference. Those methods include isolating, manipulating, and expressing the nucleic acid sequences that encode all or part of immunoglobulin Fv variable regions from at least one of a heavy or light chain. Sources of such nucleic acid are well known to those skilled in the art and, for example, may be obtained from a hybridoma producing an antibody against a 52906, 33408, or 12189 30 polypeptide or fragment thereof. The recombinant DNA encoding the humanized antibody, or fragment thereof, can then be cloned into an appropriate expression vector.

Humanized or CDR-grafted antibodies can be produced by CDR-grafting or CDR substitution, wherein one, two, or all CDR's of an immunoglobulin chain can be replaced. See e.g., U.S. Patent 5,225,539; Jones et al. 1986 *Nature* 321:552-525; Verhoeyan et al. 1988 *Science* 239:1534; Beidler et al. 1988 *J. Immunol.* 141:4053-4060; Winter US 5,225,539, the contents of all of which are hereby expressly incorporated by reference. Winter describes a CDR-grafting method which may be used to prepare the humanized antibodies of the present invention (UK Patent Application GB 2188638A, filed on March 26, 1987; Winter US 5,225,539), the contents of which is expressly incorporated by reference.

10 Also within the scope of the invention are humanized antibodies in which specific amino acids have been substituted, deleted or added. Preferred humanized antibodies have amino acid substitutions in the framework region, such as to improve binding to the antigen. For example, a humanized antibody will have framework residues identical to the donor framework residue or to another amino acid other than the recipient framework 15 residue. To generate such antibodies, a selected, small number of acceptor framework residues of the humanized immunoglobulin chain can be replaced by the corresponding donor amino acids. Preferred locations of the substitutions include amino acid residues adjacent to the CDR, or which are capable of interacting with a CDR (see e.g., US 5,585,089). Criteria for selecting amino acids from the donor are described in US 5,585,089, e.g., columns 12-16 of US 5,585,089, the e.g., columns 12-16 of US 20 5,585,089, the contents of which are hereby incorporated by reference. Other techniques for humanizing antibodies are described in Padlan et al. EP 519596 A1, published on December 23, 1992.

25 In preferred embodiments an antibody can be made by immunizing with purified 52906, 33408, or 12189 antigen, or a fragment thereof, e.g., a fragment described herein, membrane associated antigen, tissue, e.g., crude tissue preparations, whole cells, preferably living cells, lysed cells, or cell fractions, e.g., membrane fractions.

30 A full-length 52906, 33408, or 12189 protein or, antigenic peptide fragment of 52906, 33408, or 12189 can be used as an immunogen or can be used to identify anti- 35 52906, 33408, or 12189 antibodies made with other immunogens, e.g., cells, membrane preparations, and the like. The antigenic peptide of 52906, 33408, or 12189 should

include at least 8 amino acid residues of the amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:8 and encompasses an epitope of 52906, 33408, or 12189. Preferably, the antigenic peptide includes at least 10 amino acid residues, more preferably at least 15 amino acid residues, even more preferably at least 20 amino acid residues, and most preferably at least 30 amino acid residues.

5       Fragments of 52906, 33408, or 12189 which include residues about 241-265 of SEQ ID NO:2, 710-740 of SEQ ID NO:5, or 35-55 of SEQ ID NO:8 can be used to make, e.g., used as immunogens or used to characterize the specificity of an antibody, antibodies against hydrophilic regions of the 52906, 33408, or 12189 protein. Similarly, 10 fragments of 52906, 33408, or 12189 which include residues about 785-800 of SEQ ID NO:2, 585-600 of SEQ ID NO:5, or 75-95 of SEQ ID NO:8 can be used to make an antibody against a hydrophobic region of the 52906, 33408, or 12189 protein. Fragments of 52906, 33408, or 12189 which include residues 420-432 of SEQ ID NO:2, 237-244 of SEQ ID NO:5, or 153-199 of SEQ ID NO:8 can be used to make an antibody against an 15 extracellular region of the 52906, 33408, or 12189 protein. Fragments of 52906, 33408, or 12189 which include residues 1-401 of SEQ ID NO:2, 1-218 of SEQ ID NO:5, or 1-133 of SEQ ID NO:8 can be used to make an antibody against an intracellular region of the 52906, 33408, or 12189 protein. Fragments of 52906, 33408, or 12189 which include residues 616-639 of SEQ ID NO:2, 420-440 of SEQ ID NO:5, or 339-355 of SEQ ID 20 NO:8 can be used to make an antibody against the P-loop region of the 52906, 33408, or 12189 protein. Fragments of 52906, 33408, or 12189 which include amino acids 472-661 of SEQ ID NO:2, amino acids 247-467 of SEQ ID NO:5, or amino acids 198-383 of SEQ ID NO:8 can be used to make an antibody against the ion transport protein domain of the 52906, 33408, or 12189 protein. Fragments of 33408 which include amino acids 565-655 25 of SEQ ID NO:5 can be used to make an antibody against the cyclic nucleotide-binding domain of the 33408 protein. Fragments of 12189 which include amino acids 3-101 of SEQ ID NO:8 can be used to make an antibody against the potassium channel tetramerisation domain of the 12189 protein.

Antibodies reactive with, or specific for, any of these regions, or other regions or 30 domains described herein are provided.

Antibodies which bind only native 52906, 33408, or 12189 protein, only denatured or otherwise non-native 52906, 33408, or 12189 protein, or which bind both, are within the invention. Antibodies with linear or conformational epitopes are within the invention. Conformational epitopes can sometimes be identified by identifying 5 antibodies which bind to native but not denatured 52906, 33408, or 12189 protein.

Preferred epitopes encompassed by the antigenic peptide are regions of 52906, 33408, or 12189 are located on the surface of the protein, e.g., hydrophilic regions, as well as regions with high antigenicity. For example, an Emini surface probability analysis of the human 52906, 33408, or 12189 protein sequence can be used to indicate 10 the regions that have a particularly high probability of being localized to the surface of the 52906, 33408, or 12189 protein and are thus likely to constitute surface residues useful for targeting antibody production.

In a preferred embodiment the antibody can bind to the extracellular portion of the 52906, 33408, or 12189 protein, e.g., it can bind to a whole cell which expresses the 15 52906, 33408, or 12189 protein. In another embodiment, the antibody binds an intracellular portion of the 52906, 33408, or 12189 protein.

In preferred embodiments antibodies can bind one or more of purified antigen, membrane associated antigen, tissue, e.g., tissue sections, whole cells, preferably living cells, lysed cells, cell fractions, e.g., membrane fractions.

20 The anti-52906, 33408, or 12189 antibody can be a single chain antibody. A single-chain antibody (scFV) may be engineered (see, for example, Colcher, D. *et al.* (1999) *Ann N Y Acad Sci* 880:263-80; and Reiter, Y. (1996) *Clin Cancer Res* 2:245-52). The single chain antibody can be dimerized or multimerized to generate multivalent 25 antibodies having specificities for different epitopes of the same target 52906, 33408, or 12189 protein.

In a preferred embodiment the antibody has: effector function; and can fix complement. In other embodiments the antibody does not; recruit effector cells; or fix complement.

30 In a preferred embodiment, the antibody has reduced or no ability to bind an Fc receptor. For example, it is a isotype or subtype, fragment or other mutant, which does

not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region.

In a preferred embodiment, an anti-52906, 33408, or 12189 antibody alters (e.g., increases or decreases) an activity of a 52906, 33408, or 12189 polypeptide, e.g., the ability to modulate the flow of K<sup>+</sup> ions through a cell membrane and/or the ability to modulate the transmission of signals in an electrically excitable cell, e.g., a neuronal cell or a muscle cell. For example, the antibody can bind at or in proximity to a Pore loop domain, e.g., to an epitope that includes a residue located from about 616-639 of SEQ ID NO:2, 420-440 of SEQ ID NO:5, or 339-355 of SEQ ID NO:8.

The antibody can be coupled to a toxin, e.g., a polypeptide toxin, e.g., ricin or diphtheria toxin or active fragment hereof, or a radioactive nucleus, or imaging agent, e.g., a radioactive, enzymatic, or other, e.g., imaging agent, e.g., a NMR contrast agent. Labels which produce detectable radioactive emissions or fluorescence are preferred.

An anti-52906, 33408, or 12189 antibody (e.g., monoclonal antibody) can be used to isolate 52906, 33408, or 12189 by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, an anti-52906, 33408, or 12189 antibody can be used to detect 52906, 33408, or 12189 protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the protein. Anti-52906, 33408, or 12189 antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance (i.e., antibody labeling). Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase,  $\beta$ -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent

materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  or  $^3\text{H}$ .

The invention also includes a nucleic acids which encodes an anti-52906, 33408, or 12189 antibody, e.g., an anti-52906, 33408, or 12189 antibody described herein. Also 5 included are vectors which include the nucleic acid and cells transformed with the nucleic acid, particularly cells which are useful for producing an antibody, e.g., mammalian cells, e.g. CHO or lymphatic cells.

The invention also includes cell lines, e.g., hybridomas, which make an anti-52906, 33408, or 12189 antibody, e.g., and antibody described herein, and method of 10 using said cells to make a 52906, 33408, or 12189 antibody.

#### Recombinant Expression Vectors, Host Cells and Genetically Engineered Cells

In another aspect, the invention includes, vectors, preferably expression vectors, containing a nucleic acid encoding a polypeptide described herein. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked and can include a plasmid, cosmid or viral vector. The 15 vector can be capable of autonomous replication or it can integrate into a host DNA. Viral vectors include, e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses.

A vector can include a 52906, 33408, or 12189 nucleic acid in a form suitable for 20 expression of the nucleic acid in a host cell. Preferably the recombinant expression vector includes one or more regulatory sequences operatively linked to the nucleic acid sequence to be expressed. The term "regulatory sequence" includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence, as 25 well as tissue-specific regulatory and/or inducible sequences. The design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or polypeptides, including fusion proteins or polypeptides, encoded by nucleic acids as

described herein (e.g., 52906, 33408, or 12189 proteins, mutant forms of 52906, 33408, or 12189 proteins, fusion proteins, and the like).

The recombinant expression vectors of the invention can be designed for expression of 52906, 33408, or 12189 proteins in prokaryotic or eukaryotic cells. For example, polypeptides of the invention can be expressed in *E. coli*, insect cells (e.g., using baculovirus expression vectors), yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, (1990) *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA. Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Purified fusion proteins can be used in 52906, 33408, or 12189 activity assays, (e.g., direct assays or competitive assays described in detail below), or to generate antibodies specific for 52906, 33408, or 12189 proteins. In a preferred embodiment, a fusion protein expressed in a retroviral expression vector of the present invention can be used to infect bone marrow cells which are subsequently transplanted into irradiated

recipients. The pathology of the subject recipient is then examined after sufficient time has passed (e.g., six weeks).

To maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., (1990) *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

The 52906, 33408, or 12189 expression vector can be a yeast expression vector, a vector for expression in insect cells, e.g., a baculovirus expression vector or a vector suitable for expression in mammalian cells.

When used in mammalian cells, the expression vector's control functions can be provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40.

In another embodiment, the promoter is an inducible promoter, e.g., a promoter regulated by a steroid hormone, by a polypeptide hormone (e.g., by means of a signal transduction pathway), or by a heterologous polypeptide (e.g., the tetracycline-inducible systems, "Tet-On" and "Tet-Off"; see, e.g., Clontech Inc., CA, Gossen and Bujard (1992) *Proc. Natl. Acad. Sci. USA* 89:5547, and Paillard (1989) *Human Gene Therapy* 9:983).

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) *Proc. Natl. Acad. Sci. USA* 86:5473-5477), pancreas-specific promoters (Edlund *et al.*

(1985) *Science* 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example, the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the  $\alpha$ -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

5 The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. Regulatory sequences (e.g., viral promoters and/or enhancers) operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the 10 constitutive, tissue specific or cell type specific expression of antisense RNA in a variety of cell types. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus.

15 Another aspect the invention provides a host cell which includes a nucleic acid molecule described herein, e.g., a 52906, 33408, or 12189 nucleic acid molecule within a recombinant expression vector or a 52906, 33408, or 12189 nucleic acid molecule containing sequences which allow it to homologously recombine into a specific site of the host cell's genome. The terms "host cell" and "recombinant host cell" are used interchangeably herein. Such terms refer not only to the particular subject cell but to the 20 progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, a 52906, 25 33408, or 12189 protein can be expressed in bacterial cells (such as *E. coli*), insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells (African green monkey kidney cells CV-1 origin SV40 cells; Gluzman (1981) *Cell* 23:175-182)). Other suitable host cells are known to those skilled in the art.

30 Vector DNA can be introduced into host cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign

nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation.

A host cell of the invention can be used to produce (i.e., express) a 52906, 33408, or 12189 protein. Accordingly, the invention further provides methods for producing a 5 52906, 33408, or 12189 protein using the host cells of the invention. In one embodiment, the method includes culturing the host cell of the invention (into which a recombinant expression vector encoding a 52906, 33408, or 12189 protein has been introduced) in a suitable medium such that a 52906, 33408, or 12189 protein is produced. In another embodiment, the method further includes isolating a 52906, 33408, or 12189 protein 10 from the medium or the host cell.

In another aspect, the invention features, a cell or purified preparation of cells which include a 52906, 33408, or 12189 transgene, or which otherwise misexpress 52906, 33408, or 12189. The cell preparation can consist of human or non-human cells, e.g., rodent cells, e.g., mouse or rat cells, rabbit cells, or pig cells. In preferred 15 embodiments, the cell or cells include a 52906, 33408, or 12189 transgene, e.g., a heterologous form of a 52906, 33408, or 12189, e.g., a gene derived from humans (in the case of a non-human cell). The 52906, 33408, or 12189 transgene can be misexpressed, e.g., overexpressed or underexpressed. In other preferred embodiments, the cell or cells 20 include a gene that mis-expresses an endogenous 52906, 33408, or 12189, e.g., a gene the expression of which is disrupted, e.g., a knockout. Such cells can serve as a model for studying disorders that are related to mutated or mis-expressed 52906, 33408, or 25 12189 alleles or for use in drug screening.

In another aspect, the invention features, a human cell, e.g., a neuronal cell or a muscle cell, transformed with nucleic acid which encodes a subject 52906, 33408, or 12189 polypeptide.

Also provided are cells, preferably human cells, e.g., a neuronal cell, a muscle cell, a hematopoietic cell, or a fibroblast cell, in which an endogenous 52906, 33408, or 12189 is under the control of a regulatory sequence that does not normally control the expression of the endogenous 52906, 33408, or 12189 gene. The expression 30 characteristics of an endogenous gene within a cell, e.g., a cell line or microorganism, can be modified by inserting a heterologous DNA regulatory element into the genome of the

cell such that the inserted regulatory element is operably linked to the endogenous 52906, 33408, or 12189 gene. For example, an endogenous 52906, 33408, or 12189 gene which is "transcriptionally silent," e.g., not normally expressed, or expressed only at very low levels, may be activated by inserting a regulatory element which is capable of promoting

5 the expression of a normally expressed gene product in that cell. Techniques such as targeted homologous recombinations, can be used to insert the heterologous DNA as described in, e.g., Chappel, US 5,272,071; WO 91/06667, published in May 16, 1991.

In a preferred embodiment, recombinant cells described herein can be used for replacement therapy in a subject. For example, a nucleic acid encoding a 52906, 33408, 10 or 12189 polypeptide operably linked to an inducible promoter (e.g., a steroid hormone receptor-regulated promoter) is introduced into a human or nonhuman, e.g., mammalian, e.g., porcine recombinant cell. The cell is cultivated and encapsulated in a biocompatible material, such as poly-lysine alginate, and subsequently implanted into the subject. See, e.g., Lanza (1996) *Nat. Biotechnol.* 14:1107; Joki *et al.* (2001) *Nat. Biotechnol.* 19:35; 15 and U.S. Patent No. 5,876,742. Production of 52906, 33408, or 12189 polypeptide can be regulated in the subject by administering an agent (e.g., a steroid hormone) to the subject. In another preferred embodiment, the implanted recombinant cells express and secrete an antibody specific for a 52906, 33408, or 12189 polypeptide. The antibody can be any antibody or any antibody derivative described herein.

20 **Transgenic Animals**

The invention provides non-human transgenic animals. Such animals are useful for studying the function and/or activity of a 52906, 33408, or 12189 protein and for identifying and/or evaluating modulators of 52906, 33408, or 12189 activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more 25 preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, and the like. A transgene is exogenous DNA or a rearrangement, e.g., a deletion of endogenous chromosomal DNA, which preferably is integrated into or occurs in the genome of the cells of a transgenic animal.

30 A transgene can direct the expression of an encoded gene product in one or more cell

types or tissues of the transgenic animal, other transgenes, e.g., a knockout, reduce expression. Thus, a transgenic animal can be one in which an endogenous 52906, 33408, or 12189 gene has been altered by, e.g., by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

5       Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to a transgene of the invention to direct expression of a 52906, 33408, or 12189 protein to particular cells. A transgenic founder 10      animal can be identified based upon the presence of a 52906, 33408, or 12189 transgene in its genome and/or expression of 52906, 33408, or 12189 mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding a 52906, 33408, or 12189 protein can further be bred to other transgenic animals carrying 15      other transgenes.

52906, 33408, or 12189 proteins or polypeptides can be expressed in transgenic animals or plants, e.g., a nucleic acid encoding the protein or polypeptide can be introduced into the genome of an animal. In preferred embodiments the nucleic acid is placed under the control of a tissue specific promoter, e.g., a milk or egg specific promoter, and recovered from the milk or eggs produced by the animal. Suitable animals 20      are mice, pigs, cows, goats, and sheep.

The invention also includes a population of cells from a transgenic animal, as discussed, e.g., below.

### Uses

25       The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: a) screening assays; b) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenetics); and c) methods of treatment (e.g., therapeutic and prophylactic).

The isolated nucleic acid molecules of the invention can be used, for example, to express a 52906, 33408, or 12189 protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect a 52906, 33408, or 12189 mRNA (e.g., in a biological sample) or a genetic alteration in a 52906, 33408, or 12189 gene, and to modulate 52906, 33408, or 12189 activity, as described further below. The 52906, 33408, or 12189 proteins can be used to treat disorders characterized by insufficient or excessive production of a 52906, 33408, or 12189 substrate or production of 52906, 33408, or 12189 inhibitors. In addition, the 52906, 33408, or 12189 proteins can be used to screen for naturally occurring 52906, 33408, or 12189 substrates, to screen for drugs or compounds which modulate 52906, 33408, or 12189 activity, as well as to treat disorders characterized by insufficient or excessive production of 52906, 33408, or 12189 protein or production of 52906, 33408, or 12189 protein forms which have decreased, aberrant or unwanted activity compared to 52906, 33408, or 12189 wild type protein (e.g., disorders characterized by abnormal ion flux such as neurological disorders or cardiac disorders). Moreover, the anti-52906, 33408, or 12189 antibodies of the invention can be used to detect and isolate 52906, 33408, or 12189 proteins, regulate the bioavailability of 52906, 33408, or 12189 proteins, and modulate 52906, 33408, or 12189 activity.

A method of evaluating a compound for the ability to interact with, e.g., bind, a subject 52906, 33408, or 12189 polypeptide is provided. The method includes: contacting the compound with the subject 52906, 33408, or 12189 polypeptide; and evaluating ability of the compound to interact with, e.g., to bind or form a complex with the subject 52906, 33408, or 12189 polypeptide. This method can be performed in vitro, e.g., in a cell free system, or in vivo, e.g., in a two-hybrid interaction trap assay. This method can be used to identify naturally occurring molecules that interact with subject 52906, 33408, or 12189 polypeptide. It can also be used to find natural or synthetic inhibitors of subject 52906, 33408, or 12189 polypeptide. Screening methods are discussed in more detail below.

#### Screening Assays

The invention provides methods (also referred to herein as "screening assays") for identifying modulators, i.e., candidate or test compounds or agents (e.g., proteins,

peptides, peptidomimetics, peptoids, small molecules or other drugs) which bind to 52906, 33408, or 12189 proteins, have a stimulatory or inhibitory effect on, for example, 52906, 33408, or 12189 expression or 52906, 33408, or 12189 activity, or have a stimulatory or inhibitory effect on, for example, the expression or activity of a 52906, 5 33408, or 12189 substrate. Compounds thus identified can be used to modulate the activity of target gene products (e.g., 52906, 33408, or 12189 genes) in a therapeutic protocol, to elaborate the biological function of the target gene product, or to identify compounds that disrupt normal target gene interactions.

In one embodiment, the invention provides assays for screening candidate or test 10 compounds which are substrates of a 52906, 33408, or 12189 protein or polypeptide or a biologically active portion thereof. In another embodiment, the invention provides assays for screening candidate or test compounds that bind to or modulate an activity of a 52906, 33408, or 12189 protein or polypeptide or a biologically active portion thereof.

In one embodiment, an activity of a 52906, 33408, or 12189 protein can be 15 assayed by measuring the flow of K<sup>+</sup> ions through a cell membrane and/or by measuring the transmission of signals in an electrically excitable cell, e.g., a neuronal cell or a muscle cell. For example, an activity of a 52906, 33408, or 12189 protein can be assayed by measuring membrane currents as described in Köhler et al. (1996) *Science* 273:1709-1714, Saganich et al. (1999) *J. Neuroscience* 19:10789-10802, or Kalman et al. (1998) *J. 20 Biol. Chem.* 273:5851-5857.

The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: 25 biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive; see, e.g., Zuckermann, R.N. et al. (1994) *J. Med. Chem.* 37:2678-85); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library and peptoid library approaches are limited to peptide 30 libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam (1997) *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994) *J. Med. Chem.* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and Gallop *et al.* (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds may be presented in solution (e.g., Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores 10 (Ladner U.S. Patent No. 5,223,409), plasmids (Cull *et al.* (1992) *Proc Natl Acad Sci USA* 89:1865-1869) or on phage (Scott and Smith (1990) *Science* 249:386-390; Devlin (1990) *Science* 249:404-406; Cwirla *et al.* (1990) *Proc. Natl. Acad. Sci.* 87:6378-6382; Felici (1991) *J. Mol. Biol.* 222:301-310; Ladner *supra*).

In one embodiment, an assay is a cell-based assay in which a cell which expresses 15 a 52906, 33408, or 12189 protein or biologically active portion thereof is contacted with a test compound, and the ability of the test compound to modulate 52906, 33408, or 12189 activity is determined. Determining the ability of the test compound to modulate 52906, 33408, or 12189 activity can be accomplished by monitoring, for example, potassium channel activity, e.g., ion flux through a potassium channel. The cell, for 20 example, can be of mammalian origin, e.g., human.

The ability of the test compound to modulate 52906, 33408, or 12189 binding to a compound, e.g., a 52906, 33408, or 12189 substrate, or to bind to 52906, 33408, or 12189 can also be evaluated. This can be accomplished, for example, by coupling the compound, e.g., the substrate, with a radioisotope or enzymatic label such that binding of 25 the compound, e.g., the substrate, to 52906, 33408, or 12189 can be determined by detecting the labeled compound, e.g., substrate, in a complex. Alternatively, 52906, 33408, or 12189 could be coupled with a radioisotope or enzymatic label to monitor the ability of a test compound to modulate 52906, 33408, or 12189 binding to a 52906, 33408, or 12189 substrate in a complex. For example, compounds (e.g., 52906, 33408, 30 or 12189 substrates) can be labeled with  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^3\text{H}$ , either directly or indirectly, and the radioisotope detected by direct counting of radioemmission or by

scintillation counting. Alternatively, compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product.

5 The ability of a compound (e.g., a 52906, 33408, or 12189 substrate) to interact with 52906, 33408, or 12189 with or without the labeling of any of the interactants can be evaluated. For example, a microphysiometer can be used to detect the interaction of a compound with 52906, 33408, or 12189 without the labeling of either the compound or the 52906, 33408, or 12189. McConnell, H. M. *et al.* (1992) *Science* 257:1906-1912. As used herein, a "microphysiometer" (e.g., Cytosensor) is an analytical instrument that 10 measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a compound and 52906, 33408, or 12189.

15 In yet another embodiment, a cell-free assay is provided in which a 52906, 33408, or 12189 protein or biologically active portion thereof is contacted with a test compound and the ability of the test compound to bind to the 52906, 33408, or 12189 protein or biologically active portion thereof is evaluated. Preferred biologically active portions of the 52906, 33408, or 12189 proteins to be used in assays of the present invention include fragments which participate in interactions with non-52906, 33408, or 12189 molecules, e.g., fragments with high surface probability scores.

20 Soluble and/or membrane-bound forms of isolated proteins (e.g., 52906, 33408, or 12189 proteins or biologically active portions thereof) can be used in the cell-free assays of the invention. When membrane-bound forms of the protein are used, it may be desirable to utilize a solubilizing agent. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, 25 octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether)<sub>n</sub>, 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate.

30 Cell-free assays involve preparing a reaction mixture of the target gene protein and the test compound under conditions and for a time sufficient to allow the two

components to interact and bind, thus forming a complex that can be removed and/or detected.

The interaction between two molecules can also be detected, e.g., using fluorescence energy transfer (FET) (see, for example, Lakowicz *et al.*, U.S. Patent No. 5,631,169; Stavrianopoulos, *et al.*, U.S. Patent No. 4,868,103). A fluorophore label on the first, 'donor' molecule is selected such that its emitted fluorescent energy will be absorbed by a fluorescent label on a second, 'acceptor' molecule, which in turn is able to fluoresce due to the absorbed energy. Alternately, the 'donor' protein molecule may simply utilize the natural fluorescent energy of tryptophan residues. Labels are chosen that emit different wavelengths of light, such that the 'acceptor' molecule label may be differentiated from that of the 'donor'. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, the spatial relationship between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal. An FET binding event can be conveniently measured through standard fluorometric detection means well known in the art (e.g., using a fluorimeter).

In another embodiment, determining the ability of the 52906, 33408, or 12189 protein to bind to a target molecule can be accomplished using real-time Biomolecular Interaction Analysis (BIA) (see, e.g., Sjolander, S. and Urbaniczky, C. (1991) *Anal. Chem.* 63:2338-2345 and Szabo *et al.* (1995) *Curr. Opin. Struct. Biol.* 5:699-705). "Surface plasmon resonance" or "BIA" detects biospecific interactions in real time, without labeling any of the interactants (e.g., BIACore). Changes in the mass at the binding surface (indicative of a binding event) result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)), resulting in a detectable signal which can be used as an indication of real-time reactions between biological molecules.

In one embodiment, the target gene product or the test substance is anchored onto a solid phase. The target gene product/test compound complexes anchored on the solid phase can be detected at the end of the reaction. Preferably, the target gene product can be anchored onto a solid surface, and the test compound, (which is not anchored), can be labeled, either directly or indirectly, with detectable labels discussed herein.

It may be desirable to immobilize either 52906, 33408, or 12189, an anti- $\alpha$ 2900, 33408, or 12189 antibody or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to a 52906, 33408, or 12189 protein, or interaction of a 52906, 33408, or 12189 protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/52906, 33408, or 12189 fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or 52906, 33408, or 12189 protein, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of 52906, 33408, or 12189 binding or activity determined using standard techniques.

Other techniques for immobilizing either a 52906, 33408, or 12189 protein or a target molecule on matrices include using conjugation of biotin and streptavidin. Biotinylated 52906, 33408, or 12189 protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).

In order to conduct the assay, the non-immobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways.

Where the previously non-immobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously non-immobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the immobilized component (the antibody, in turn, can be directly labeled or indirectly labeled with, e.g., a labeled anti-Ig antibody).

5 In one embodiment, this assay is performed utilizing antibodies reactive with 52906, 33408, or 12189 protein or target molecules but which do not interfere with binding of the 52906, 33408, or 12189 protein to its target molecule. Such antibodies can 10 be derivatized to the wells of the plate, and unbound target or 52906, 33408, or 12189 protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the 52906, 33408, or 12189 protein or target molecule, as well as enzyme-linked assays which rely on 15 detecting an enzymatic activity associated with the 52906, 33408, or 12189 protein or target molecule.

Alternatively, cell free assays can be conducted in a liquid phase. In such an assay, the reaction products are separated from unreacted components, by any of a number of standard techniques, including but not limited to: differential centrifugation 20 (see, for example, Rivas, G., and Minton, A.P., (1993) *Trends Biochem Sci* 18:284-7); chromatography (gel filtration chromatography, ion-exchange chromatography); electrophoresis (see, e.g., Ausubel, F. *et al.*, eds. *Current Protocols in Molecular Biology* 1999, J. Wiley: New York.); and immunoprecipitation (see, for example, Ausubel, F. *et al.*, eds. (1999) *Current Protocols in Molecular Biology*, J. Wiley: New York). Such 25 resins and chromatographic techniques are known to one skilled in the art (see, e.g., Heegaard, N.H., (1998) *J Mol Recognit* 11:141-8; Hage, D.S., and Tweed, S.A. (1997) *J Chromatogr B Biomed Sci Appl.* 699:499-525). Further, fluorescence energy transfer may also be conveniently utilized, as described herein, to detect binding without further purification of the complex from solution.

30 In a preferred embodiment, the assay includes contacting the 52906, 33408, or 12189 protein or biologically active portion thereof with a known compound which binds

52906, 33408, or 12189 to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a 52906, 33408, or 12189 protein, wherein determining the ability of the test compound to interact with a 52906, 33408, or 12189 protein includes determining the ability of the test compound to preferentially bind to 52906, 33408, or 12189 or biologically active portion thereof, or to modulate the activity of a target molecule, as compared to the known compound.

10 The target gene products of the invention can, *in vivo*, interact with one or more cellular or extracellular macromolecules, such as proteins. For the purposes of this discussion, such cellular and extracellular macromolecules are referred to herein as "binding partners." Compounds that disrupt such interactions can be useful in regulating the activity of the target gene product. Such compounds can include, but are not limited to molecules such as antibodies, peptides, and small molecules. The preferred target genes/products for use in this embodiment are the 52906, 33408, or 12189 genes herein identified. In an alternative embodiment, the invention provides methods for determining the ability of the test compound to modulate the activity of a 52906, 33408, or 12189 protein through modulation of the activity of a downstream effector of a 52906, 33408, or 12189 target molecule. For example, the activity of the effector molecule on an appropriate target can be determined, or the binding of the effector to an appropriate target can be determined, as previously described.

15 To identify compounds that interfere with the interaction between the target gene product and its cellular or extracellular binding partner(s), a reaction mixture containing the target gene product and the binding partner is prepared, under conditions and for a time sufficient, to allow the two products to form complex. In order to test an inhibitory agent, the reaction mixture is provided in the presence and absence of the test compound. The test compound can be initially included in the reaction mixture, or can be added at a time subsequent to the addition of the target gene and its cellular or extracellular binding partner. Control reaction mixtures are incubated without the test compound or with a placebo. The formation of any complexes between the target gene product and the cellular or extracellular binding partner is then detected. The formation of a complex in the control reaction, but not in the reaction mixture containing the test compound,

5 indicates that the compound interferes with the interaction of the target gene product and the interactive binding partner. Additionally, complex formation within reaction mixtures containing the test compound and normal target gene product can also be compared to complex formation within reaction mixtures containing the test compound and mutant target gene product. This comparison can be important in those cases wherein it is desirable to identify compounds that disrupt interactions of mutant but not normal target gene products.

10 These assays can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the target gene product or the binding partner onto a solid phase, and detecting complexes anchored on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction between the target gene products and the binding 15 partners, e.g., by competition, can be identified by conducting the reaction in the presence of the test substance. Alternatively, test compounds that disrupt preformed complexes, e.g., compounds with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. The various formats are briefly described below.

20 In a heterogeneous assay system, either the target gene product or the interactive cellular or extracellular binding partner, is anchored onto a solid surface (e.g., a microtiter plate), while the non-anchored species is labeled, either directly or indirectly. The anchored species can be immobilized by non-covalent or covalent attachments. Alternatively, an immobilized antibody specific for the species to be anchored can be 25 used to anchor the species to the solid surface.

30 In order to conduct the assay, the partner of the immobilized species is exposed to the coated surface with or without the test compound. After the reaction is complete, unreacted components are removed (e.g., by washing) and any complexes formed will remain immobilized on the solid surface. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the non-immobilized species is not pre-labeled, an indirect label can be

used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the initially non-immobilized species (the antibody, in turn, can be directly labeled or indirectly labeled with, e.g., a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds that inhibit complex formation or that disrupt preformed complexes can be detected.

Alternatively, the reaction can be conducted in a liquid phase in the presence or absence of the test compound, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes. Again, depending upon the order of addition of reactants to the liquid phase, test compounds that inhibit complex or that disrupt preformed complexes can be identified.

In an alternate embodiment of the invention, a homogeneous assay can be used. For example, a preformed complex of the target gene product and the interactive cellular or extracellular binding partner product is prepared in that either the target gene products or their binding partners are labeled, but the signal generated by the label is quenched due to complex formation (see, e.g., U.S. Patent No. 4,109,496 that utilizes this approach for immunoassays). The addition of a test substance that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances that disrupt target gene product-binding partner interaction can be identified.

In yet another aspect, the 52906, 33408, or 12189 proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with 52906, 33408, or 12189 ("52906, 33408, or 12189 -binding proteins" or "52906, 33408, or 12189 -bp") and are involved in 52906, 33408, or 12189 activity. Such 52906, 33408, or 12189 -bps can be activators or inhibitors of signals by the 52906, 33408, or 12189 proteins or 52906, 33408, or 12189 targets as, for example, downstream elements of a 52906, 33408, or 12189 -mediated signaling pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a 52906, 33408, or 12189 protein is fused to a gene encoding the DNA binding domain of a 5 known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. (Alternatively the: 52906, 33408, or 12189 protein can be the fused to the activator domain.) If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a 10 52906, 33408, or 12189 -dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., lacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated 15 52906, 33408, or 12189 protein. and used to obtain the cloned gene which encodes the protein which interacts with the 52906, 33408, or 12189 protein.

In another embodiment, modulators of 52906, 33408, or 12189 expression are identified. For example, a cell or cell free mixture is contacted with a candidate 20 compound and the expression of 52906, 33408, or 12189 mRNA or protein evaluated relative to the level of expression of 52906, 33408, or 12189 mRNA or protein in the absence of the candidate compound. When expression of 52906, 33408, or 12189 mRNA or protein is greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of 52906, 33408, or 12189 mRNA or 25 protein expression. Alternatively, when expression of 52906, 33408, or 12189 mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of 52906, 33408, or 12189 mRNA or protein expression. The level of 52906, 33408, or 12189 mRNA or protein expression can be determined by methods described herein for detecting 52906, 33408, or 12189 mRNA or protein.

30 In another aspect, the invention pertains to a combination of two or more of the assays described herein. For example, a modulating agent can be identified using a cell-

based or a cell free assay, and the ability of the agent to modulate the activity of a 52906, 33408, or 12189 protein can be confirmed *in vivo*, e.g., in an animal such as an animal model for a disorder characterized by abnormal ion flux such as a neurological disorder or a cardiac disorder.

5 This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein (e.g., a 52906, 33408, or 12189 modulating agent, an antisense 52906, 33408, or 12189 nucleic acid molecule, a 52906, 33408, or 12189 - specific antibody, or a 52906, 33408, or 12189 -binding partner) in an appropriate animal 10 model to determine the efficacy, toxicity, side effects, or mechanism of action, of treatment with such an agent. Furthermore, novel agents identified by the above-described screening assays can be used for treatments as described herein.

#### Detection Assays

15 Portions or fragments of the nucleic acid sequences identified herein can be used as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome e.g., to locate gene regions associated with genetic disease or to associate 52906, 33408, or 12189 with a disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.

20 Chromosome Mapping

The 52906, 33408, or 12189 nucleotide sequences or portions thereof can be used to map the location of the 52906, 33408, or 12189 genes on a chromosome. This process is called chromosome mapping. Chromosome mapping is useful in correlating the 52906, 33408, or 12189 sequences with genes associated with disease.

25 Briefly, 52906, 33408, or 12189 genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the 52906, 33408, or 12189 nucleotide sequences. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the

human gene corresponding to the 52906, 33408, or 12189 sequences will yield an amplified fragment.

5 A panel of somatic cell hybrids in which each cell line contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, can allow easy mapping of individual genes to specific human chromosomes. (D'Eustachio P. *et al.* (1983) *Science* 220:919-924).

10 Other mapping strategies e.g., *in situ* hybridization (described in Fan, Y. *et al.* (1990) *Proc. Natl. Acad. Sci. USA*, 87:6223-27), pre-screening with labeled flow-sorted chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries can be used to map 52906, 33408, or 12189 to a chromosomal location.

15 Fluorescence *in situ* hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma *et al.*, *Human Chromosomes: A Manual of Basic Techniques* ((1988) Pergamon Press, New York).

20 Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

25 Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, *Mendelian Inheritance in Man*, available on-line through Johns Hopkins University Welch Medical Library). The relationship between a gene and a disease, mapped to the same chromosomal region, can 30 then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, for example, Egeland, J. *et al.* (1987) *Nature*, 325:783-787.

Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the 52906, 33408, or 12189 gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

#### Tissue Typing

5 52906, 33408, or 12189 sequences can be used to identify individuals from biological samples using, e.g., restriction fragment length polymorphism (RFLP). In this technique, an individual's genomic DNA is digested with one or more restriction 15 enzymes, the fragments separated, e.g., in a Southern blot, and probed to yield bands for identification. The sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Patent 5,272,057).

Furthermore, the sequences of the present invention can also be used to determine the actual base-by-base DNA sequence of selected portions of an individual's genome. 20 Thus, the 52906, 33408, or 12189 nucleotide sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it. Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA 25 sequences due to allelic differences.

Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur 30 in the noncoding regions, fewer sequences are necessary to differentiate individuals. The

noncoding sequences of SEQ ID NO:1, SEQ ID NO:4, or SEQ ID NO:7 can provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NO:3, SEQ ID NO:6, or SEQ ID NO:7 are used, a more appropriate 5 number of primers for positive individual identification would be 500-2,000.

If a panel of reagents from 52906, 33408, or 12189 nucleotide sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique identification database, positive identification of the individual, living or dead, 10 can be made from extremely small tissue samples.

#### Use of Partial 52906, 33408, or 12189 Sequences in Forensic Biology

DNA-based identification techniques can also be used in forensic biology. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, 15 e.g., blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.

The sequences of the present invention can be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can 20 enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (i.e. another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to noncoding regions of SEQ ID NO:1, SEQ ID 25 NO:4, or SEQ ID NO:7 (e.g., fragments derived from the noncoding regions of SEQ ID NO:1, SEQ ID NO:4, or SEQ ID NO:7 having a length of at least 20 bases, preferably at least 30 bases) are particularly appropriate for this use.

The 52906, 33408, or 12189 nucleotide sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be 30 used in, for example, an *in situ* hybridization technique, to identify a specific tissue. This

can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such 52906, 33408, or 12189 probes can be used to identify tissue by species and/or by organ type.

5 In a similar fashion, these reagents, e.g., 52906, 33408, or 12189 primers or probes can be used to screen tissue culture for contamination (i.e. screen for the presence of a mixture of different types of cells in a culture).

### Predictive Medicine

10 The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual.

Generally, the invention provides, a method of determining if a subject is at risk for a disorder related to a lesion in or the misexpression of a gene which encodes 52906, 33408, or 12189 .

15 Such disorders include, e.g., a disorder associated with the misexpression of 52906, 33408, or 12189 gene, or a disorder characterized by abnormal ion flux such as a neurological disorder or a cardiac disorder.

The method includes one or more of the following:

20 detecting, in a tissue of the subject, the presence or absence of a mutation which affects the expression of the 52906, 33408, or 12189 gene, or detecting the presence or absence of a mutation in a region which controls the expression of the gene, e.g., a mutation in the 5' control region;

detecting, in a tissue of the subject, the presence or absence of a mutation which alters the structure of the 52906, 33408, or 12189 gene;

25 detecting, in a tissue of the subject, the misexpression of the 52906, 33408, or 12189 gene, at the mRNA level, e.g., detecting a non-wild type level of a mRNA ;

detecting, in a tissue of the subject, the misexpression of the gene, at the protein level, e.g., detecting a non-wild type level of a 52906, 33408, or 12189 polypeptide.

30 In preferred embodiments the method includes: ascertaining the existence of at least one of: a deletion of one or more nucleotides from the 52906, 33408, or 12189 gene; an insertion of one or more nucleotides into the gene, a point mutation, e.g., a substitution

of one or more nucleotides of the gene, a gross chromosomal rearrangement of the gene, e.g., a translocation, inversion, or deletion.

For example, detecting the genetic lesion can include: (i) providing a probe/primer including an oligonucleotide containing a region of nucleotide sequence which hybridizes to a sense or antisense sequence from SEQ ID NO:1, SEQ ID NO:4, or SEQ ID NO:7, or naturally occurring mutants thereof or 5' or 3' flanking sequences naturally associated with the 52906, 33408, or 12189 gene; (ii) exposing the probe/primer to nucleic acid of the tissue; and detecting, by hybridization, e.g., *in situ* hybridization, of the probe/primer to the nucleic acid, the presence or absence of the genetic lesion.

10 In preferred embodiments detecting the misexpression includes ascertaining the existence of at least one of: an alteration in the level of a messenger RNA transcript of the 52906, 33408, or 12189 gene; the presence of a non-wild type splicing pattern of a messenger RNA transcript of the gene; or a non-wild type level of 52906, 33408, or 12189.

15 Methods of the invention can be used prenatally or to determine if a subject's offspring will be at risk for a disorder.

In preferred embodiments the method includes determining the structure of a 52906, 33408, or 12189 gene, an abnormal structure being indicative of risk for the disorder.

20 In preferred embodiments the method includes contacting a sample from the subject with an antibody to the 52906, 33408, or 12189 protein or a nucleic acid, which hybridizes specifically with the gene. These and other embodiments are discussed below.

#### Diagnostic and Prognostic Assays

Diagnostic and prognostic assays of the invention include methods for assessing 25 the expression level of 52906, 33408, or 12189 molecules and for identifying variations and mutations in the sequence of 52906, 33408, or 12189 molecules.

#### Expression Monitoring and Profiling

30 The presence, level, or absence of 52906, 33408, or 12189 protein or nucleic acid in a biological sample can be evaluated by obtaining a biological sample from a test

subject and contacting the biological sample with a compound or an agent capable of detecting 52906, 33408, or 12189 protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes 52906, 33408, or 12189 protein such that the presence of 52906, 33408, or 12189 protein or nucleic acid is detected in the biological sample. The term "biological sample" includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. A preferred biological sample is serum. The level of expression of the 52906, 33408, or 12189 gene can be measured in a number of ways, including, but not limited to: measuring the mRNA encoded by the 52906, 33408, or 12189 genes; measuring the amount of protein encoded by the 52906, 33408, or 12189 genes; or measuring the activity of the protein encoded by the 52906, 33408, or 12189 genes.

The level of mRNA corresponding to the 52906, 33408, or 12189 gene in a cell can be determined both by *in situ* and by *in vitro* formats.

The isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses and probe arrays. One preferred diagnostic method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to the mRNA encoded by the gene being detected. The nucleic acid probe can be, for example, a full-length 52906, 33408, or 12189 nucleic acid, such as the nucleic acid of SEQ ID NO:1, SEQ ID NO:4, or SEQ ID NO:7, or a portion thereof, such as an oligonucleotide of at least 7, 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to 52906, 33408, or 12189 mRNA or genomic DNA. The probe can be disposed on an address of an array, e.g., an array described below. Other suitable probes for use in the diagnostic assays are described herein.

In one format, mRNA (or cDNA) is immobilized on a surface and contacted with the probes, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative format, the probes are immobilized on a surface and the mRNA (or cDNA) is contacted with the probes, for example, in a two-dimensional gene chip array described below. A skilled

artisan can adapt known mRNA detection methods for use in detecting the level of mRNA encoded by the 52906, 33408, or 12189 genes.

The level of mRNA in a sample that is encoded by one of 52906, 33408, or 12189 can be evaluated with nucleic acid amplification, e.g., by rtPCR (Mullis (1987) U.S.

5 Patent No. 4,683,202), ligase chain reaction (Barany (1991) *Proc. Natl. Acad. Sci. USA* 88:189-193), self sustained sequence replication (Guatelli *et al.*, (1990) *Proc. Natl. Acad. Sci. USA* 87:1874-1878), transcriptional amplification system (Kwoh *et al.*, (1989), *Proc. Natl. Acad. Sci. USA* 86:1173-1177), Q-Beta Replicase (Lizardi *et al.*, (1988) *Bio/Technology* 6:1197), rolling circle replication (Lizardi *et al.*, U.S. Patent No.

10 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques known in the art. As used herein, amplification primers are defined as being a pair of nucleic acid molecules that can anneal to 5' or 3' regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between. In general, amplification primers are from about 10 to 30 nucleotides

15 in length and flank a region from about 50 to 200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule comprising the nucleotide sequence flanked by the primers.

For *in situ* methods, a cell or tissue sample can be prepared/processed and 20 immobilized on a support, typically a glass slide, and then contacted with a probe that can hybridize to mRNA that encodes the 52906, 33408, or 12189 gene being analyzed.

In another embodiment, the methods further contacting a control sample with a 25 compound or agent capable of detecting 52906, 33408, or 12189 mRNA, or genomic DNA, and comparing the presence of 52906, 33408, or 12189 mRNA or genomic DNA in the control sample with the presence of 52906, 33408, or 12189 mRNA or genomic DNA in the test sample. In still another embodiment, serial analysis of gene expression, as described in U.S. Patent No. 5,695,937, is used to detect 52906, 33408, or 12189 transcript levels.

A variety of methods can be used to determine the level of protein encoded by 30 52906, 33408, or 12189. In general, these methods include contacting an agent that selectively binds to the protein, such as an antibody with a sample, to evaluate the level

of protein in the sample. In a preferred embodiment, the antibody bears a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')<sub>2</sub>) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with a detectable substance. Examples of detectable substances are provided herein.

5 The detection methods can be used to detect 52906, 33408, or 12189 protein in a biological sample *in vitro* as well as *in vivo*. *In vitro* techniques for detection of 52906, 10 33408, or 12189 protein include enzyme linked immunosorbent assays (ELISAs), immunoprecipitations, immunofluorescence, enzyme immunoassay (EIA), radioimmunoassay (RIA), and Western blot analysis. *In vivo* techniques for detection of 52906, 33408, or 12189 protein include introducing into a subject a labeled anti-52906, 15 33408, or 12189 antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. In another embodiment, the sample is labeled, e.g., biotinylated and then contacted to the antibody, e.g., an anti-52906, 33408, or 12189 antibody positioned on an antibody array (as described below). The sample can be detected, e.g., with avidin coupled to a fluorescent label.

20 In another embodiment, the methods further include contacting the control sample with a compound or agent capable of detecting 52906, 33408, or 12189 protein, and comparing the presence of 52906, 33408, or 12189 protein in the control sample with the presence of 52906, 33408, or 12189 protein in the test sample.

25 The invention also includes kits for detecting the presence of 52906, 33408, or 12189 in a biological sample. For example, the kit can include a compound or agent capable of detecting 52906, 33408, or 12189 protein or mRNA in a biological sample; and a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect 52906, 33408, or 12189 protein or nucleic acid.

30 For antibody-based kits, the kit can include: (1) a first antibody (e.g., attached to a solid support) which binds to a polypeptide corresponding to a marker of the invention;

and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable agent.

For oligonucleotide-based kits, the kit can include: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide corresponding to a marker of the invention or (2) a pair of primers useful for amplifying a nucleic acid molecule corresponding to a marker of the invention. The kit can also includes a buffering agent, a preservative, or a protein stabilizing agent. The kit can also includes components necessary for detecting the detectable agent (e.g., an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained. Each component of the kit can be enclosed within an individual container and all of the various containers can be within a single package, along with instructions for interpreting the results of the assays performed using the kit.

The diagnostic methods described herein can identify subjects having, or at risk of developing, a disease or disorder associated with misexpressed or aberrant or unwanted 52906, 33408, or 12189 expression or activity. As used herein, the term "unwanted" includes an unwanted phenomenon involved in a biological response such disorders characterized by abnormal ion flux such as neurological disorders or cardiac disorders.

In one embodiment, a disease or disorder associated with aberrant or unwanted 52906, 33408, or 12189 expression or activity is identified. A test sample is obtained from a subject and 52906, 33408, or 12189 protein or nucleic acid (e.g., mRNA or genomic DNA) is evaluated, wherein the level, e.g., the presence or absence, of 52906, 33408, or 12189 protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant or unwanted 52906, 33408, or 12189 expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest, including a biological fluid (e.g., serum), cell sample, or tissue.

The prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant or unwanted 52906, 33408, or 12189 expression or

activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for disorders characterized by abnormal ion flux such as neurological disorders or cardiac disorders.

5 In another aspect, the invention features a computer medium having a plurality of digitally encoded data records. Each data record includes a value representing the level of expression of 52906, 33408, or 12189 in a sample, and a descriptor of the sample. The descriptor of the sample can be an identifier of the sample, a subject from which the sample was derived (e.g., a patient), a diagnosis, or a treatment (e.g., a preferred treatment). In a preferred embodiment, the data record further includes values 10 representing the level of expression of genes other than 52906, 33408, or 12189 (e.g., other genes associated with a 52906, 33408, or 12189 -disorder, or other genes on an array). The data record can be structured as a table, e.g., a table that is part of a database such as a relational database (e.g., a SQL database of the Oracle or Sybase database environments).

15 Also featured is a method of evaluating a sample. The method includes providing a sample, e.g., from the subject, and determining a gene expression profile of the sample, wherein the profile includes a value representing the level of 52906, 33408, or 12189 expression. The method can further include comparing the value or the profile (i.e., multiple values) to a reference value or reference profile. The gene expression profile of 20 the sample can be obtained by any of the methods described herein (e.g., by providing a nucleic acid from the sample and contacting the nucleic acid to an array). The method can be used to diagnose an ion flux-related disorder in a subject wherein a modulation (increase or decrease) in 52906, 33408, or 12189 expression is an indication that the subject has or is disposed to having a disorder characterized by abnormal ion flux such as 25 a neurological disorder or a cardiac disorder. The method can be used to monitor a treatment for an ion flux-related disorder in a subject. For example, the gene expression profile can be determined for a sample from a subject undergoing treatment. The profile can be compared to a reference profile or to a profile obtained from the subject prior to treatment or prior to onset of the disorder (see, e.g., Golub *et al.* (1999) *Science* 286:531).

30 In yet another aspect, the invention features a method of evaluating a test compound (see also, "Screening Assays", above). The method includes providing a cell

and a test compound; contacting the test compound to the cell; obtaining a subject expression profile for the contacted cell; and comparing the subject expression profile to one or more reference profiles. The profiles include a value representing the level of 52906, 33408, or 12189 expression. In a preferred embodiment, the subject expression profile is compared to a target profile, e.g., a profile for a normal cell or for desired condition of a cell. The test compound is evaluated favorably if the subject expression profile is more similar to the target profile than an expression profile obtained from an uncontacted cell.

In another aspect, the invention features, a method of evaluating a subject. The 10 method includes: a) obtaining a sample from a subject, e.g., from a caregiver, e.g., a caregiver who obtains the sample from the subject; b) determining a subject expression profile for the sample. Optionally, the method further includes either or both of steps: c) comparing the subject expression profile to one or more reference expression profiles; and d) selecting the reference profile most similar to the subject reference profile. The 15 subject expression profile and the reference profiles include a value representing the level of 52906, 33408, or 12189 expression. A variety of routine statistical measures can be used to compare two reference profiles. One possible metric is the length of the distance vector that is the difference between the two profiles. Each of the subject and reference profile is represented as a multi-dimensional vector, wherein each dimension is a value in 20 the profile.

The method can further include transmitting a result to a caregiver. The result can be the subject expression profile, a result of a comparison of the subject expression profile with another profile, a most similar reference profile, or a descriptor of any of the aforementioned. The result can be transmitted across a computer network, e.g., the 25 result can be in the form of a computer transmission, e.g., a computer data signal embedded in a carrier wave.

Also featured is a computer medium having executable code for effecting the following steps: receive a subject expression profile; access a database of reference expression profiles; and either i) select a matching reference profile most similar to the 30 subject expression profile or ii) determine at least one comparison score for the similarity of the subject expression profile to at least one reference profile. The subject expression

profile, and the reference expression profiles each include a value representing the level of 52906, 33408, or 12189 expression.

#### Arrays and Uses Thereof

In another aspect, the invention features an array that includes a substrate having a plurality of addresses. At least one address of the plurality includes a capture probe that binds specifically to a 52906, 33408, or 12189 molecule (e.g., a 52906, 33408, or 12189 nucleic acid or a 52906, 33408, or 12189 polypeptide). The array can have a density of at least than 10, 50, 100, 200, 500, 1,000, 2,000, or 10,000 or more addresses/cm<sup>2</sup>, and ranges between. In a preferred embodiment, the plurality of addresses includes at least 10, 100, 500, 1,000, 5,000, 10,000, 50,000 addresses. In a preferred embodiment, the plurality of addresses includes equal to or less than 10, 100, 500, 1,000, 5,000, 10,000, or 50,000 addresses. The substrate can be a two-dimensional substrate such as a glass slide, a wafer (e.g., silica or plastic), a mass spectroscopy plate, or a three-dimensional substrate such as a gel pad. Addresses in addition to address of the plurality can be disposed on the array.

In a preferred embodiment, at least one address of the plurality includes a nucleic acid capture probe that hybridizes specifically to a 52906, 33408, or 12189 nucleic acid, e.g., the sense or anti-sense strand. In one preferred embodiment, a subset of addresses of the plurality of addresses has a nucleic acid capture probe for 52906, 33408, or 12189.

Each address of the subset can include a capture probe that hybridizes to a different region of a 52906, 33408, or 12189 nucleic acid. In another preferred embodiment, addresses of the subset include a capture probe for a 52906, 33408, or 12189 nucleic acid. Each address of the subset is unique, overlapping, and complementary to a different variant of 52906, 33408, or 12189 (e.g., an allelic variant, or all possible hypothetical variants). The array can be used to sequence 52906, 33408, or 12189 by hybridization (see, e.g., U.S. Patent No. 5,695,940).

An array can be generated by various methods, e.g., by photolithographic methods (see, e.g., U.S. Patent Nos. 5,143,854; 5,510,270; and 5,527,681), mechanical methods (e.g., directed-flow methods as described in U.S. Patent No. 5,384,261), pin-based

methods (e.g., as described in U.S. Pat. No. 5,288,514), and bead-based techniques (e.g., as described in PCT US/93/04145).

In another preferred embodiment, at least one address of the plurality includes a polypeptide capture probe that binds specifically to a 52906, 33408, or 12189 polypeptide or fragment thereof. The polypeptide can be a naturally-occurring interaction partner of 52906, 33408, or 12189 polypeptide. Preferably, the polypeptide is an antibody, e.g., an antibody described herein (see "Anti-52906, 33408, or 12189 Antibodies," above), such as a monoclonal antibody or a single-chain antibody.

In another aspect, the invention features a method of analyzing the expression of 52906, 33408, or 12189. The method includes providing an array as described above; contacting the array with a sample and detecting binding of a 52906, 33408, or 12189 - molecule (e.g., nucleic acid or polypeptide) to the array. In a preferred embodiment, the array is a nucleic acid array. Optionally the method further includes amplifying nucleic acid from the sample prior or during contact with the array.

In another embodiment, the array can be used to assay gene expression in a tissue to ascertain tissue specificity of genes in the array, particularly the expression of 52906, 33408, or 12189. If a sufficient number of diverse samples is analyzed, clustering (e.g., hierarchical clustering, k-means clustering, Bayesian clustering and the like) can be used to identify other genes which are co-regulated with 52906, 33408, or 12189. For example, the array can be used for the quantitation of the expression of multiple genes. Thus, not only tissue specificity, but also the level of expression of a battery of genes in the tissue is ascertained. Quantitative data can be used to group (e.g., cluster) genes on the basis of their tissue expression *per se* and level of expression in that tissue.

For example, array analysis of gene expression can be used to assess the effect of cell-cell interactions on 52906, 33408, or 12189 expression. A first tissue can be perturbed and nucleic acid from a second tissue that interacts with the first tissue can be analyzed. In this context, the effect of one cell type on another cell type in response to a biological stimulus can be determined, e.g., to monitor the effect of cell-cell interaction at the level of gene expression.

In another embodiment, cells are contacted with a therapeutic agent. The expression profile of the cells is determined using the array, and the expression profile is

compared to the profile of like cells not contacted with the agent. For example, the assay can be used to determine or analyze the molecular basis of an undesirable effect of the therapeutic agent. If an agent is administered therapeutically to treat one cell type but has an undesirable effect on another cell type, the invention provides an assay to determine 5 the molecular basis of the undesirable effect and thus provides the opportunity to co-administer a counteracting agent or otherwise treat the undesired effect. Similarly, even within a single cell type, undesirable biological effects can be determined at the molecular level. Thus, the effects of an agent on expression of other than the target gene can be ascertained and counteracted.

10 In another embodiment, the array can be used to monitor expression of one or more genes in the array with respect to time. For example, samples obtained from different time points can be probed with the array. Such analysis can identify and/or characterize the development of a 52906, 33408, or 12189 -associated disease or disorder; and processes, such as a cellular transformation associated with a 52906, 33408, 15 or 12189 -associated disease or disorder. The method can also evaluate the treatment and/or progression of a 52906, 33408, or 12189 -associated disease or disorder

20 The array is also useful for ascertaining differential expression patterns of one or more genes in normal and abnormal cells. This provides a battery of genes (e.g., including 52906, 33408, or 12189 ) that could serve as a molecular target for diagnosis or therapeutic intervention.

25 In another aspect, the invention features an array having a plurality of addresses. Each address of the plurality includes a unique polypeptide. At least one address of the plurality has disposed thereon a 52906, 33408, or 12189 polypeptide or fragment thereof. Methods of producing polypeptide arrays are described in the art, e.g., in De Wildt *et al.* (2000). *Nature Biotech.* 18, 989-994; Lueking *et al.* (1999). *Anal. Biochem.* 270, 103-111; Ge, H. (2000). *Nucleic Acids Res.* 28, e3, I-VII; MacBeath, G., and Schreiber, S.L. (2000). *Science* 289, 1760-1763; and WO 99/51773A1. In a preferred embodiment, each address of the plurality has disposed thereon a polypeptide at least 60, 70, 80, 85, 90, 95 or 99 % identical to a 52906, 33408, or 12189 polypeptide or fragment thereof. For 30 example, multiple variants of a 52906, 33408, or 12189 polypeptide (e.g., encoded by allelic variants, site-directed mutants, random mutants, or combinatorial mutants) can be

disposed at individual addresses of the plurality. Addresses in addition to the address of the plurality can be disposed on the array.

The polypeptide array can be used to detect a 52906, 33408, or 12189 binding compound, e.g., an antibody in a sample from a subject with specificity for a 52906, 5 33408, or 12189 polypeptide or the presence of a 52906, 33408, or 12189 -binding protein or ligand.

The array is also useful for ascertaining the effect of the expression of a gene on the expression of other genes in the same cell or in different cells (e.g., ascertaining the effect of 52906, 33408, or 12189 expression on the expression of other genes). This 10 provides, for example, for a selection of alternate molecular targets for therapeutic intervention if the ultimate or downstream target cannot be regulated.

In another aspect, the invention features a method of analyzing a plurality of probes. The method is useful, e.g., for analyzing gene expression. The method includes: providing a two dimensional array having a plurality of addresses, each address of the 15 plurality being positionally distinguishable from each other address of the plurality having a unique capture probe, e.g., wherein the capture probes are from a cell or subject which express 52906, 33408, or 12189 or from a cell or subject in which a 52906, 33408, or 12189 mediated response has been elicited, e.g., by contact of the cell with 52906, 33408, or 12189 nucleic acid or protein, or administration to the cell or subject 52906, 20 33408, or 12189 nucleic acid or protein; providing a two dimensional array having a plurality of addresses, each address of the plurality being positionally distinguishable from each other address of the plurality, and each address of the plurality having a unique capture probe, e.g., wherein the capture probes are from a cell or subject which does not express 52906, 33408, or 12189 (or does not express as highly as in the case of the 25 52906, 33408, or 12189 positive plurality of capture probes) or from a cell or subject which in which a 52906, 33408, or 12189 mediated response has not been elicited (or has been elicited to a lesser extent than in the first sample); contacting the array with one or more inquiry probes (which is preferably other than a 52906, 33408, or 12189 nucleic acid, polypeptide, or antibody), and thereby evaluating the plurality of capture probes. 30 Binding, e.g., in the case of a nucleic acid, hybridization with a capture probe at an

address of the plurality, is detected, e.g., by signal generated from a label attached to the nucleic acid, polypeptide, or antibody.

In another aspect, the invention features a method of analyzing a plurality of probes or a sample. The method is useful, e.g., for analyzing gene expression. The method includes: providing a two dimensional array having a plurality of addresses, each address of the plurality being positionally distinguishable from each other address of the plurality having a unique capture probe, contacting the array with a first sample from a cell or subject which express or mis-express 52906, 33408, or 12189 or from a cell or subject in which a 52906, 33408, or 12189 -mediated response has been elicited, e.g., by contact of the cell with 52906, 33408, or 12189 nucleic acid or protein, or administration to the cell or subject 52906, 33408, or 12189 nucleic acid or protein; providing a two dimensional array having a plurality of addresses, each address of the plurality being positionally distinguishable from each other address of the plurality, and each address of the plurality having a unique capture probe, and contacting the array with a second sample from a cell or subject which does not express 52906, 33408, or 12189 (or does not express as highly as in the case of the 52906, 33408, or 12189 positive plurality of capture probes) or from a cell or subject which in which a 52906, 33408, or 12189 mediated response has not been elicited (or has been elicited to a lesser extent than in the first sample); and comparing the binding of the first sample with the binding of the second sample. Binding, e.g., in the case of a nucleic acid, hybridization with a capture probe at an address of the plurality, is detected, e.g., by signal generated from a label attached to the nucleic acid, polypeptide, or antibody. The same array can be used for both samples or different arrays can be used. If different arrays are used the plurality of addresses with capture probes should be present on both arrays.

In another aspect, the invention features a method of analyzing 52906, 33408, or 12189, e.g., analyzing structure, function, or relatedness to other nucleic acid or amino acid sequences. The method includes: providing a 52906, 33408, or 12189 nucleic acid or amino acid sequence; comparing the 52906, 33408, or 12189 sequence with one or more preferably a plurality of sequences from a collection of sequences, e.g., a nucleic acid or protein sequence database; to thereby analyze 52906, 33408, or 12189.

Detection of Variations or Mutations

The methods of the invention can also be used to detect genetic alterations in a 52906, 33408, or 12189 gene, thereby determining if a subject with the altered gene is at risk for a disorder characterized by misregulation in 52906, 33408, or 12189 protein. 5 activity or nucleic acid expression, such as a disorder characterized by abnormal ion flux such as a neurological disorder or a cardiac disorder. In preferred embodiments, the methods include detecting, in a sample from the subject, the presence or absence of a genetic alteration characterized by at least one of an alteration affecting the integrity of a gene encoding a 52906, 33408, or 12189 -protein, or the mis-expression of the 52906, 10 33408, or 12189 gene. For example, such genetic alterations can be detected by ascertaining the existence of at least one of 1) a deletion of one or more nucleotides from a 52906, 33408, or 12189 gene; 2) an addition of one or more nucleotides to a 52906, 33408, or 12189 gene; 3) a substitution of one or more nucleotides of a 52906, 33408, or 12189 gene, 4) a chromosomal rearrangement of a 52906, 33408, or 12189 gene; 5) an 15 alteration in the level of a messenger RNA transcript of a 52906, 33408, or 12189 gene, 6) aberrant modification of a 52906, 33408, or 12189 gene, such as of the methylation pattern of the genomic DNA, 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a 52906, 33408, or 12189 gene, 8) a non-wild type level of a 52906, 33408, or 12189 -protein, 9) allelic loss of a 52906, 33408, or 12189 gene, and 20 10) inappropriate post-translational modification of a 52906, 33408, or 12189 -protein.

An alteration can be detected without a probe/primer in a polymerase chain reaction, such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR), the latter of which can be particularly useful for detecting point mutations in the 52906, 33408, or 12189 -gene. This method can include the steps of collecting a sample 25 of cells from a subject, isolating nucleic acid (e.g., genomic, mRNA or both) from the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a 52906, 33408, or 12189 gene under conditions such that hybridization and amplification of the 52906, 33408, or 12189 -gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification 30 product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any

of the techniques used for detecting mutations described herein. Alternatively, other amplification methods described herein or known in the art can be used.

In another embodiment, mutations in a 52906, 33408, or 12189 gene from a sample cell can be identified by detecting alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined, e.g., by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in 52906, 33408, or 12189 can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, two-dimensional arrays, e.g., chip based arrays. Such arrays include a plurality of addresses, each of which is positionally distinguishable from the other. A different probe is located at each address of the plurality. A probe can be complementary to a region of a 52906, 33408, or 12189 nucleic acid or a putative variant (e.g., allelic variant) thereof. A probe can have one or more mismatches to a region of a 52906, 33408, or 12189 nucleic acid (e.g., a destabilizing mismatch). The arrays can have a high density of addresses, e.g., can contain hundreds or thousands of oligonucleotides probes (Cronin, M.T. *et al.* (1996) *Human Mutation* 7: 244-255; Kozal, M.J. *et al.* (1996) *Nature Medicine* 2: 753-759). For example, genetic mutations in 52906, 33408, or 12189 can be identified in two-dimensional arrays containing light-generated DNA probes as described in Cronin, M.T. *et al. supra*. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the 52906, 33408, or 12189 gene and detect mutations by comparing the sequence of the sample 52906, 33408, or 12189 with the corresponding wild-type (control) sequence. Automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) *Biotechniques* 19:448), including sequencing by mass spectrometry.

Other methods for detecting mutations in the 52906, 33408, or 12189 gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers *et al.* (1985) *Science* 230:1242; Cotton *et al.* (1988) *Proc. Natl Acad Sci USA* 85:4397; Saleeba *et al.* (1992) *Methods Enzymol.* 217:286-295).

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in 52906, 33408, or 12189 cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu *et al.* (1994) *Carcinogenesis* 15:1657-1662; U.S. Patent No. 5,459,039).

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in 52906, 33408, or 12189 genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita *et al.* (1989) *Proc Natl. Acad. Sci USA*: 86:2766, see also Cotton (1993) *Mutat. Res.* 285:125-144; and Hayashi (1992) *Genet. Anal. Tech. Appl.* 9:73-79). Single-stranded DNA fragments of sample and control 52906, 33408, or 12189 nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double

stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen *et al.* (1991) *Trends Genet* 7:5).

In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing 5 gradient gel electrophoresis (DGGE) (Myers *et al.* (1985) *Nature* 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and 10 sample DNA (Rosenbaum and Reissner (1987) *Biophys Chem* 265:12753).

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension (Saiki *et al.* (1986) *Nature* 324:163); Saiki *et al.* (1989) *Proc. Natl Acad. Sci USA* 86:6230). A further method of detecting point mutations is the chemical 15 ligation of oligonucleotides as described in Xu *et al.* ((2001) *Nature Biotechnol.* 19:148). Adjacent oligonucleotides, one of which selectively anneals to the query site, are ligated together if the nucleotide at the query site of the sample nucleic acid is complementary to the query oligonucleotide; ligation can be monitored, e.g., by fluorescent dyes coupled to the oligonucleotides.

20 Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention.

Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential 25 hybridization) (Gibbs *et al.* (1989) *Nucleic Acids Res.* 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) *Tibtech* 11:238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini *et al.* (1992) *Mol. Cell Probes* 6:1). It is anticipated that in certain 30 embodiments amplification may also be performed using Taq ligase for amplification (Barany (1991) *Proc. Natl. Acad. Sci USA* 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence making it possible to detect

the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

In another aspect, the invention features a set of oligonucleotides. The set includes a plurality of oligonucleotides, each of which is at least partially complementary (e.g., at least 50%, 60%, 70%, 80%, 90%, 92%, 95%, 97%, 98%, or 99% complementary) to a 52906, 33408, or 12189 nucleic acid.

5 In a preferred embodiment the set includes a first and a second oligonucleotide. The first and second oligonucleotide can hybridize to the same or to different locations of SEQ ID NO:1, SEQ ID NO:4, or SEQ ID NO:7 or the complement of SEQ ID NO:1, 10 SEQ ID NO:4, or SEQ ID NO:7. Different locations can be different but overlapping, or non-overlapping on the same strand. The first and second oligonucleotide can hybridize to sites on the same or on different strands.

15 The set can be useful, e.g., for identifying SNP's, or identifying specific alleles of 52906, 33408, or 12189. In a preferred embodiment, each oligonucleotide of the set has a different nucleotide at an interrogation position. In one embodiment, the set includes 20 two oligonucleotides, each complementary to a different allele at a locus, e.g., a biallelic or polymorphic locus.

25 In another embodiment, the set includes four oligonucleotides, each having a different nucleotide (e.g., adenine, guanine, cytosine, or thymidine) at the interrogation position. The interrogation position can be a SNP or the site of a mutation. In another preferred embodiment, the oligonucleotides of the plurality are identical in sequence to one another (except for differences in length). The oligonucleotides can be provided with differential labels, such that an oligonucleotide that hybridizes to one allele provides a signal that is distinguishable from an oligonucleotide that hybridizes to a second allele. 30 In still another embodiment, at least one of the oligonucleotides of the set has a nucleotide change at a position in addition to a query position, e.g., a destabilizing mutation to decrease the  $T_m$  of the oligonucleotide. In another embodiment, at least one oligonucleotide of the set has a non-natural nucleotide, e.g., inosine. In a preferred embodiment, the oligonucleotides are attached to a solid support, e.g., to different addresses of an array or to different beads or nanoparticles.

In a preferred embodiment the set of oligo nucleotides can be used to specifically amplify, e.g., by PCR, or detect, a 52906, 33408, or 12189 nucleic acid.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a 52906, 33408, or 12189 gene.

#### Use of 52906, 33408, or 12189 Molecules as Surrogate Markers

The 52906, 33408, or 12189 molecules of the invention are also useful as markers of disorders or disease states, as markers for precursors of disease states, as markers for predisposition of disease states, as markers of drug activity, or as markers of the pharmacogenomic profile of a subject. Using the methods described herein, the presence, absence and/or quantity of the 52906, 33408, or 12189 molecules of the invention may be detected, and may be correlated with one or more biological states in vivo. For example, the 52906, 33408, or 12189 molecules of the invention may serve as surrogate markers for one or more disorders or disease states or for conditions leading up to disease states. As used herein, a "surrogate marker" is an objective biochemical marker which correlates with the absence or presence of a disease or disorder, or with the progression of a disease or disorder (e.g., with the presence or absence of a tumor). The presence or quantity of such markers is independent of the disease. Therefore, these markers may serve to indicate whether a particular course of treatment is effective in lessening a disease state or disorder. Surrogate markers are of particular use when the presence or extent of a disease state or disorder is difficult to assess through standard methodologies (e.g., early stage tumors), or when an assessment of disease progression is desired before a potentially dangerous clinical endpoint is reached (e.g., an assessment of cardiovascular disease may be made using cholesterol levels as a surrogate marker, and an analysis of HIV infection may be made using HIV RNA levels as a surrogate marker, well in advance of the undesirable clinical outcomes of myocardial infarction or fully-developed AIDS). Examples of the use of surrogate markers in the art include: Koomen *et al.*

(2000) *J. Mass. Spectrom.* 35: 258-264; and James (1994) *AIDS Treatment News Archive* 209.

The 52906, 33408, or 12189 molecules of the invention are also useful as pharmacodynamic markers. As used herein, a "pharmacodynamic marker" is an objective biochemical marker which correlates specifically with drug effects. The presence or quantity of a pharmacodynamic marker is not related to the disease state or disorder for which the drug is being administered; therefore, the presence or quantity of the marker is indicative of the presence or activity of the drug in a subject. For example, a pharmacodynamic marker may be indicative of the concentration of the drug in a biological tissue, in that the marker is either expressed or transcribed or not expressed or transcribed in that tissue in relationship to the level of the drug. In this fashion, the distribution or uptake of the drug may be monitored by the pharmacodynamic marker. Similarly, the presence or quantity of the pharmacodynamic marker may be related to the presence or quantity of the metabolic product of a drug, such that the presence or quantity of the marker is indicative of the relative breakdown rate of the drug *in vivo*.

Pharmacodynamic markers are of particular use in increasing the sensitivity of detection of drug effects, particularly when the drug is administered in low doses. Since even a small amount of a drug may be sufficient to activate multiple rounds of marker (e.g., a 52906, 33408, or 12189 marker) transcription or expression, the amplified marker may be in a quantity which is more readily detectable than the drug itself. Also, the marker may be more easily detected due to the nature of the marker itself; for example, using the methods described herein, anti-52906, 33408, or 12189 antibodies may be employed in an immune-based detection system for a 52906, 33408, or 12189 protein marker, or 52906, 33408, or 12189-specific radiolabeled probes may be used to detect a 52906, 33408, or 12189 mRNA marker. Furthermore, the use of a pharmacodynamic marker may offer mechanism-based prediction of risk due to drug treatment beyond the range of possible direct observations. Examples of the use of pharmacodynamic markers in the art include: Matsuda *et al.* US 6,033,862; Hattis *et al.* (1991) *Env. Health Perspect.* 90: 229-238; Schentag (1999) *Am. J. Health-Syst. Pharm.* 56 Suppl. 3: S21-S24; and Nicolau (1999) *Am. J. Health-Syst. Pharm.* 56 Suppl. 3: S16-S20.

The 52906, 33408, or 12189 molecules of the invention are also useful as pharmacogenomic markers. As used herein, a "pharmacogenomic marker" is an objective biochemical marker which correlates with a specific clinical drug response or susceptibility in a subject (see, e.g., McLeod *et al.* (1999) *Eur. J. Cancer* 35:1650-1652).

5 The presence or quantity of the pharmacogenomic marker is related to the predicted response of the subject to a specific drug or class of drugs prior to administration of the drug. By assessing the presence or quantity of one or more pharmacogenomic markers in a subject, a drug therapy which is most appropriate for the subject, or which is predicted to have a greater degree of success, may be selected. For example, based on the presence  
10 or quantity of RNA, or protein (e.g., 52906, 33408, or 12189 protein or RNA) for specific tumor markers in a subject, a drug or course of treatment may be selected that is optimized for the treatment of the specific tumor likely to be present in the subject. Similarly, the presence or absence of a specific sequence mutation in 52906, 33408, or  
15 12189 DNA may correlate 52906, 33408, or 12189 drug response. The use of pharmacogenomic markers therefore permits the application of the most appropriate treatment for each subject without having to administer the therapy.

#### Pharmaceutical Compositions

The nucleic acid and polypeptides, fragments thereof, as well as anti-52906, 33408, or 12189 antibodies (also referred to herein as "active compounds") of the  
20 invention can be incorporated into pharmaceutical compositions. Such compositions typically include the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical  
25 administration. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical),  
30 transmucosal, and rectal administration. Solutions or suspensions used for parenteral,

intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

10 Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethyleneglycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

30 Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients

enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, 5 the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with 10 excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules.

Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain 15 any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

20 For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For 25 transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active 30 compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will 5 protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. 10 The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

15 It is advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical 20 carrier.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose 25 therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds which exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

30 The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies

preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

As defined herein, a therapeutically effective amount of protein or polypeptide (i.e., an effective dosage) ranges from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The protein or polypeptide can be administered one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments.

For antibodies, the preferred dosage is 0.1 mg/kg of body weight (generally 10 mg/kg to 20 mg/kg). If the antibody is to act in the brain, a dosage of 50 mg/kg to 100 mg/kg is usually appropriate. Generally, partially human antibodies and fully human antibodies have a longer half-life within the human body than other antibodies. Accordingly, lower dosages and less frequent administration is often possible. Modifications such as lipidation can be used to stabilize antibodies and to enhance uptake and tissue penetration (e.g., into the brain). A method for lipidation of antibodies is

described by Cruikshank *et al.* ((1997) *J. Acquired Immune Deficiency Syndromes and Human Retrovirology* 14:193).

The present invention encompasses agents which modulate expression or activity. An agent may, for example, be a small molecule. For example, such small molecules include, but are not limited to, peptides, peptidomimetics (e.g., peptoids), amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.

Exemplary doses include milligram or microgram amounts of the small molecule per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram, or about 1 microgram per kilogram to about 50 micrograms per kilogram. It is furthermore understood that appropriate doses of a small molecule depend upon the potency of the small molecule with respect to the expression or activity to be modulated. When one or more of these small molecules is to be administered to an animal (e.g., a human) in order to modulate expression or activity of a polypeptide or nucleic acid of the invention, a physician, veterinarian, or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained. In addition, it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated.

An antibody (or fragment thereof) may be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent or a radioactive metal ion. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include taxol,

cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which

the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

5 The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

#### Methods of Treatment

The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated 10 with aberrant or unwanted 52906, 33408, or 12189 expression or activity. As used herein, the term "treatment" is defined as the application or administration of a therapeutic agent to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has a disease, a symptom of disease or a 15 predisposition toward a disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease, the symptoms of disease or the predisposition toward disease. A therapeutic agent includes, but is not limited to, small molecules, peptides, antibodies, ribozymes and antisense oligonucleotides.

With regards to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from 20 the field of pharmacogenomics. "Pharmacogenomics", as used herein, refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on the market. More specifically, the term refers the study of how a patient's genes determine his or her response to a drug (e.g., a patient's "drug response phenotype", or "drug response 25 genotype".) Thus, another aspect of the invention provides methods for tailoring an individual's prophylactic or therapeutic treatment with either the 52906, 33408, or 12189 molecules of the present invention or 52906, 33408, or 12189 modulators according to that individual's drug response genotype. Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most

benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.

In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant or unwanted 52906, 33408, or 12189 expression or activity, by administering to the subject a 52906, 33408, or 12189 or an agent which modulates 52906, 33408, or 12189 expression or at least one 52906, 33408, or 12189 activity. Subjects at risk for a disease which is caused or contributed to by aberrant or unwanted 52906, 33408, or 12189 expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein.

10 Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the 52906, 33408, or 12189 aberrance, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of 52906, 33408, or 12189 aberrance, for example, a 52906, 33408, or 12189, 52906, 33408, or 12189 agonist or 52906, 33408, or 12189 antagonist agent can be used for treating the

15 subject. The appropriate agent can be determined based on screening assays described herein.

It is possible that some 52906, 33408, or 12189 disorders can be caused, at least in part, by an abnormal level of gene product, or by the presence of a gene product exhibiting abnormal activity. As such, the reduction in the level and/or activity of such gene products would bring about the amelioration of disorder symptoms.

20 The 52906, 33408, or 12189 molecules can act as novel diagnostic targets and therapeutic agents for controlling one or more of cellular proliferative and/or differentiative disorders, disorders associated with bone metabolism, immune disorders, liver disorders, viral diseases, pain or metabolic disorders.

25 Examples of cellular proliferative and/or differentiative disorders include cancer, e.g., carcinoma, sarcoma, metastatic disorders or hematopoietic neoplastic disorders, e.g., leukemias. A metastatic tumor can arise from a multitude of primary tumor types, including but not limited to those of prostate, colon, lung, breast and liver origin.

30 As used herein, the terms "cancer", "hyperproliferative" and "neoplastic" refer to cells having the capacity for autonomous growth, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth. Hyperproliferative and neoplastic

disease states may be categorized as pathologic, i.e., characterizing or constituting a disease state, or may be categorized as non-pathologic, i.e., a deviation from normal but not associated with a disease state. The term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, 5 tissues, or organs, irrespective of histopathologic type or stage of invasiveness.

"Pathologic hyperproliferative" cells occur in disease states characterized by malignant tumor growth. Examples of non-pathologic hyperproliferative cells include proliferation of cells associated with wound repair.

10 The terms "cancer" or "neoplasms" include malignancies of the various organ systems, such as affecting lung, breast, thyroid, lymphoid, gastrointestinal, and genitourinary tract, as well as adenocarcinomas which include malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer and/or testicular tumors, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.

15 The term "carcinoma" is art recognized and refers to malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas. Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary. The term also includes carcinosarcomas, e.g., which include 20 malignant tumors composed of carcinomatous and sarcomatous tissues. An "adenocarcinoma" refers to a carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures.

The term "sarcoma" is art recognized and refers to malignant tumors of mesenchymal derivation.

25 Additional examples of proliferative disorders include hematopoietic neoplastic disorders. As used herein, the term "hematopoietic neoplastic disorders" includes diseases involving hyperplastic/neoplastic cells of hematopoietic origin, e.g., arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof. Preferably, the diseases arise from poorly differentiated acute leukemias, e.g., erythroblastic leukemia 30 and acute megakaryoblastic leukemia. Additional exemplary myeloid disorders include, but are not limited to, acute promyeloid leukemia (APML), acute myelogenous leukemia

(AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus, L. (1991) *Crit Rev. in Oncol./Hemotol.* 11:267-97); lymphoid malignancies include, but are not limited to acute lymphoblastic leukemia (ALL) which includes B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM). Additional forms of malignant lymphomas include, but are not limited to non-Hodgkin lymphoma and variants thereof, peripheral T cell lymphomas, adult T cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF), Hodgkin's disease and Reed-Sternberg disease.

5

10 Aberrant expression and/or activity of 52906, 33408, or 12189 molecules may mediate disorders associated with bone metabolism. "Bone metabolism" refers to direct or indirect effects in the formation or degeneration of bone structures, e.g., bone formation, bone resorption, etc., which may ultimately affect the concentrations in serum of calcium and phosphate. This term also includes activities mediated by 52906, 33408, or 12189 molecules effects in bone cells, e.g. osteoclasts and osteoblasts, that may in turn result in bone formation and degeneration. For example, 52906, 33408, or 12189 molecules may support different activities of bone resorbing osteoclasts such as the stimulation of differentiation of monocytes and mononuclear phagocytes into osteoclasts. Accordingly, 52906, 33408, or 12189 molecules that modulate the production of bone

15

20 cells can influence bone formation and degeneration, and thus may be used to treat bone disorders. Examples of such disorders include, but are not limited to, osteoporosis, osteodystrophy, osteomalacia, rickets, osteitis fibrosa cystica, renal osteodystrophy, osteosclerosis, anti-convulsant treatment, osteopenia, fibrogenesis-imperfecta ossium, secondary hyperparathyroidism, hypoparathyroidism, hyperparathyroidism, cirrhosis,

25

obstructive jaundice, drug induced metabolism, medullary carcinoma, chronic renal disease, rickets, sarcoidosis, glucocorticoid antagonism, malabsorption syndrome, steatorrhea, tropical sprue, idiopathic hypercalcemia and milk fever.

The 52906, 33408, or 12189 nucleic acid and protein of the invention can be used to treat and/or diagnose a variety of immune disorders. Examples of immune disorders or 30 diseases include, but are not limited to, autoimmune diseases (including, for example, diabetes mellitus, arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis,

osteoarthritis, psoriatic arthritis), multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematosis, autoimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, Sjögren's Syndrome, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, 5 asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, drug eruptions, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic 10 active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Graves' disease, sarcoidosis, primary biliary cirrhosis, uveitis posterior, and interstitial lung fibrosis), graft-versus-host disease, cases of transplantation, and allergy such as, atopic allergy.

Disorders which may be treated or diagnosed by methods described herein 15 include, but are not limited to, disorders associated with an accumulation in the liver of fibrous tissue, such as that resulting from an imbalance between production and degradation of the extracellular matrix accompanied by the collapse and condensation of preexisting fibers. The methods described herein can be used to diagnose or treat hepatocellular necrosis or injury induced by a wide variety of agents including processes 20 which disturb homeostasis, such as an inflammatory process, tissue damage resulting from toxic injury or altered hepatic blood flow, and infections (e.g., bacterial, viral and parasitic). For example, the methods can be used for the early detection of hepatic injury, such as portal hypertension or hepatic fibrosis. In addition, the methods can be employed to detect liver fibrosis attributed to inborn errors of metabolism, for example, fibrosis 25 resulting from a storage disorder such as Gaucher's disease (lipid abnormalities) or a glycogen storage disease, A1-antitrypsin deficiency; a disorder mediating the accumulation (e.g., storage) of an exogenous substance, for example, hemochromatosis (iron-overload syndrome) and copper storage diseases (Wilson's disease), disorders resulting in the accumulation of a toxic metabolite (e.g., tyrosinemia, fructosemia and 30 galactosemia) and peroxisomal disorders (e.g., Zellweger syndrome). Additionally, the methods described herein may be useful for the early detection and treatment of liver

injury associated with the administration of various chemicals or drugs, such as for example, methotrexate, isonizaid, oxyphenisatin, methyldopa, chlorpromazine, tolbutamide or alcohol, or which represents a hepatic manifestation of a vascular disorder such as obstruction of either the intrahepatic or extrahepatic bile flow or an alteration in hepatic circulation resulting, for example, from chronic heart failure, veno-occlusive disease, portal vein thrombosis or Budd-Chiari syndrome.

Additionally, 52906, 33408, or 12189 molecules may play an important role in the etiology of certain viral diseases, including but not limited to Hepatitis B, Hepatitis C and Herpes Simplex Virus (HSV). Modulators of 52906, 33408, or 12189 activity could be used to control viral diseases. The modulators can be used in the treatment and/or diagnosis of viral infected tissue or virus-associated tissue fibrosis, especially liver and liver fibrosis. Also, 52906, 33408, or 12189 modulators can be used in the treatment and/or diagnosis of virus-associated carcinoma, especially hepatocellular cancer.

Additionally, 52906, 33408, or 12189 may play an important role in the regulation of metabolism or pain disorders. Diseases of metabolic imbalance include, but are not limited to, obesity, anorexia nervosa, cachexia, lipid disorders, and diabetes. Examples of pain disorders include, but are not limited to, pain response elicited during various forms of tissue injury, e.g., inflammation, infection, and ischemia, usually referred to as hyperalgesia (described in, for example, Fields, H.L. (1987) *Pain*, New York:McGraw-Hill); pain associated with musculoskeletal disorders, e.g., joint pain; tooth pain; headaches; pain associated with surgery; pain related to irritable bowel syndrome; or chest pain.

As discussed, successful treatment of 52906, 33408, or 12189 disorders can be brought about by techniques that serve to inhibit the expression or activity of target gene products. For example, compounds, e.g., an agent identified using an assays described above, that proves to exhibit negative modulatory activity, can be used in accordance with the invention to prevent and/or ameliorate symptoms of 52906, 33408, or 12189 disorders. Such molecules can include, but are not limited to peptides, phosphopeptides, small organic or inorganic molecules, or antibodies (including, for example, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and Fab,

F(ab')<sub>2</sub> and Fab expression library fragments, scFV molecules, and epitope-binding fragments thereof).

Further, antisense and ribozyme molecules that inhibit expression of the target gene can also be used in accordance with the invention to reduce the level of target gene expression, thus effectively reducing the level of target gene activity. Still further, triple helix molecules can be utilized in reducing the level of target gene activity. Antisense, ribozyme and triple helix molecules are discussed above.

It is possible that the use of antisense, ribozyme, and/or triple helix molecules to reduce or inhibit mutant gene expression can also reduce or inhibit the transcription

10 (triple helix) and/or translation (antisense, ribozyme) of mRNA produced by normal target gene alleles, such that the concentration of normal target gene product present can be lower than is necessary for a normal phenotype. In such cases, nucleic acid molecules that encode and express target gene polypeptides exhibiting normal target gene activity can be introduced into cells via gene therapy method. Alternatively, in instances in that  
15 the target gene encodes an extracellular protein, it can be preferable to co-administer normal target gene protein into the cell or tissue in order to maintain the requisite level of cellular or tissue target gene activity.

Another method by which nucleic acid molecules may be utilized in treating or preventing a disease characterized by 52906, 33408, or 12189 expression is through the  
20 use of aptamer molecules specific for 52906, 33408, or 12189 protein. Aptamers are nucleic acid molecules having a tertiary structure which permits them to specifically bind to protein ligands (see, e.g., Osborne, *et al.* (1997) *Curr. Opin. Chem Biol.* 1: 5-9; and Patel, D.J. (1997) *Curr Opin Chem Biol* 1:32-46). Since nucleic acid molecules may in many cases be more conveniently introduced into target cells than therapeutic protein  
25 molecules may be, aptamers offer a method by which 52906, 33408, or 12189 protein activity may be specifically decreased without the introduction of drugs or other molecules which may have pluripotent effects.

Antibodies can be generated that are both specific for target gene product and that reduce target gene product activity. Such antibodies may, therefore, be administered in  
30 instances whereby negative modulatory techniques are appropriate for the treatment of

52906, 33408, or 12189 disorders. For a description of antibodies, see the Antibody section above.

In circumstances wherein injection of an animal or a human subject with a 52906, 33408, or 12189 protein or epitope for stimulating antibody production is harmful to the 5 subject, it is possible to generate an immune response against 52906, 33408, or 12189 through the use of anti-idiotypic antibodies (see, for example, Herlyn, D. (1999) *Ann Med* 31:66-78; and Bhattacharya-Chatterjee, M., and Foon, K.A. (1998) *Cancer Treat Res.* 94:51-68). If an anti-idiotypic antibody is introduced into a mammal or human subject, it should stimulate the production of anti-anti-idiotypic antibodies, which should be specific 10 to the 52906, 33408, or 12189 protein. Vaccines directed to a disease characterized by 52906, 33408, or 12189 expression may also be generated in this fashion.

In instances where the target antigen is intracellular and whole antibodies are used, internalizing antibodies may be preferred. Lipofectin or liposomes can be used to deliver the antibody or a fragment of the Fab region that binds to the target antigen into 15 cells. Where fragments of the antibody are used, the smallest inhibitory fragment that binds to the target antigen is preferred. For example, peptides having an amino acid sequence corresponding to the Fv region of the antibody can be used. Alternatively, single chain neutralizing antibodies that bind to intracellular target antigens can also be administered. Such single chain antibodies can be administered, for example, by 20 expressing nucleotide sequences encoding single-chain antibodies within the target cell population (see e.g., Marasco *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:7889-7893).

The identified compounds that inhibit target gene expression, synthesis and/or activity can be administered to a patient at therapeutically effective doses to prevent, treat or ameliorate 52906, 33408, or 12189 disorders. A therapeutically effective dose refers 25 to that amount of the compound sufficient to result in amelioration of symptoms of the disorders. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures as described above.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies 30 preferably within a range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage can vary within this range depending upon the dosage form

employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the  $IC_{50}$  (i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

Another example of determination of effective dose for an individual is the ability 10 to directly assay levels of "free" and "bound" compound in the serum of the test subject. Such assays may utilize antibody mimics and/or "biosensors" that have been created through molecular imprinting techniques. The compound which is able to modulate 52906, 33408, or 12189 activity is used as a template, or "imprinting molecule", to spatially organize polymerizable monomers prior to their polymerization with catalytic 15 reagents. The subsequent removal of the imprinted molecule leaves a polymer matrix which contains a repeated "negative image" of the compound and is able to selectively rebind the molecule under biological assay conditions. A detailed review of this technique can be seen in Ansell, R. J. *et al* (1996) *Current Opinion in Biotechnology* 7:89-94 and in Shea, K.J. (1994) *Trends in Polymer Science* 2:166-173. Such 20 "imprinted" affinity matrixes are amenable to ligand-binding assays, whereby the immobilized monoclonal antibody component is replaced by an appropriately imprinted matrix. An example of the use of such matrixes in this way can be seen in Vlatakis, G. *et al* (1993) *Nature* 361:645-647. Through the use of isotope-labeling, the "free" 25 concentration of compound which modulates the expression or activity of 52906, 33408, or 12189 can be readily monitored and used in calculations of  $IC_{50}$ .

Such "imprinted" affinity matrixes can also be designed to include fluorescent groups whose photon-emitting properties measurably change upon local and selective binding of target compound. These changes can be readily assayed in real time using appropriate fiberoptic devices, in turn allowing the dose in a test subject to be quickly 30 optimized based on its individual  $IC_{50}$ . An rudimentary example of such a "biosensor" is discussed in Kriz, D. *et al* (1995) *Analytical Chemistry* 67:2142-2144.

Another aspect of the invention pertains to methods of modulating 52906, 33408, or 12189 expression or activity for therapeutic purposes. Accordingly, in an exemplary embodiment, the modulatory method of the invention involves contacting a cell with a 52906, 33408, or 12189 or agent that modulates one or more of the activities of 52906, 33408, or 12189 protein activity associated with the cell. An agent that modulates 52906, 33408, or 12189 protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring target molecule of a 52906, 33408, or 12189 protein (e.g., a 52906, 33408, or 12189 substrate or receptor), a 52906, 33408, or 12189 antibody, a 52906, 33408, or 12189 agonist or antagonist, a peptidomimetic of a 52906, 33408, or 12189 agonist or antagonist, or other small molecule.

In one embodiment, the agent stimulates one or 52906, 33408, or 12189 activities. Examples of such stimulatory agents include active 52906, 33408, or 12189 protein and a nucleic acid molecule encoding 52906, 33408, or 12189. In another embodiment, the agent inhibits one or more 52906, 33408, or 12189 activities. Examples of such inhibitory agents include antisense 52906, 33408, or 12189 nucleic acid molecules, anti-52906, 33408, or 12189 antibodies, and 52906, 33408, or 12189 inhibitors. These modulatory methods can be performed *in vitro* (e.g., by culturing the cell with the agent) or, alternatively, *in vivo* (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant or unwanted expression or activity of a 52906, 33408, or 12189 protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up regulates or down regulates) 52906, 33408, or 12189 expression or activity. In another embodiment, the method involves administering a 52906, 33408, or 12189 protein or nucleic acid molecule as therapy to compensate for reduced, aberrant, or unwanted 52906, 33408, or 12189 expression or activity.

Stimulation of 52906, 33408, or 12189 activity is desirable in situations in which 52906, 33408, or 12189 is abnormally downregulated and/or in which increased 52906, 33408, or 12189 activity is likely to have a beneficial effect. For example, stimulation of 52906, 33408, or 12189 activity is desirable in situations in which a 52906, 33408, or

12189 is downregulated and/or in which increased 52906, 33408, or 12189 activity is likely to have a beneficial effect. Likewise, inhibition of 52906, 33408, or 12189 activity is desirable in situations in which 52906, 33408, or 12189 is abnormally upregulated and/or in which decreased 52906, 33408, or 12189 activity is likely to have a beneficial effect.

5

### Pharmacogenomics

The 52906, 33408, or 12189 molecules of the present invention, as well as agents, or modulators which have a stimulatory or inhibitory effect on 52906, 33408, or 12189 activity (e.g., 52906, 33408, or 12189 gene expression) as identified by a screening assay 10 described herein can be administered to individuals to treat (prophylactically or therapeutically) 52906, 33408, or 12189 associated disorders (e.g., a disorder characterized by abnormal ion flux such as a neurological disorder or a cardiac disorder) associated with aberrant or unwanted 52906, 33408, or 12189 activity. In conjunction with such treatment, pharmacogenomics (i.e., the study of the relationship between an 15 individual's genotype and that individual's response to a foreign compound or drug) may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, a physician or clinician may consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to 20 administer a 52906, 33408, or 12189 molecule or 52906, 33408, or 12189 modulator as well as tailoring the dosage and/or therapeutic regimen of treatment with a 52906, 33408, or 12189 molecule or 52906, 33408, or 12189 modulator.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. 25 See, for example, Eichelbaum, M. *et al.* (1996) *Clin. Exp. Pharmacol. Physiol.* 23:983-985 and Linder, M.W. *et al.* (1997) *Clin. Chem.* 43:254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered 30 drug metabolism). These pharmacogenetic conditions can occur either as rare genetic

defects or as naturally-occurring polymorphisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

5 One pharmacogenomics approach to identifying genes that predict drug response, known as "a genome-wide association", relies primarily on a high-resolution map of the human genome consisting of already known gene-related markers (e.g., a "bi-allelic" gene marker map which consists of 60,000-100,000 polymorphic or variable sites on the human genome, each of which has two variants.) Such a high-resolution genetic map can  
10 be compared to a map of the genome of each of a statistically significant number of patients taking part in a Phase II/III drug trial to identify markers associated with a particular observed drug response or side effect. Alternatively, such a high resolution map can be generated from a combination of some ten-million known single nucleotide polymorphisms (SNPs) in the human genome. As used herein, a "SNP" is a common  
15 alteration that occurs in a single nucleotide base in a stretch of DNA. For example, a SNP may occur once per every 1000 bases of DNA. A SNP may be involved in a disease process, however, the vast majority may not be disease-associated. Given a genetic map based on the occurrence of such SNPs, individuals can be grouped into genetic categories depending on a particular pattern of SNPs in their individual genome. In such a manner,  
20 treatment regimens can be tailored to groups of genetically similar individuals, taking into account traits that may be common among such genetically similar individuals.

Alternatively, a method termed the "candidate gene approach," can be utilized to identify genes that predict drug response. According to this method, if a gene that encodes a drug's target is known (e.g., a 52906, 33408, or 12189 protein of the present  
25 invention), all common variants of that gene can be fairly easily identified in the population and it can be determined if having one version of the gene versus another is associated with a particular drug response.

Alternatively, a method termed the "gene expression profiling," can be utilized to identify genes that predict drug response. For example, the gene expression of an animal  
30 dosed with a drug (e.g., a 52906, 33408, or 12189 molecule or 52906, 33408, or 12189

modulator of the present invention) can give an indication whether gene pathways related to toxicity have been turned on.

Information generated from more than one of the above pharmacogenomics approaches can be used to determine appropriate dosage and treatment regimens for prophylactic or therapeutic treatment of an individual. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a 52906, 33408, or 12189 molecule or 52906, 33408, or 12189 modulator, such as a modulator identified by one of the exemplary screening assays described herein.

10 The present invention further provides methods for identifying new agents, or combinations, that are based on identifying agents that modulate the activity of one or more of the gene products encoded by one or more of the 52906, 33408, or 12189 genes of the present invention, wherein these products may be associated with resistance of the cells to a therapeutic agent. Specifically, the activity of the proteins encoded by the  
15 52906, 33408, or 12189 genes of the present invention can be used as a basis for identifying agents for overcoming agent resistance. By blocking the activity of one or more of the resistance proteins, target cells, e.g., human cells, will become sensitive to treatment with an agent that the unmodified target cells were resistant to.

Monitoring the influence of agents (e.g., drugs) on the expression or activity of a  
20 52906, 33408, or 12189 protein can be applied in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase 52906, 33408, or 12189 gene expression, protein levels, or upregulate 52906, 33408, or 12189 activity, can be monitored in clinical trials of subjects exhibiting decreased 52906, 33408, or 12189 gene expression, protein levels, or downregulated 52906, 33408, or  
25 12189 activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease 52906, 33408, or 12189 gene expression, protein levels, or downregulate 52906, 33408, or 12189 activity, can be monitored in clinical trials of subjects exhibiting increased 52906, 33408, or 12189 gene expression, protein levels, or upregulated 52906, 33408, or 12189 activity. In such clinical trials, the expression or  
30 activity of a 52906, 33408, or 12189 gene, and preferably, other genes that have been

implicated in, for example, a 52906, 33408, or 12189 -associated disorder can be used as a "read out" or markers of the phenotype of a particular cell.

52906, 33408, or 12189 Informatics

The sequence of a 52906, 33408, or 12189 molecule is provided in a variety of 5 media to facilitate use thereof. A sequence can be provided as a manufacture, other than an isolated nucleic acid or amino acid molecule, which contains a 52906, 33408, or 12189. Such a manufacture can provide a nucleotide or amino acid sequence, e.g., an open reading frame, in a form which allows examination of the manufacture using means not directly applicable to examining the nucleotide or amino acid sequences, or a subset 10 thereof, as they exists in nature or in purified form. The sequence information can include, but is not limited to, 52906, 33408, or 12189 full-length nucleotide and/or amino acid sequences, partial nucleotide and/or amino acid sequences, polymorphic sequences including single nucleotide polymorphisms (SNPs), epitope sequence, and the like. In a preferred embodiment, the manufacture is a machine-readable medium, e.g., a magnetic, 15 optical, chemical or mechanical information storage device.

As used herein, "machine-readable media" refers to any medium that can be read and accessed directly by a machine, e.g., a digital computer or analogue computer. Non-limiting examples of a computer include a desktop PC, laptop, mainframe, server (e.g., a web server, network server, or server farm), handheld digital assistant, pager, mobile 20 telephone, and the like. The computer can be stand-alone or connected to a communications network, e.g., a local area network (such as a VPN or intranet), a wide area network (e.g., an Extranet or the Internet), or a telephone network (e.g., a wireless, DSL, or ISDN network). Machine-readable media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic 25 tape; optical storage media such as CD-ROM; electrical storage media such as RAM, ROM, EPROM, EEPROM, flash memory, and the like; and hybrids of these categories such as magnetic/optical storage media.

A variety of data storage structures are available to a skilled artisan for creating a machine-readable medium having recorded thereon a nucleotide or amino acid sequence 30 of the present invention. The choice of the data storage structure will generally be based

on the means chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the nucleotide sequence information of the present invention on computer readable medium. The sequence information can be represented in a word processing text file, formatted in commercially-available software such as WordPerfect and Microsoft Word, or represented in the form of an ASCII file, stored in a database application, such as DB2, Sybase, Oracle, or the like. The skilled artisan can readily adapt any number of data processor structuring formats (e.g., text file or database) in order to obtain computer readable medium having recorded thereon the nucleotide sequence information of the present invention.

10        In a preferred embodiment, the sequence information is stored in a relational database (such as Sybase or Oracle). The database can have a first table for storing sequence (nucleic acid and/or amino acid sequence) information. The sequence information can be stored in one field (e.g., a first column) of a table row and an identifier for the sequence can be stored in another field (e.g., a second column) of the 15 table row. The database can have a second table, e.g., storing annotations. The second table can have a field for the sequence identifier, a field for a descriptor or annotation text (e.g., the descriptor can refer to a functionality of the sequence, a field for the initial position in the sequence to which the annotation refers, and a field for the ultimate position in the sequence to which the annotation refers. Non-limiting examples for 20 annotation to nucleic acid sequences include polymorphisms (e.g., SNP's) translational regulatory sites and splice junctions. Non-limiting examples for annotations to amino acid sequence include polypeptide domains, e.g., a domain described herein; active sites and other functional amino acids; and modification sites.

25        By providing the nucleotide or amino acid sequences of the invention in computer readable form, the skilled artisan can routinely access the sequence information for a variety of purposes. For example, one skilled in the art can use the nucleotide or amino acid sequences of the invention in computer readable form to compare a target sequence or target structural motif with the sequence information stored within the data storage means. A search is used to identify fragments or regions of the sequences of the 30 invention which match a particular target sequence or target motif. The search can be a BLAST search or other routine sequence comparison, e.g., a search described herein.

Thus, in one aspect, the invention features a method of analyzing 52906, 33408, or 12189, e.g., analyzing structure, function, or relatedness to one or more other nucleic acid or amino acid sequences. The method includes: providing a 52906, 33408, or 12189 nucleic acid or amino acid sequence; comparing the 52906, 33408, or 12189 sequence with a second sequence, e.g., one or more preferably a plurality of sequences from a collection of sequences, e.g., a nucleic acid or protein sequence database to thereby analyze 52906, 33408, or 12189. The method can be performed in a machine, e.g., a computer, or manually by a skilled artisan.

5 The method can include evaluating the sequence identity between a 52906, 33408, or 12189 sequence and a database sequence. The method can be performed by accessing the database at a second site, e.g., over the Internet.

10 As used herein, a "target sequence" can be any DNA or amino acid sequence of six or more nucleotides or two or more amino acids. A skilled artisan can readily recognize that the longer a target sequence is, the less likely a target sequence will be 15 present as a random occurrence in the database. Typical sequence lengths of a target sequence are from about 10 to 100 amino acids or from about 30 to 300 nucleotide residues. However, it is well recognized that commercially important fragments, such as sequence fragments involved in gene expression and protein processing, may be of shorter length.

20 Computer software is publicly available which allows a skilled artisan to access sequence information provided in a computer readable medium for analysis and comparison to other sequences. A variety of known algorithms are disclosed publicly and a variety of commercially available software for conducting search means are and can be used in the computer-based systems of the present invention. Examples of such software 25 include, but are not limited to, MacPattern (EMBL), BLASTN and BLASTX (NCBI).

Thus, the invention features a method of making a computer readable record of a sequence of a 52906, 33408, or 12189 sequence which includes recording the sequence 25 on a computer readable matrix. In a preferred embodiment the record includes one or more of the following: identification of an ORF; identification of a domain, region, or site; identification of the start of transcription; identification of the transcription 30

terminator; the full length amino acid sequence of the protein, or a mature form thereof, the 5' end of the translated region.

In another aspect, the invention features, a method of analyzing a sequence. The method includes: providing a 52906, 33408, or 12189 sequence, or record, in machine-readable form; comparing a second sequence to the 52906, 33408, or 12189 sequence; thereby analyzing a sequence. Comparison can include comparing to sequences for sequence identity or determining if one sequence is included within the other, e.g., determining if the 52906, 33408, or 12189 sequence includes a sequence being compared. In a preferred embodiment the 52906, 33408, or 12189 or second sequence is stored on a first computer, e.g., at a first site and the comparison is performed, read, or recorded on a second computer, e.g., at a second site. E.g., the 52906, 33408, or 12189 or second sequence can be stored in a public or proprietary database in one computer, and the results of the comparison performed, read, or recorded on a second computer. In a preferred embodiment the record includes one or more of the following: identification of an ORF; identification of a domain, region, or site; identification of the start of transcription; identification of the transcription terminator; the full length amino acid sequence of the protein, or a mature form thereof; the 5' end of the translated region.

In another aspect, the invention provides a machine-readable medium for holding instructions for performing a method for determining whether a subject has a 52906, 33408, or 12189 -associated disease or disorder or a pre-disposition to a 52906, 33408, or 12189 -associated disease or disorder, wherein the method comprises the steps of determining 52906, 33408, or 12189 sequence information associated with the subject and based on the 52906, 33408, or 12189 sequence information, determining whether the subject has a 52906, 33408, or 12189 -associated disease or disorder or a pre-disposition to a 52906, 33408, or 12189 -associated disease or disorder and/or recommending a particular treatment for the disease, disorder or pre-disease condition.

The invention further provides in an electronic system and/or in a network, a method for determining whether a subject has a 52906, 33408, or 12189 -associated disease or disorder or a pre-disposition to a disease associated with a 52906, 33408, or 12189 wherein the method comprises the steps of determining 52906, 33408, or 12189 sequence information associated with the subject, and based on the 52906, 33408, or

12189 sequence information, determining whether the subject has a 52906, 33408, or 12189 -associated disease or disorder or a pre-disposition to a 52906, 33408, or 12189 -associated disease or disorder, and/or recommending a particular treatment for the disease, disorder or pre-disease condition. In a preferred embodiment, the method further includes the step of receiving information, e.g., phenotypic or genotypic information, associated with the subject and/or acquiring from a network phenotypic information associated with the subject. The information can be stored in a database, e.g., a relational database. In another embodiment, the method further includes accessing the database, e.g., for records relating to other subjects, comparing the 52906, 33408, or 12189 sequence of the subject to the 52906, 33408, or 12189 sequences in the database to thereby determine whether the subject has a 52906, 33408, or 12189 -associated disease or disorder, or a pre-disposition for such.

The present invention also provides in a network, a method for determining whether a subject has a 52906, 33408, or 12189 associated disease or disorder or a pre-disposition to a 52906, 33408, or 12189 -associated disease or disorder associated with 52906, 33408, or 12189 , said method comprising the steps of receiving 52906, 33408, or 12189 sequence information from the subject and/or information related thereto, receiving phenotypic information associated with the subject, acquiring information from the network corresponding to 52906, 33408, or 12189 and/or corresponding to a 52906, 33408, or 12189-associated disease or disorder (e.g., a disorder characterized by abnormal ion flux such as a neurological disorder or a cardiac disorder), and based on one or more of the phenotypic information, the 52906, 33408, or 12189 information (e.g., sequence information and/or information related thereto), and the acquired information, determining whether the subject has a 52906, 33408, or 12189-associated disease or disorder or a pre-disposition to a 52906, 33408, or 12189 -associated disease or disorder. The method may further comprise the step of recommending a particular treatment for the disease, disorder or pre-disease condition.

The present invention also provides a method for determining whether a subject has a 52906, 33408, or 12189 -associated disease or disorder or a pre-disposition to a 52906, 33408, or 12189 -associated disease or disorder, said method comprising the steps of receiving information related to 52906, 33408, or 12189 (e.g., sequence information

and/or information related thereto), receiving phenotypic information associated with the subject, acquiring information from the network related to 52906, 33408, or 12189 and/or related to a 52906, 33408, or 12189-associated disease or disorder, and based on one or more of the phenotypic information, the 52906, 33408, or 12189 information, and the 5 acquired information, determining whether the subject has a 52906, 33408, or 12189-associated disease or disorder or a pre-disposition to a 52906, 33408, or 12189-associated disease or disorder. The method may further comprise the step of recommending a particular treatment for the disease, disorder or pre-disease condition.

This invention is further illustrated by the following examples that should not be 10 construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.

### EXAMPLES

#### Example 1: Identification and Characterization of Human 52906, 33408, and 12189 cDNAs

15 The human 52906 nucleic acid sequence is recited as follows:

GCGTCCGCAGATCCAGAGCCTGCCGGCTGGGAAAGATCCGGTCTCGGGGTC  
GGCTATGATCCCGCAGCGGCCAAGGCAGGGCTCAGGCCCGGGATTCTCCCC  
ACACGCTGCTGCACTGGCGCAGCCGGTCGCCAAACTTTTCTCCCCAAAGCC  
AGTGCCCGCAATTACTGGCGGGCAGCCGGCAGCCCCTCTCGGCAGGGAT  
20 GATCTGGGAGAGCGGGCGTGGGACGAGGGGGCTGCTGTTGCAGCCCTGC  
GAGGCGTGCAGTCGGAGAAAGTGGTCGGGTTCCACACCGTCCCTGAGCCTGC  
CCCCCTGGCCAAGGTGGCCGACGTGCTGCAGTGGCTGGCGCAGGTGATCCGG  
GCAGCGCGTCCGGCACTAGTCAAGGGGGCAGCGGCACGGGAGGGAGGGCG  
CCTTCTCTTCTCCCTCCCCCTGCAGCCCAGCTGCACTGCGTGGGGCTCTCC  
25 ATCTCCACGCAATCAGCAGGCAGGAATCCCTGCCCTGGAGCGCCCTGGCTCTG  
GAUTGCACCCCCCTAGGGTTGTCCCTGCAGATTCTCCTCCCCATCTTCTCTGC  
CACACACGCTTCCCTAACGCCGCGCGCCGCAAACACTCAGTCTCGGTCCCCGC  
AGGTGATGTCATGCCATTGTTGGTGCGCCAACCAATCGGACTCGCCGCC

TGGATTCTACCGGAGCCGGCATGGGCCCTCCTCGCACCAAGCAGCAGGAGTC  
CCCGCTCCCGACCATAACGCATTGCGCAGGGTGCACCACCGCTGGTCTCCCT  
GCAGCTTAACAGCCCTGACATGGAAACCCCATTGCAGTCCAGCGCGGCTT  
CTTCCCAGAGCAGCCGCCGCCGCCGCCGCTCCTCACACACCTGCATTGCCAG  
5 CAGCAGCAACAGAGCCAGGACAAGCCGTGCCGCCCTCGCGCCCCCTCCCGC  
ACCCTCACCACCACCCGCACCTCGCGCACAGCAGCCGGCAGCGCGGAGCAG  
CAGCCCATGCCTCCGGTGCAACAGCTGCGCCTCCTCCGGTGCCTCGCCGGCG  
GGGGCGGGAGATAACCTGTCCCTGCTGCTCCGCACCTCCTCGCCGGCG  
CCTTCCGGACCCGCACCTCCTCGCCGCTGCGGCTCGTCTGCTGCTGCTGC  
10 TGCTGCTCGCGCCGGGGCAGCCAGCTCAATGTGAGCGAGCTGACGCCGT  
CCAGCCATGCCAGTGCCTCCGGCAGCAGTACGCGCAGCAGTCCCGCAGCA  
GTCGGCGTCCGCCTCCCAGTACCAACCGAGTGCCACAGCCTGCAGCCCCGCC  
AGCCCCACGGGCAGCCTCGGAGTCTGGGCTCCGGGCCCCGCTCTCGCACC  
ACCACCAACCCGCACCCGGCGACCACCAAGCACCACCAAGCCCCAGGCGCG  
15 CCGCGAGAGCAACCCCTCACCGAAATAGCCATGAGCAGCTGCAGGTACAAC  
GGGGCGTCATGCGGCCGCTCAGCAACTTGAGCGCGTCCGCCGGAACCTGC  
ACGAGATGGACTCAGAGGCGCAGCCCCCTGCAGCCCCCGCGTCTGCGGAGG  
AGGTGGCGCGCGTCCCTCCCCGTCTGCAGCCGCTGCCGCCGCCGCTGTT  
CGTCCTCAGCCCCCGAGATCGTGGTCTAAGCCGAGCACACAACACTCAA  
20 CAACCTGGCGCTCTATGGAACCAGGGCGGAGGCAGCAGCACTGGAGGAGGCGG  
CGGCGGTGGCGGGAGCGGGCACGGCAGCAGCAGTGGCACCAAGTCCAGCAA  
AAAGAAAAACCAAGAACATCGGCTACAAGCTGGGCCACCGCGCCCTGTC  
GAAAAGCGCAAGCGGCTAGCGACTACGCGCTCATCTCGGATGTTGGCA  
TCGTGGTCATGGTCATCGAGACCGAGCTGCGTGGGGCGCTACGACAAGGC  
25 GTCGCTGTATTCCCTAGCTCTGAAATGCCTTATCAGTCTCTCCACGATCATCCT  
GCTCGGTCTGATCATCGTGTACCAAGCCAGGGAAATACAGTTGTCATGGTG  
GACAATGGAGCAGATGACTGGAGAATAGCCATGACTTATGAGCGTATTCT  
TCATCTGCTGGAAATACTGGTGTGTGCTATTCATCCCACCTGGAAATTAT  
ACATTACATGGACGGCCCGCTTGCCTCTCCTATGCCCATCCACAAACAC  
30 CGCTGATGTGGATATTATTATCTATACCAATGTTCTTAAGACTCTATCTGAT  
TGCCAGAGTCATGCTTTACATAGCAAACCTTCACTGATACCTCCTCTAGAA

GCATTGGAGCACTTAATAAGATAAAACTCAATACACGTTTGTATGAAGACT  
TTAATGACTATATGCCAGGAACTGTACTCTTGGTTTAGTATCTCATTATG  
GATAATTGCCGCATGGACTGTCCGAGCTGTGAAAGGTACCATGATCAACAG  
GATGTTACTAGCAACTCCTGGAGCGATGTGGTTGATATCAATAACTTTCT  
5 CTCCATTGGTTATGGTGACATGGTACCTAACACATACTGTGGAAAAGGAGTC  
TGCTTACTTACTGGAATTATGGGTGCTGGTGCACAGCCTGGTGGTAGCTGT  
AGTGGCAAGGAAGCTAGAACTTACCAAAGCAGAAAAACACGTGCACAATT  
CATGATGGATACTCAGCTGACTAAAAGAGTAAAAAATGCAGCTGCCAATGTA  
10 CTCAGGGAAACATGGCTAATTACAAAATACAAAGCTAGTGGAAAAAGATA  
GATCATGCAAAAGTAAGAAAACATCAACGAAAATTCTGCAAGCTATTCATC  
AATTAAGAAGTGTAAAAATGGAGCAGAGGAAACTGAATGACCAAGCAAACA  
CTTGGTGGACTTGGCAAAGACCCAGAACATCATGTATGATATGATTCTGAC  
TTAACGAAAGGAGTGAAGACTTCGAGAAGAGGATTGTTACCTGGAAACA  
AAACTAGAGACTTGATTGGTAGCATCCACGCCCTCCCTGGCTCATAGCC  
15 AGACCATCAGGCAGCAGCAGAGAGATTCTATTGAGGCTCAGATGGAGAGCTA  
CGACAAGCACGTCACTTACAATGCTGAGCGGTCCCGGTCTCGCAGGAGG  
CGGCGGTCTCTTCCACAGCACCACCAACTTCATCAGAGAGTAGCTAGAAGA  
GAATAAGTTAACCAAAATAAGACTTTGCCATCATGGTCAATATTAA  
GCTTTATTGAAAGCCCTATGGTCTAATCAGCGTTATCCGGTTCTGATG  
20 TCAGAATCCTGGAACCTGAACACTAAGTTAGGCCAAATGAGTGAAAAC  
TCTTTTTTTCTTCAGATGCACAGGAATGCACCTATTATTGCTATAGAT  
TGTCCTCCTGTAATTCACTTATTCACTGCACCTCAAACAAACTTTA  
CTACTACATTATGATATATAATAAAAAAGTTAATTCTGCAAAAAAAA  
AAAAAAAACGGACGGG (SEQ ID NO:1).

25 The human 52906 sequence (Fig. 1; SEQ ID NO:1) is approximately 3525 nucleotides long. The nucleic acid sequence includes an initiation codon (ATG) and a termination codon (TAG), which are underscored above. The region between and inclusive of the initiation codon and the termination codon is a methionine-initiated coding sequence of about 2544 nucleotides, including the termination codon (nucleotides indicated as "coding" of SEQ ID NO:1; SEQ ID NO:3). The coding sequence encodes a 30 847 amino acid protein (SEQ ID NO:2), which is recited as follows:

MPIVLVRPTNRTTLDSTGAGMGPSSHQQQESPLPTITHCAGCTTAWSPCSFNSP  
 DMETPLQFQRGFFPEQPPPPRSSHLCQQQQSQDKPCPPFAPLPHPHHHPLA  
 HQQPASGGSSPCLRCNSCASSGAPAAGAGDNLSSLRTSSPGAFRTRTSSPLSGS  
 SCCCCCSSRRGSQNLNVSELTSSHASALRQQYAQQSAQQSASASQYHQCHSLQ  
 5 PAASPTGSLGSLGSGPPLSHHHHHPHPAHHQHHQPQARRESNPTEIAMSSCRYN  
 GGVMRPLSNLSASRRNLHEMDSEAQPLQPPASVGGGGASSPSAAAAAAA  
 SSAPEIVVSKPEHNNNNLALYGTGGGGSTGGGGGGGGSGHSSGTKSSKKKN  
 QNIGYKLGHRRALFEKRKRLSDYALIFGMFGIVVMVIETLSWGAYDKASLYSL  
 ALKCLISLSTIILLGLIIVYHAREIQLFMVDNGADDWRIAMTYERIFFICLEILVCAI  
 10 HPIPGNYTFTWTARLAFLSYAPSTTADVDIILSIPMFLRLYLIARVMILLHSKLFDT  
 SSRSIGALNKINFNTRFVMKTLMTICPGTVLLVFSISLWIIAAWTVRACERYHDQQ  
 DVTSNFLGAMWLISITFLSIGYGDMVPNTYCGKGVCLLTGIMGAGCTALVVAVV  
 ARKLELTKAEKHVHNFMMDTQLTKRVKNAANVLRETWLIYKNTKLVKKIDH  
 AKVRKHQRKFLQAIHQLRSVKMEQRKLNDQANTLVDLAKTNIMYDMISDLNE  
 15 RSEDFEKRIVTLETKLETLIGSIHALPGLISQTIRQQQRDFIEAQMESYDKHVTYNA  
 ERSRSSSSRRRSSSTAPPTSSESS (SEQ ID NO:2).

The human 33408 nucleic acid sequence is recited as follows:

GACCCACCGCGTCCGCTCCCCGTGTGCGGCACCGCCACAGTCTGGCAGCGG  
 CGGCCGGGGAGCGCTACTACCATGAACACTGCCTGGCCTCCCTCCCCAGAGCT  
 20 GCTCATCCGGGTGGCTGGAGACACAGTCAGGGGACCCCGTCCGCCGCC  
 GCGCCCCCTTCTTCGGCTCAATCTTCTTCCACCTTCCCTCTTCCCT  
 CACCTTCTTGCCTGCATCCCCCCTCCCCGCCGGATCCTGGCCGCTGCT  
 CTCCAGACCCAGGATGCCGGGGCAAGAGAGGGCTGGTGGCACCGCAGAA  
 CACATTTGGAGAACATCGTCAGGCGCTCCAGTGAATCAAGTTCTTACTGG  
 25 GAAATGCCAGATTGGATTGGCCTGTAGTTATAGTAATGACGGTTTTGT  
 AAACTCTCTGGATATCATCGAGCTGACGTATGCAGAAAAGCAGCACTTGCA  
 GTTTATGTATGGGAATTGACTGACAAGAAGACCATTGAGAAAGTCAGGCA  
 AACTTTGACAACGAAACTACGAATCAAACGCTTGAAGTTCTCTGTACAAGAAAA  
 ACAGAACCCCTGTTGGTTTATATGCAAATTGCACCAATAAGAAATGAACA  
 30 TGAAAAGGTGGCTTGTCTGTACTTCAAGGATATTACGTTGTTCAAAC  
 AGCCAATAGAGGATGATTCAACAAAAGGTGGACGAAATTGCCGATTGAC

ACGGGCTTGACAAATAGCCGAAGTGTTCAGCAGCTCACGCCAATGAAT  
AAAACAGAGGTGGTCCATAAACATTCAAGACTAGCTGAAGTTCTCAGCTGG  
GATCAGATATCCTCCTCAGTATAAACAAAGAAGCGCCAAGACGCCACCACA  
CATTATTTACATTATTGTGCTTTAAAACACTTGGGATTGGGTGATTTAAT  
5 TCTTACCTTCTACACCGCCATTATGGTCCTTATAATGTTCTTCAAAACAAA  
GCAGAACAAACATAGCCTGGCTGGTACTGGATAGTGTGGGACGTTATTTTC  
TGGTTGACATCGTTAAATTTCACACGACTTCGTGGGGCCCGGTGGAGAG  
GTCATTTCTGACCCCTAACGCTCATAAGGATGAACATCTGAAAAACTTGGTTGT  
GATCGATCTGCTGTCTTACCTTATGACATCATCAATGCCTTGAAAATG  
10 TGGATGAGGGAATCAGCAGTCTTCAGTTAAAAGTGGTGCCTCTTA  
CGACTGGGCCGTGTGGCTAGGAAACTGGACCATTACCTAGAATATGGAGCAG  
CAGTCCTCGTGCCTGGTGTGTGTTGGACTGGTGGCCACTGGCTGGCC  
TGCATATGGTATAGCATCGGAGACTACGAGGTATTGATGAAGTCACTAACAA  
CCATCCAAATAGACAGTTGGCTTACCAAGCTGGCTTGAGCATTGGACTCCA  
15 TATCGCTACAATACCAAGTGCTGGATATGGGAAGGAGGACCCAGCAAGGATT  
CATTGTACGTGTCCTCTCTACTTACCATGACAAGCCTACAACCATAAGGA  
TTTGGAAACATAGCTCCTACCACAGATGTGGAGAAGATGTTGGCTTAC  
GATGATGGTTGGCTCTCTTATGCAACTATTTGGAAATGTTACAACAA  
TTTCCAGCAAATGTATGCCAACACCAACCGATACCATGAGATGCTGAATAA  
20 TGTACGGACTCCTAAAACCTATCAGGTCCAAAAGGCCTTAGTGAGCGA  
GTCATGGATTATATTGTCTCAACATGGCCATGTCAAAAGGCATTGATA  
AAAGGTCCCTCCATCTGTCCAAAGGACATGAGAGCTGATATCTGTGTT  
TAAACCGGAAGGTTTTAATGAACATCCTGCTTTCGATTGGCCAGCGATGGG  
TGTCTGCGCGCCTGGCGGTAGAGTCCAAACCATTCACTGTGCTCCGGGA  
25 CCTCATTACCATGCTGGAGAAAGTGTGGATGCCCTTGCTTGTGGTGT  
GATCCTGGAAAGTCATCCAGGATGATGAGGTGGCTATTTAGGAAAGGG  
TGATGTATTGGAGACATCTCTGGAAAGGAAACCACCCCTGCCATGCATGT  
CGAACGTCCGGCACTGACGTACTGTGACCTACACATCATCAAGCGGGAAAGC  
CTTGCCTCAAAGTCTGGACTTTATACAGCTTGCAGAAACTCCTCTCAAGGA  
30 ATCTCACTCTTACTTGCATCTGAGGAAACGGATCATCTTGTAAAGATCAGT  
GATGTGAAGAAAGAGGAGGAGGAGCGCCTCCGGCAGAAGAATGAGGTGACC

CTCAGCATTCCCGTGGACCACCCAGTCAGAAAGCTCTCCAGAAGITCAAGC  
AGCAGAAGGAGCTCGGAATCAGGGCTCAACACAGGGTGACCCTGAGAGGA  
ACCAACTCCAGGTAGAGAGCCGCTCCTACAGAATGGAACCTCCATCACCGG  
AACCAGCGTGGTACTGTGTACAGATTACTCCCATTACAGACGTCTCTGGCCT  
5 ATGTGAAAACCAGTGAATCCCTTAAGCAGAACACCGTGATGCCATGGAACCT  
CAAGCCCAACGGCGGTGCTGACCAAAAATGTCTCAAAGTCAACAGCCCAATA  
AGAATGAAGAATGGAAATGGAAAAGGGTGGCTGCGACTCAAGAATAATATG  
GGAGCCCATTGAGGAGAAAAGGAAGACTGGAATAATGTCACTAAAGCTGAG  
TCAATGGGCTATTGTCTGAGGACCCCAAGAGCAGTGATTACAGAGAACAGTG  
10 TGACCAAAAACCCACTAAGGAAAACAGATTCTGTGACAGTGGATTACAAA  
AAAGTGACCTTCGTTGGATAAGGCTGGGAGGCCGAAGTCCGCTAGAGCAC  
AGTCCCATTCCAGGCTGATGCCAAGCACCCCTTATCCCATCCCCGAGCAGGC  
CTTACAGACCACACTGCAGGAAGTCAAACACGAACACTCAAAGAGGACATCCA  
GCTGCTCAGCTGCAGAATGACTGCCCTAGAAAAGCAGGTGGCAGAAATTAA  
15 AAAATACTGTCGGAAAAAAAGCGTACCCAGGCCTCATCTCCAAATCCAAA  
TGCCACTCCAAGTACCCCCCAGATACCATGTCAGGATATTTAGTGTCTCA  
AGGCCTGAATCACCTGAATCTGACAAAGATGAAATCCACTTTAATATATAT  
ACATATATATTGTTAATATATTAAAACAGTATATACATATGTGTGTATATAC  
AGTATATACATATATATTTCACTGCTTCAAGATGATGACCACACATGG  
20 ATTTGATATGAAATATTGCATGTCCAGCTGGATTCTGGCCTGCCAAAGAAG  
ATGATGATTAAAACATAGATATTGCTGTATATTATGCAGTTGACTGCATGC  
ACACTTACATTATTATAATCTCTATTCTATAATAAAAGAGTATGATTGG  
TTAAAAAAAAAAAAAAAAAAATTCCCTGCCCGA (SEQ ID NO:4).

The human 33408 sequence (Fig. 3; SEQ ID NO:4) is approximately 3555  
25 nucleotides long. The nucleic acid sequence includes an initiation codon (ATG) and a  
termination codon (TAA), which are underscored above. The region between and  
inclusive of the initiation codon and the termination codon is a methionine-initiated  
coding sequence of about 2967 nucleotides, including the termination codon (nucleotides  
indicated as "coding" of SEQ ID NO:4; SEQ ID NO:6). The coding sequence encodes a  
30 988 amino acid protein (SEQ ID NO:5), which is recited as follows:  
MPGGKRLVAPQNTFLENIVRRSSESSFLLGNAQIVDWPVVYSDGFCKLSGYH

RADVMQKSSTCSFMYGELTDKKTIEKVRQTFDNYESNCFEVLLYKKNRTPVWF  
 YMQIAPIRNEHEKVVLFLCTFKDITLFQPIEDDSTKGWTKFARLTRALTNRSVL  
 QQLTPMNKTEVVHKHSRLAEVLQLGSDILPQYKQEAPKTPPHIILHYCAFKTTWD  
 WVILILTFYTAIMVPYNVSFKTKQNNIAWLVLDSVVDVIFLVDIVLFNFHTFVGPG  
 5 GEVISDPKLIJRMNYLKTWFVIDLLSCLPYDIINAFENVDEGISSLFSSLKVVRLRL  
 GRVARKLDHYLEYGAAVLVLLVCVFGLV AHLACIWYSIGDYEVIDEVNTNIQI  
 DSWLYQLALSIGTPYRYNTSAGIWEGGPSKDSL VYSSLYFTMTSLTTIGFGNIAPT  
 TDVEKMFSVAMMMVGSL YATIFGNVTIFQQMYANTNRYHEMLNNVRDFLK  
 LYQVPKGLSERVMDYIVSTWSMSKGIDTEKVL SICPKDMRADICVHLNRKVFNE  
 10 HPAFRLASDGCLRALA VEFQTIHCAPGDLIYHAGESVDALCFVVSGSLEVIQDDE  
 VVAILGKGDVFGDIFWKETTLAHACANVRALTYCDLHIIKREALLKVLDFYTAF  
 ANSFSRNLTLCNLRKRIIFRKISDVKKEEEERLRQKNEVTL SIPVDHPVRKLFQKF  
 KQQKELRNQGSTQGDPERNQLQVESRSLQNGTSITGTSVVTVSQITPIQTSLAYV  
 KTSESLKQNNRDAMELKPN GGADQKCLKVN SIRMKNGNGKGWLRLKNNMGA  
 15 HEEKKEDWNNVTKAESMGLLSEDPKSSDSENSVTKNPLRKT DSCDSGITKSDLR  
 LDKAGEARSPLEHSPIQADAKHPFYPIPEQALQTTLQEVKHELKEDIQLLSCRMTA  
 LEKQVAEILKILSEKSV P QASSPKSQMPLQVPPQIPCQDIFS VSRPESPE SDKDEIH  
 (SEQ ID NO:5).

The human 12189 nucleic acid sequence is recited as follows:

20 TGCTGCGAGCGGCTGGTGCTAACGTGGCCGGCTGCCTCGAGACGCGGG  
 CGCGCACGCTGGCCGCTCCGGACACTCTGCTAGGGGACCCAGCGCGCCG  
 CGGCCGCTCTACGACGACGCCGCGAGTATTCTCGACCGGCACCGG  
 CCCAGCTCGACGCCGTGCTCTACTACTACCAGTCCGGTGGCGGCTGCGGC  
 GGCCGGCGCACGTGCCGCTCGACGTCTCCTGGAAGAGGGTGGCCTTACGG  
 25 GCTGGGCGCGGCGGCCCTGGCACGCCCTGCCGCGAGGACGAGGGCTGCCCGT  
 GCCGCCGAGCGCCCCCTGCCCGCCCTCGCCGCCAGCTGTGCCCTGC  
 TTTCGAGTTCCCGAGAGAGCTCTCAGGCCGCGCGTGCCTCGCCGTAGTCTCC  
 GTGCTGGTCATCCTCGTCTCCATCGTCGTTCTGCCTCGAGACGCTGCCCTGA  
 CTTCCGCGACGACCGCGACGGCACGGGCTTGCTGCTGCAGCCGAGCCGGC  
 30 CCGTCCCCGCTCCGCTGAATGGCTCCAGCAAATGCCTGGAAATCCACCCCC  
 GCCTGCCCTCAATGACCCGTTCTCGTGGAGACGCTGTGTATTGTTGG

TTCTCCTTGAGCTGCTGGTACGCCCTGGTCTGTCCAAGCAAGGCTATCTT  
 CTTCAAGAACGTGATGAACCTCATCGATTGTGGCTATCCTCCCTACTTGT  
 5 GGCACGGGCACCGAGCTGGCCCGCAGCGAGGGGTGGGCCAGCAGGCCAT  
 GTCACGGCCATCCTGAGAGTCATCCGATTGGTGCCTGTCTCCGCATCTCA  
 AGCTGTCCCGGCACTCAAAGGGCCTGCAAATCTTGGGCCAGACGCTCGGGC  
 CTCCATGCGTGAGCTGGGCCTCCTCATCTTCCCTTCATCGGTGTGGCCT  
 CTTTCCAGCGCCGTCTACTTGCGAAGTTGACCGGGTGGACTCCCATTCA  
 CTAGCATCCCTGAGTCCTCTGGTGGCGGTAGTCACCATGACTACAGTTGGC  
 TATGGAGACATGGCACCCGTCACTGTGGGTGGCAAGATAGTGGCTCTGT  
 10 GTGCCATTGCGGGCGTGCTGACTATTCCCTGCCAGTGCCGTATTGCTCC  
 AATTTCAGCTACTTTATCACCGGGAGACAGAGGGCGAAGAGGGCTGGATGT  
 TCAGCCATGTGGACATGCAGCCTGTGGCCACTGGAGGGCAAGGCCAATGG  
 GGGGCTGGTGGACGGGGAGGTACCTGAGCTACCACCTCCACTCTGGCACCC  
 CCAGGGAAACACCTGGTACCGAAGGTGA (SEQ ID NO:7).

15 The human 12189 sequence (Fig. 5; SEQ ID NO:7) is approximately 1341 nucleotides long. The nucleic acid sequence includes a termination codon (TGA), which is underscored above. The coding sequence encodes a 446 amino acid protein (SEQ ID NO:8), which is recited as follows:

CCERLVNVAGLRFETRARTLGRFPDTLLGDPARRGRFYDDARREYFFDRHRPSF  
 20 DAVLYYYQSGGRLRRPAHVPLDVFLEEVAFYGLGAAALARLREDEGCPVPPERP  
 LPRRAFARQLCLLFEFPESQQAARVLA VSVLVL VSI VFCLETLPDFRDDR DGT  
 GLAAAAAAAGPFPAPLN GSSQMPGNPPRLPFNDPFFVETLCICWFSFELLVRLLV  
 CPSKAIFFKNVMNLIDFVAILPYFVALGTELARQRGVGQQAMSLAILRVIRLVRV  
 FRIFKLSRHSKGLQILGQTLRASMRELGLLIFFLFIGVVLFSSAVYFAEVDRVDSHF  
 25 TSIPESFWAVVTMTVGYGDMAPVTVGKIVGSLCAIAGVLTISLPVPVIVSNF  
 SYFYHRETEGEEAGMFSHVDMQPCGPLEGKANGGLVDGEVPELPPPLWAPPGK  
 HLVTEV (SEQ ID NO:8).

Example 2: Tissue Distribution of 52906 and 33408 mRNA by TaqMan Analysis

Endogenous human 52906 and 33408 gene expression was determined using the  
 30 Perkin-Elmer/ABI 7700 Sequence Detection System which employs TaqMan technology.

Briefly, TaqMan technology relies on standard RT-PCR with the addition of a third gene-specific oligonucleotide (referred to as a probe) which has a fluorescent dye coupled to its 5' end (typically 6-FAM) and a quenching dye at the 3' end (typically TAMRA). When the fluorescently tagged oligonucleotide is intact, the fluorescent signal from the 5' dye is quenched. As PCR proceeds, the 5' to 3' nucleolytic activity of Taq polymerase digests the labeled primer, producing a free nucleotide labeled with 6-FAM, which is now detected as a fluorescent signal. The PCR cycle where fluorescence is first released and detected is directly proportional to the starting amount of the gene of interest in the test sample, thus providing a quantitative measure of the initial template concentration.

5

10 Samples can be internally controlled by the addition of a second set of primers/probe specific for a housekeeping gene such as GAPDH which has been labeled with a different fluorophore on the 5' end (typically VIC).

To determine the level of 52906 and 33408 in various human tissues a primer/probe set was designed. Total RNA was prepared from a series of human tissues 15 using an RNeasy kit from Qiagen. First strand cDNA was prepared from 1 µg total RNA using an oligo-dT primer and Superscript II reverse transcriptase (Gibco/BRL). cDNA obtained from approximately 50 ng total RNA was used per TaqMan reaction. Tissues tested include the human tissues and several cell lines shown in Tables 3 and 4. 52906 mRNA was detected in brain, prostate tumor, and heart samples (Table 3). 33408 20 expression was found in brain, heart, skin, and adipose samples (Table 4).

**Table 3: Expression of 52906 mRNA in Human Tissues and Cell Lines**

<u>Tissue</u>	<u>Relative Expression</u>
Artery / normal	0
Aorta / diseased	0
Vein / normal	0
Coronary smooth muscle cells	0
Human umbilical vein endothelial cells	0
Hemangioma	0
Heart / normal	0
Heart / congestive heart failure	0.1902
Kidney	0
Skeletal muscle	0
Adipose / normal	0
Pancreas	0
Primary osteoblasts	0
Osteoclasts (differentiated)	0
Skin / normal	0
Spinal cord / normal	0
Brain Cortex / normal	1.6367
Brain Hypothalamus / normal	0
Nerve	0
Dorsal Root Ganglion	0
Breast / normal	0
Breast / tumor	0
Ovary / normal	0
Ovary / tumor	0
Prostate / normal	0
Prostate / tumor	1.1613
Salivary glands	0
Colon / normal	0
Colon / tumor	0
Lung / normal	0
Lung / tumor	0
Lung / chronic obstructive pulmonary disease	0
Colon / inflammatory bowel disease	0
Liver / normal	0
Liver fibrosis	0
Spleen / normal	0
Tonsil / normal	0
Lymph node / normal	0
Small intestine / normal	0
Macrophages	0
Synovium	0

Bone marrow / mononuclear cells	0
Activated peripheral blood mononuclear cells	0
Neutrophils	0
Megakaryocytes	0
Erythroid cells	0
positive control	0

**Table 4: Expression of 33408 mRNA in Human Tissues and Cell Lines**

<u>Tissue</u>	<u>Relative Expression</u>
Prostate	0.00
Osteoclasts	0.00
Liver	0.00
Breast	0.00
Breast	0.00
Skeletal Muscle	2.60
Skeletal Muscle	0.13
Brain	33.03
Colon	0.06
Colon	0.01
Heart	30.71
Heart	0.00
Ovary	0.00
Ovary	0.00
Kidney	0.00
Kidney	0.01
Lung	0.01
Lung	0.00
Vein	0.10
Vein	0.01
Adipose	0.00
Adipose	4.26
Small Intestine	0.00
Thyroid	0.00
Bone Marrow	0.00
Skin	11.72
Testes	0.37
Placenta	0.01
Fetal Liver	0.00
Fetal Liver	0.00
Fetal Heart	0.00
Fetal Heart	0.00

Osteoblasts / undifferentiated	0.00
Osteoblasts / differentiated	0.00
Osteoblasts / primary culture	0.00
Spinal Cord	0.00
Cervix	0.00
Spleen	0.00
Spinal Cord	0.00
Thymus	0.00
Tonsil	0.00
Lymph Node	0.00
Aorta	0.00

Example 3: Tissue Distribution of 52906, 33408, or 12189 mRNA by Northern Analysis

Northern blot hybridizations with various RNA samples can be performed under standard conditions and washed under stringent conditions, i.e., 0.2xSSC at 65°C. A DNA probe corresponding to all or a portion of the 52906, 33408, or 12189 cDNA (SEQ ID NO:1, SEQ ID NO:4, or SEQ ID NO:7) can be used. The DNA is radioactively labeled with <sup>32</sup>P-dCTP using the Prime-It Kit (Stratagene, La Jolla, CA) according to the instructions of the supplier. Filters containing, for example, mRNA from mouse hematopoietic and endocrine tissues, and cancer cell lines (Clontech, Palo Alto, CA) can be probed in ExpressHyb hybridization solution (Clontech) and washed at high stringency according to manufacturer's recommendations.

Example 4: Recombinant Expression of 52906, 33408, or 12189 in Bacterial Cells

In this example, 52906, 33408, or 12189 is expressed as a recombinant glutathione-S-transferase (GST) fusion polypeptide in *E. coli* and the fusion polypeptide is isolated and characterized. Specifically, 52906, 33408, or 12189 is fused to GST and this fusion polypeptide is expressed in *E. coli*, e.g., strain PEB199. Expression of the GST-52906, 33408, or 12189 fusion protein in PEB199 is induced with IPTG. The recombinant fusion polypeptide is purified from crude bacterial lysates of the induced PEB199 strain by affinity chromatography on glutathione beads. Using polyacrylamide gel electrophoretic analysis of the polypeptide purified from the bacterial lysates, the molecular weight of the resultant fusion polypeptide is determined.

Example 5: Expression of Recombinant 52906, 33408, or 12189 Protein in COS Cells

To express the 52906, 33408, or 12189 gene in COS cells (e.g., COS-7 cells, CV-1 origin SV40 cells; Gluzman (1981) *Cell* 23:175-182), the pcDNA/Amp vector by Invitrogen Corporation (San Diego, CA) is used. This vector contains an SV40 origin of replication, an ampicillin resistance gene, an *E. coli* replication origin, a CMV promoter followed by a polylinker region, and an SV40 intron and polyadenylation site. A DNA fragment encoding the entire 52906, 33408, or 12189 protein and an HA tag (Wilson *et al.* (1984) *Cell* 37:767) or a FLAG tag fused in-frame to its 3' end of the fragment is cloned into the polylinker region of the vector, thereby placing the expression of the recombinant protein under the control of the CMV promoter.

To construct the plasmid, the 52906, 33408, or 12189 DNA sequence is amplified by PCR using two primers. The 5' primer contains the restriction site of interest followed by approximately twenty nucleotides of the 52906, 33408, or 12189 coding sequence starting from the initiation codon; the 3' end sequence contains complementary sequences to the other restriction site of interest, a translation stop codon, the HA tag or FLAG tag and the last 20 nucleotides of the 52906, 33408, or 12189 coding sequence. The PCR amplified fragment and the pCDNA/Amp vector are digested with the appropriate restriction enzymes and the vector is dephosphorylated using the CIAP enzyme (New England Biolabs, Beverly, MA). Preferably the two restriction sites chosen are different so that the 52906, 33408, or 12189 gene is inserted in the correct orientation. The ligation mixture is transformed into *E. coli* cells (strains HB101, DH5 $\alpha$ , SURE, available from Stratagene Cloning Systems, La Jolla, CA, can be used), the transformed culture is plated on ampicillin media plates, and resistant colonies are selected. Plasmid DNA is isolated from transformants and examined by restriction analysis for the presence of the correct fragment.

COS cells are subsequently transfected with the 52906, 33408, or 12189 - pcDNA/Amp plasmid DNA using the calcium phosphate or calcium chloride co-precipitation methods, DEAE-dextran-mediated transfection, lipofection, or electroporation. Other suitable methods for transfecting host cells can be found in Sambrook, J., Fritsh, E. F., and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press,

Cold Spring Harbor, NY. The expression of the 52906, 33408, or 12189 polypeptide is detected by radiolabelling ( $^{35}\text{S}$ -methionine or  $^{35}\text{S}$ -cysteine available from NEN, Boston, MA, can be used) and immunoprecipitation (Harlow, E. and Lane, D. (1988) *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) 5 using an HA specific monoclonal antibody. Briefly, the cells are labeled for 8 hours with  $^{35}\text{S}$ -methionine (or  $^{35}\text{S}$ -cysteine). The culture media are then collected and the cells are lysed using detergents (RIPA buffer, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM Tris, pH 7.5). Both the cell lysate and the culture media are precipitated with an HA specific monoclonal antibody. Precipitated polypeptides are then analyzed by SDS-10 PAGE.

Alternatively, DNA containing the 52906, 33408, or 12189 coding sequence is cloned directly into the polylinker of the pCDNA/Amp vector using the appropriate restriction sites. The resulting plasmid is transfected into COS cells in the manner described above, and the expression of the 52906, 33408, or 12189 polypeptide is 15 detected by radiolabelling and immunoprecipitation using a 52906, 33408, or 12189 specific monoclonal antibody.

#### Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention 20 described herein. Such equivalents are intended to be encompassed by the following claims.

#### What is claimed is:

1. An isolated nucleic acid molecule selected from the group consisting of:
  - a) a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, at least 95% identical to the nucleotide sequence of SEQ ID NO:4, or at least 90% identical to the nucleotide sequence of SEQ ID NO:7;
  - b) a nucleic acid molecule comprising a fragment of at least 1750 nucleotides of the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, at least 2980 nucleotides of the nucleotide sequence of SEQ ID NO:4, or at least 300 nucleotides of the nucleotide sequence of SEQ ID NO:7;
  - c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8;
  - d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8, wherein the fragment comprises at least 580 contiguous amino acids of SEQ ID NO:2 or at least 80 contiguous amino acids of SEQ ID NO:8; and
  - e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, or a complement thereof, under stringent conditions.
2. The isolated nucleic acid molecule of claim 1, which is selected from the group consisting of:
  - a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:7; and
  - b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8.
3. The nucleic acid molecule of claim 1, further comprising a vector nucleic acid sequence.

4. The nucleic acid molecule of claim 1, further comprising a nucleic acid sequence encoding a heterologous polypeptide.

5. A host cell which contains the nucleic acid molecule of claim 1.

6. The host cell of claim 5, which is a mammalian host cell.

7. A non-human mammalian host cell containing the nucleic acid molecule  
10 of claim 1.

8. An isolated polypeptide selected from the group consisting of:

a) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleic acid comprising the  
15 nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3 or at least 90% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:7;

b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID  
20 NO:1, SEQ ID NO:3, SEQ ID NO:7, or a complement thereof under stringent conditions; and

c) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8, wherein the fragment comprises at least 580 contiguous amino acids of SEQ ID NO:2 or at least 80 contiguous amino acids of SEQ ID NO:8.

25

9. The isolated polypeptide of claim 8, comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8.

10. The polypeptide of claim 8, further comprising a heterologous amino acid sequence.

11. An antibody which selectively binds to the polypeptide of claim 8.
12. A method for producing a polypeptide selected from the group consisting of:
  - a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8;
  - b) a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8, wherein the fragment comprises at least 580 contiguous amino acids of SEQ ID NO:2 or at least 80 contiguous amino acids of SEQ ID NO:8; and
  - c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, or a complement thereof under stringent conditions; the method comprising culturing the host cell of claim 5 under conditions in which the nucleic acid molecule is expressed.
13. A method for detecting the presence of a polypeptide of claim 8 in a sample, comprising:
  - a) contacting the sample with a compound which selectively binds to a polypeptide of claim 8; and
  - b) determining whether the compound binds to the polypeptide in the sample.
14. The method of claim 13, wherein the compound which binds to the polypeptide is an antibody.
15. A kit comprising a compound which selectively binds to a polypeptide of claim 8 and instructions for use.
16. A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample, comprising the steps of:

- a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
- b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.

5

17. The method of claim 16, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.

18. A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 1 and instructions for use.

19. A method for identifying a compound which binds to a polypeptide of claim 8 comprising the steps of:

- a) contacting a polypeptide, or a cell expressing a polypeptide of claim 8 with a test compound; and
- b) determining whether the polypeptide binds to the test compound.

20. The method of claim 19, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

- a) detection of binding by direct detecting of test compound/polypeptide binding;
- b) detection of binding using a competition binding assay;
- c) detection of binding using an assay for 52906 or 12189-mediated signal transduction.

25

21. A method for modulating the activity of a polypeptide of claim 8 comprising contacting a polypeptide or a cell expressing a polypeptide of claim 8 with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.

30

22. A method for identifying a compound which modulates the activity of a polypeptide of claim 8, comprising:

- a) contacting a polypeptide of claim 8 with a test compound; and
- b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

23. A method of treating or preventing an ion flux-related disorder in a subject, the method comprising administering to the subject an agent that modulates the activity or expression of a 52906 or 12189 polypeptide or nucleic acid, in an amount effective to treat or prevent the ion flux-related disorder.

24. The method of claim 23, wherein the agent is a peptide, a phosphopeptide, a small molecule, an antibody, or any combination thereof.

25. The method of claim 23, wherein the agent is an antisense, a ribozyme, a triple helix molecule, a 52906 or 12189 nucleic acid, or any combination thereof.

26. A method for identifying an agent that modulates the activity or expression of a 52906 or 12189 polypeptide or nucleic acid, comprising contacting the 52906 or 12189 polypeptide or nucleic acid with an agent, and determining the effect of the agent on the activity or expression of the polypeptide or nucleic acid.

27. The method of claim 26, wherein the agent is a peptide, a phosphopeptide, a small molecule, an antibody, or any combination thereof.

28. The method of claim 26, wherein the agent is an antisense, a ribozyme, a triple helix molecule, a 52906 or 12189 nucleic acid, or any combination thereof.

29. The method of claim 26, wherein the method comprises determining the effect of the agent on an ion channel activity of the polypeptide.

30. The method of claim 26, wherein the effect of the agent on the activity or expression of the polypeptide or nucleic acid is determined in a neuronal cell or a muscle cell.

5

31. An antibody which selectively binds to an extracellular domain of the polypeptide of SEQ ID NO:5.




Figure 1

ion\_trans: domain 1 of 1, from 472 to 661: score 0.1, E = 1.2  
(SEQ ID NO:9) \*->ilfildllfvllflleivlkfiayglkstsniaakylksifnildll  
      ++ i + ++f++ ++l +++++ ++ y +++ +  
52906 472 DWRIAMTYERIFFICLEILVCAIHP-----PGNYTFTWTA-RLAF 511  
      ailplllllvlflsgteqvakkrlrerfslelsqwyrrilrfllrlLrllR  
      ++ p+ + + + 1++ +Lrl+  
52906 512 SYAPS--TTTADVDII-----LSIPMFLRLYL 536  
      1Lrllrllrrletlf.e.....fe.lgtlaWslqslgralksilrfllll  
      + r++ ++ +lf+ +++++++ l ++ +k+++ ++ +  
52906 537 ---IARVMLLHSKLFtDtssrsIGaLNKI---NFNTRFVMKTLMTICPGT 580  
      1llligfsvigyllfkgyedlsenevdgnsefssyfdafyflfvtlttvG  
      +ll++ s+ +++++ + + +e+ d+ + s++ a++ +t++++G  
52906 581 VLLVF--SISLWIIAAWTVRACERYHDQQDVTSNFLGAMWLISITFLSIG 628  
      fGdlvpvwlgiffvlfiiivglllnlliavi<-\*  
      +Gd+vp++++ ++l+ i+g ++l +av+  
52906 629 YGDMVPNTYCGKGVCLLTGIMGAGCTALVVAVV 661

Figure 2




Figure 3

Figure 4A

```

cNMP_binding: domain 1 of 1, from 565 to 655: score 78.3, E = 1.5e-19
(SEQ ID NO:10) *-->aleersypaGeviirqGdpqgdsfYivlsGevevykltedGartpevs
                     ++ + ++G+ i++ G+ d + +v+sG++ev++
33408      565      EFQTIHCAPGDLIYHAGESVDAFCVVSGSLEVIQ----- 599

                     qkqdtreqvvatlgpGdfFGElalltndgnknavlpsldqgaprtatvrA
                     +++vva+lg+Gd+FG++ + + + +a+ a+vrA
33408      600      -----DDEVVAILKGKDVGDFIW-KE-----TTLAHACANVRA 632

                     ltdsellrldredFrrllqkype<-*
                     lt+++l+ + re+++ +l+ y +
33408      633      LTYCDLHIKREALLKVLDFYTA      655

```

Figure 4B

33408  
rat EAG2  
(SEQ ID NO:12)

MPGGKRLVA PQNTFLENIV RRSSESSFLL GNAQIVDWPV VYSNDGFCKL  
MPGGKRLVA PQNTFLENIV RRSSESSFLL GNAQIVDWPV VYSNDGFCKL

SGYHRADVMQ KSSTCSFMYG ELTDKKTIK VRQTFDNYES NCFEVLLYKK  
SGYHRADVMQ KSSTCSFMYG ELTDKKTIK VRQTFDNYES NCFEVLLYKK

NRTPVWFYMQ IAPIRNEHEK VVLFLLCTFKD ITLFKQPIED DSTKGWTKFA  
NRTPVWFYMQ IAPIRNEHEK VVLFLLCTFKD ITLFKQPIED DSTKGWTKFA

RLTRALTNR SVLQLTPMN KTEVVHKHSR LAEVLQLGSD ILPQYKQEAP  
RLTRALTNR SVLQLTPMN KTETVHKHSR LAEVLQLGSD ILPQYKQEAP

KTPPHIILHY CAFKTTWDWV ILILTFYTAI MYPYNVSFKT KQNNIAWLVL  
KTPPHIILHY CAFKTTWDWV ILILTFYTAI MYPYNVSFKT KQNNIAWLVL

DSVVDVIFLV DIVLNFHTTF VGPGEVISD PKLIRMNYLK TWFVIDLLSC  
DSVVDVIFLV DIVLNFHTTF VGPGEVISD PKLIRMNYLK TWFVIDLLSC

LPYDIINAFE NVDEGISSLF SSLKVVRLLR LGRVARKLDH YLEYGAAVLV  
LPYDIINAFE NVDEGISSLF SSLKVVRLLR LGRVARKLDH YLEYGAAVLV

LLVCVFGGLVA HWLACIWYSI GDYEVIDEVT NTIQIDSWLY QLALSIGTPY  
LLVCVFGGLVA HWLACIWYSI GDYEVIDEVT NTIQIDSWLY QLALSIRTPY

RYNTSAGIWE GGPSKDSLYV SSLYFTMTSL TTIGFGNIAP TTDVEKMFV  
RYNTSAGIWE GGPSKDSLYV SSLYFTMTSL TTIGFGNIAP TTDVEKMFV

AMMMVGSLLY ATIFGNVTI FQQMYANTNR YHEMLNNVRD FLKLYQVPKG  
AMMMVGSLLY ATIFGNVTI FQQMYANTNR YHEMLNNVRD FLKLYQVPKG

LSERVMDYIV STWSMSKGID TEKVLSICPK DMRADICVHL NRKVFNEHPA  
LSERVMDYIV STWSMSKGID TEKVLSICPK DMRADICVHL NRKVFNEHPA

FRLASDGCLR ALAVEFQTIH CAPGDLIYHA GESVDALCFV VSGSLEVIQD  
FRLASDGCLR ALAVEFQTIH CAPGDLIYHA GESVDALCFV VSGSLEVIQD

DEVVAILGKG DVFGDIFWKE TTLAHACANV RALTYCDLHI IKREALLKVL  
EEVVAILGKG DVFGDIFWKE TTLAHACANV RALTYCDLHI IKREALLKVL

## Figure 4C

DFYTAFANSF SRNLTLTCNL RKRIIFRKIS DVKKEEEERL RQKNEVTLSI  
DFYTAFANSF SRNLTLTCNL RKRIIFRKIS DVKKEEEERL RQKNEVTLSI

PVDHPVRKLF QKFKQQKELR NQGSTQGDPE RNQLQVESRS LQNGTSITGT  
PVDHPVRKLF QKFKQQKELR NQGSAQSDPE RSQQLQVESRP LQNGASITGT

SVVTVSQITP IQTSLAYVKT SESLKQNNRD AMELKPNNGA DQKCLKVNSP  
SVVTVSQITP IQTSLAYVKT SETLKQNNRD AMELKPNNGA EPKCLKVNSP

IRMKNGNGKG WLRLKNNMGA HEEKKEDWNN VTKAESMGLL SEDPKSSDSE  
IRMKNGNGKG WLRLKNNMGA HEEKKEEWNN VTKAESMGLL SEDPKGSDSE

NSVTKNPLRK TDSCDSSGITK SDLRLDKAGE ARSPLEHSPI QADAKHPFYP  
NSVTKNPLRK TDSCDSSGITK SDLRLDKAGE ARSPLEHSPS QADAKHPFYP

IPEQALQTTL QEVKHELKED IQLLSCRMTA LEKQVAEILK ILSEKSVPQA  
IPEQALQTTL QEVKHELKED IQLLSCRMTA LEKQVAEILK LLSEKSVPQT

SSPKSQMPLQ VPPQIPCQDI FSVSRPESPE SDKDEIHF  
SSPKPQIPLQ VPPQIPCQDI FSVSRPESPE SDKDEINF

Figure 4D




Figure 5

K\_tetra: domain 1 of 1, from 3 to 101: score 169.0, E = 7.9e-47  
 (SEQ ID NO:11) \*->ErvrLNVGGkrFeTsksTLtrfkpdT1Lgr11ktdsdvhear1rlcd  
 Er++LNV G+rFeT+++TL rf pdT1Lg+++++r ++  
 12189 3 ERLVLNVAGLRFETRARTLGRF-PDTLLGDPAR-----R-GR 37

fyddetgEyFFDRsPkhFetILnfYRtGdGkLhrp.evcldsfleEleFy  
 fydd++ EyFFDR++++F+++L++Y++G G+L+rp +v+ld+fleE +Fy  
 12189 38 FYDDARREYFFDRHRPSFDAVLYYYQSG-GRLRRPaHVPLDVFLEEVAFY 86

glde laiesCcdeY<-\*  
 gl+ a++ +ede+  
 12189 87 GLGAAALARLREDEG 101

Figure 6A

ion\_trans: domain 1 of 1, from 198 to 383: score 144.8, E = 1.5e-39  
 (SEQ ID NO:9) \*->ilfildllfvllflleivlkfiayglkstsnsiaakylksifnildll  
 ++f+++++l++ +f +e+++++ ++ k a ++k+++n++d+  
 12189 198 PFFVVETLCICWFSFELLVRLLVCPSK-----AIFFKNVMNLIDFV 238

ailplllllvlflsgteqvakkrlrerfslelsqwyrrirflrlLrllR  
 ailp+++ l+ l+++ +++++ + +L +1R  
 12189 239 AILPYFVALGTELARQ-----RGVGQQAMSLAILR 268

1Lrllrllrrletlfe felgtlaWslqslg.ralksilrfllllllig  
 ++rl+r++r ++ + +++ lq+lg+++ +s+ ++ll+++l+ig  
 12189 269 VIRLVRVFRIFKLSR---HSKG---LQILGqTLRASMRELGLLIFFLFIG 312

fsvigyllfkgyedlsenevdgnsefssyfdafyflfvttvGfGdlvp  
 + +++ +++++ + d+ +s f+s++++f++++vt+ttvG+Gd+ p  
 12189 313 VVLFSSAVYFAEVDRV-----DSHFTSIPESFWAVVTMTVGYGDMAP 356

v.wlg iiffvlfiiivglllnlliavi<-\*  
 v+++g+i++ +++i+g+l+++l+++vi  
 12189 357 VtVGGKIVG-SLCAlAGVLTISLPVPVI 383

Figure 6B

Mouse Kv1.7  
(SEQ ID NO:13)  
12189

MTTRKAQEIH GKAPGGSVST GVGTAEGAPS PAGVTPPPPP RPGRTFHAIF

.....  
TRRHRTPDWG GCGVGATRPF TGRPGCARHG ATVPAALRCC ERLVLNVAGL  
..... CC ERLVLNVAGL

RFETRARTLG RFPDTLLGDP VRRSRFYDGA RAEYFFDRHR PSFDAVLYYYY  
RFETRARTLG RFPDTLLGDP ARRGRFYDDA RREYFFDRHR PSFDAVLYYYY

QSGGRLRRPA HVPLDVFLEE VSFYGLG RR LARLREDEGC AVA ERPLPP  
QSGGRLRRPA HVPLDVFLEE VAFYGLGAAA LARLREDEGC PVP PERPLPR

.PFARQLWLL FEFPESSQAA RVLAVVSVLV ILVSIVVFCL ETLPDFRDDR  
RAFARQLCLL FEFPESSQAA RVLAVVSVLV ILVSIVVFCL ETLPDFRDDR

DDPGLAPVAA ATGSFLARLN GSSPMPGAPP RQPFNDPFFV VETLCICWFS  
DGTGLA AAA AAGPPAPLN GSSQMPGNPP RLPPFNDPFFV VETLCICWFS

FELLVHLVAC PSKAVFFKNV MNLIDFVAIL PYFVALGTEL ARQRGVGQPA  
FELLVRLLVC PSKAIFFKNV MNLIDFVAIL PYFVALGTEL ARQRGVGQQA

MSLAILRVIR LVRVFRIFKL SRHSKGLQIL QTLRASMRE LGLLIFFLFI  
MSLAILRVIR LVRVFRIFKL SRHSKGLQIL QTLRASMRE LGLLIFFLFI

GVVLFSSAVY FAEVDRVDTW FTSIPESFWW AVVTMTTVGY GDMAPVTVGG  
GVVLFSSAVY FAEVDRVDSH FTSIPESFWW AVVTMTTVGY GDMAPVTVGG

KIVGSLCAIA GVLTISLPVP VIVSNFSYFY HRETEGEEAG MSHVDTQPC  
KIVGSLCAIA GVLTISLPVP VIVSNFSYFY HRETEGEEAG MSHVDMQPC

GTLEGKANGG LVDSEVPELL PPLWPPAGKH MVTEV  
GPLEGKANGG LVDGEVPELP PPLWAPPGKH LVTEV

Figure 6C

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 December 2001 (13.12.2001)

PCT

(10) International Publication Number  
WO 01/094390 A3

(51) International Patent Classification<sup>7</sup>: C12N 15/12, C07K 14/705, 16/28, C12Q 1/68, G01N 33/53, 33/68

(74) Agents: MYERS, Louis et al.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).

(21) International Application Number: PCT/US01/18340

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 6 June 2001 (06.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/209,845 6 June 2000 (06.06.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 60/209,845 (CIP)  
Filed on 6 June 2000 (06.06.2000)

(71) Applicant (for all designated States except US): MILLENNIUM PHARMACEUTICALS, INC. [US/US]; 75 Sidney Street, Cambridge, MA 02139 (US).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
15 August 2002

(72) Inventor; and

(75) Inventor/Applicant (for US only): CURTIS, Rory, A., J. [US/US]; 31 Constitution Drive, Southborough, MA 01772 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/094390 A3

(54) Title: 52906, 33408, AND 12189, POTASSIUM CHANNEL FAMILY MEMBERS AND USES THEREOF

(57) Abstract: The invention provides isolated nucleic acids molecules, designated 52906, 33408, or 12189 nucleic acid molecules, which encode potassium channel members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 52906, 33408, or 12189 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 52906, 33408, or 12189 gene has been introduced or disrupted. The invention still further provides isolated 52906, 33408, or 12189 proteins, fusion proteins, antigenic peptides and anti-52906, 33408, or 12189 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/18340

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/705 C07K16/28 C12Q1/68 G01N33/53  
G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12N C07K C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EMBL, EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 98 11139 A (UNIV OREGON HEALTH SCIENCES ;ADELMAN JOHN P (US); BOND CHRIS T (US) 19 March 1998 (1998-03-19) Note: 99.8% nt seq identity of SEQ ID NO:21 with SEQ ID NO:3 in 1740 nt overlap (1-1740:805-2544), 99.8% aa seq identity of SEQ ID NO:19 with SEQ ID NO:2 in 579 aa overlap (1-579:269-847) the whole document page 5, line 14 -page 12, line 3 page 26, line 12 -page 29, line 30 page 106-108 page 110-111 claims 2-4,12-14,21,22,24-48 ----</p> <p style="text-align: center;">-/-</p>	1-30

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

26 February 2002

Date of mailing of the international search report

31 05 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

van de Kamp, M

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/18340

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE EM_EST [Online]        EMBL;        ID AI271784, AC AI271784,        19 November 1998 (1998-11-19)        NCI-CGAP: "qj82f08.x1 NCI CGAP_Kid3 Homo        sapiens cDNA clone IMAGE:1865991 3'        similar to contains element TAR1        repetitive element ;, mRNA sequence"        XP002191022        Note: 100.0% nt seq identity with SEQ ID        NO:3 in 413 nt overlap (1-413:818-406)        the whole document</p> <p>---</p>	1-30
Y	<p>JÄGER H ET AL.: "SK2 encodes the        apamin-sensitive Ca<sup>2+</sup> -activated K+        channels in the human leukemic T cell        line, Jurkat."        FEBS LETTERS,        vol. 469, no. 2-3,        10 March 2000 (2000-03-10), pages 196-202,        XP002191020        ISSN: 0014-5793        abstract        page 201, left-hand column, line 1-17        page 201, right-hand column, line 23-60</p> <p>---</p>	1-30
A	<p>WO 99 47923 A (MACKINNON RODERICK ;UNIV        ROCKEFELLER (US))        23 September 1999 (1999-09-23)        the whole document</p> <p>---</p>	19-30
A	<p>WO 99 03882 A (ZENECA LTD)        28 January 1999 (1999-01-28)        the whole document</p> <p>---</p>	1-30
P,A	<p>DESAI R ET AL.: "Ca<sup>2+</sup>-activated K+        channels in human leukemic Jurkat T cells:        Molecular cloning, biochemical and        functional characterization."        JOURNAL OF BIOLOGICAL CHEMISTRY,        vol. 275, no. 51,        22 December 2000 (2000-12-22), pages        39954-39963, XP002191021        ISSN: 0021-9258        Note: 99.7% aa seq identity of hSK2 (KCN2)        with SEQ ID NO:2 in 579 aa overlap        (1-579:269-847)        the whole document</p> <p>-----</p>	1-30

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/18340

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
**Although claims 21 and 23-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.**
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
**see FURTHER INFORMATION sheet PCT/ISA/210**
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

**see additional sheet**

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
**1-30 (all partially)**

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 01/18340

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

#### Continuation of Box I.2

Present claims 15, 18, 21 and 23-25 relate to a compound/agent defined by reference to a desirable characteristic or property, namely binding or hybridizing to or modulating the activity or expression of a 52906 polypeptide or nucleic acid. The claims cover all compounds/agents having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds/agents. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound/agent by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to antibody and antisense molecules.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 01/18340

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-30 (all partially)

An isolated nucleic acid molecule which is at least 95% identical to SEQ ID NO:1 or 3, or comprising a fragment of at least 1750 nucleotides of SEQ ID NO:1 or 3, or which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or a fragment comprising at least 580 contiguous amino acids of SEQ ID NO:2 or a naturally occurring allelic variant thereof. A vector and a host cell comprising said nucleic acid molecule. An isolated polypeptide encoded by said nucleic acid molecule and a method for producing it. An antibody binding to said polypeptide. Methods for detecting said polypeptide and said nucleic acid molecule. A method for identifying a compound binding to said polypeptide. A method for modulating the activity of said polypeptide comprising contacting with a compound binding to said polypeptide. A method for identifying a compound which modulates the activity of said polypeptide. A method of treating or preventing an ion flux-related disorder comprising administering an agent modulating the activity or expression of said polypeptide or nucleic acid. A method for identifying an agent that modulates the activity or expression of said polypeptide or nucleic acid.

2. Claims: 1-7,16-18 (all partially); 31 (completely)

An isolated nucleic acid molecule which is at least 95% identical to SEQ ID NO:4, or comprising a fragment of at least 2980 nucleotides of SEQ ID NO:4. A vector and a host cell comprising said nucleic acid molecule. A method for detecting said nucleic acid molecule. An antibody binding to an extracellular domain of the polypeptide of SEQ ID NO:5.

3. Claims: 1-30 (all partially)

An isolated nucleic acid molecule which is at least 90% identical to SEQ ID NO:7, or comprising a fragment of at least 300 nucleotides of SEQ ID NO:7, or which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:8 or a fragment comprising at least 80 contiguous amino acids of SEQ ID NO:8 or a naturally occurring allelic variant thereof. A vector and a host cell comprising said nucleic acid molecule. An isolated polypeptide encoded by said nucleic acid molecule and a method for producing it. An antibody binding to said polypeptide. Methods for detecting said polypeptide and said nucleic acid molecule. A method for identifying a compound binding to said polypeptide. A method for modulating the activity of said polypeptide comprising contacting with a compound binding to said polypeptide. A method for identifying a compound which

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 01/18340

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

modulates the activity of said polypeptide. A method of treating or preventing an ion flux-related disorder comprising administering an agent modulating the activity or expression of said polypeptide or nucleic acid. A method for identifying an agent that modulates the activity or expression of said polypeptide or nucleic acid.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/18340

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9811139	A 19-03-1998	AU	726158 B2	02-11-2000
		AU	4266097 A	02-04-1998
		EP	0948542 A1	13-10-1999
		JP	2000514310 T	31-10-2000
		WO	9811139 A1	19-03-1998
-----	-----	-----	-----	-----
WO 9947923	A 23-09-1999	AU	3198899 A	11-10-1999
		CA	2323725 A1	23-09-1999
		EP	1062508 A1	27-12-2000
		WO	9947923 A2	23-09-1999
-----	-----	-----	-----	-----
WO 9903882	A 28-01-1999	AU	8348498 A	10-02-1999
		EP	1012281 A2	28-06-2000
		WO	9903882 A2	28-01-1999
		JP	2001520524 T	30-10-2001
-----	-----	-----	-----	-----